

CITATION REPORT

List of articles citing

The consensus coding sequences of human breast and colorectal cancers

DOI: 10.1126/science.1133427
Science, 2006, 314, 268-74.

Source: <https://exaly.com/paper-pdf/39751208/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2266	.		
2265	TESTING SIGNIFICANCE OF FEATURES BY LASSOED PRINCIPAL COMPONENTS. 2008 , 2, 986-1012		6
2264	A quantum leap in our knowledge of breast cancer mutations. 2006 , 8, 304		2
2263	Analysis of cytoskeletal and motility proteins in the sea urchin genome assembly. 2006 , 300, 219-37		52
2262	Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study. 2006 , 6, 268		39
2261	The system of the world. 2006 , 7, 368		1
2260	The cancer genome and diagnostic blood tests. 2006 , 15, 2017-8		2
2259	Baffled by bafilomycin: an anticancer agent that induces hypoxia-inducible factor-1alpha expression. 2006 , 70, 1841-3		9
2258	Random mutations, selected mutations: A PIN opens the door to new genetic landscapes. 2006 , 103, 18033-4		30
2257	Human cancers express a mutator phenotype. 2006 , 103, 18238-42		292
2256	Tumor-associated antigens and biomarkers in cancer and immune therapy. 2007 , 26, 223-47		20
2255	TGF-beta signaling alterations and susceptibility to colorectal cancer. 2007 , 16 Spec No 1, R14-20		175
2254	A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. 2007 , 104, 4036-41		126
2253	Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. 2007 , 104, 16633-8		207
2252	Unique human tumor antigens: immunobiology and use in clinical trials. 2007 , 178, 1975-9		132
2251	Multigene amplification and massively parallel sequencing for cancer mutation discovery. 2007 , 104, 9387-92		143
2250	Multiplex amplification of all coding sequences within 10 cancer genes by Gene-Collector. 2007 , 35, e47		54

2249	Senescence as an anticancer mechanism. 2007 , 25, 1852-7	68
2248	Systematic analysis of genetic alterations in tumors using Cancer Genome WorkBench (CGWB). 2007 , 17, 1111-7	19
2247	WNKs: protein kinases with a unique kinase domain. 2007 , 39, 565-73	40
2246	Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. 2007 , 104, 20007-12	812
2245	CanPredict: a computational tool for predicting cancer-associated missense mutations. 2007 , 35, W595-8	112
2244	Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion. 2007 , 5, e276	58
2243	Computational identification of candidate loci for recessively inherited mutation using high-throughput SNP arrays. 2007 , 23, 1952-61	2
2242	Genetic progression and the waiting time to cancer. 2007 , 3, e225	280
2241	Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. 2007 , 3, 1709-23	272
2240	Expression profiling of rat mammary epithelial cells reveals candidate signaling pathways in dietary protection from mammary tumors. 2007 , 30, 8-16	76
2239	Comprehensive annotation of bidirectional promoters identifies co-regulation among breast and ovarian cancer genes. 2007 , 3, e72	69
2238	Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. 2007 , 28, 1851-8	94
2237	DNA alkylation and DNA methylation: cooperating mechanisms driving the formation of colorectal adenomas and adenocarcinomas?. 2007 , 56, 318-20	12
2236	Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. 2007 , 99, 1668-82	85
2235	Meeting report: targeting the kinome--20 years of tyrosine kinase inhibitor research in Basel. 2007 , 2007, pe8	8
2234	Identification of Mom7, a novel modifier of Apc(Min/+) on mouse chromosome 18. 2007 , 176, 1237-44	39
2233	Finding Plk3. 2007 , 6, 1314-8	20
2232	Following the tracks of AKT1 gene. 2007 , 6, 1521-4	15

2231	Genomic landscapes of cancers: prospects for targeted therapies. 2007 , 8, 1629-33	10
2230	Steroid-mediated regulation of the epithelial sodium channel subunits in mammary epithelial cells. 2007 , 148, 3958-67	16
2229	Targeted diagnostics and therapeutics for individualized patient management. 2007 , 1, 3-8	9
2228	Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion. 2008 , 29, 629-37	66
2227	Targeting signal transduction in pancreatic cancer treatment. 2007 , 11, 673-94	43
2226	Distinguishing cancer-associated missense mutations from common polymorphisms. 2007 , 67, 465-73	103
2225	Osteoactivin promotes breast cancer metastasis to bone. 2007 , 5, 1001-14	130
2224	Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. 2007 , 67, 2632-42	189
2223	Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. 2007 , 67, 9364-70	124
2222	4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. 2007 , 67, 7551-5	225
2221	Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. 2007 , 6, 1997-2011	164
2220	Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. 2007 , 67, 11368-76	71
2219	Cancer genetics of epigenetic genes. 2007 , 16 Spec No 1, R28-49	200
2218	Raft-dependent endocytosis of autocrine motility factor is phosphatidylinositol 3-kinase-dependent in breast carcinoma cells. 2007 , 282, 29305-13	40
2217	Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. 2007 , 67, 8468-76	28
2216	Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. 2007 , 67, 10736-43	59
2215	Cancer Stem Cells. 2007 ,	2
2214	Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. 2007 , 104, 10974-9	57

2213	Genome-epigenome interactions in cancer. 2007 , 16 Spec No 1, R96-105	50
2212	Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. 2007 , 13, 3883-91	189
2211	Impaired expression of NER gene network in sporadic solid tumors. 2007 , 35, 1859-67	22
2210	Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. 2007 , 67, 3545-50	136
2209	Investigation of human protein variants and their frequency in the general population. 2007 , 6, 1183-7	46
2208	The mystery of chromosomal translocations in cancer. 2007 , 118, 247-51	4
2207	Using Pharmacogenomic Tumor Profiling to Identify Biomarkers of 5-fluorouracil Response in Colorectal Cancer. 2007 , 5, 167-177	
2206	Evidence for mutation showers. 2007 , 104, 8403-8	64
2205	Nonrandom variations in human cancer ESTs indicate that mRNA heterogeneity increases during carcinogenesis. 2007 , 104, 7522-7	14
2204	CARGO: a web portal to integrate customized biological information. 2007 , 35, W16-20	14
2203	Genomic mutation consequence calculator. 2007 , 23, 3091-2	13
2202	Induction of mutations in <i>Drosophila melanogaster</i> gypsy retroelements by modulation of intracellular deoxynucleoside triphosphate pools in vivo. 2007 , 81, 4900-3	
2201	A multidimensional analysis of genes mutated in breast and colorectal cancers. 2007 , 17, 1304-18	106
2200	A non-genetic basis for cancer progression and metastasis: self-organizing attractors in cell regulatory networks. 2006 , 26, 27-54	120
2199	Previously unrecognized genetic mutations in colorectal and breast cancers. 2007 , 4, 9-9	
2198	JAK2 617V>F positive polycythemia rubra vera maintained by approximately 18 stochastic stem-cell divisions per year, explaining age of onset by a single rate-limiting mutation. 2007 , 110, 1675-80	7
2197	Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. 2007 , 406, 57-66	44
2196	Rarity of Somatic Mutation and Frequency of Normal Sequence Variation Detected in Sporadic Colon Adenocarcinoma Using High-Throughput cDNA Sequencing. 2007 , 1, 117793220700100	1

2195	Alterações genéticas no cancro do pulmão: Avaliação das limitações ao seu uso na rotina clínica. 2007 , 13, 9-34	
2194	No evidence of RALGDS mutations in cutaneous melanoma. 2007 , 17, 410-2	3
2193	Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. 2007 , 10, 59-67	147
2192	Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. 2007 , 358, 399-403	41
2191	A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. 2007 , 362, 816-21	176
2190	Genetic screening for signal transduction in the era of network biology. 2007 , 128, 225-31	145
2189	HEF1-dependent Aurora A activation induces disassembly of the primary cilium. 2007 , 129, 1351-63	611
2188	Non-oncogene addiction and the stress phenotype of cancer cells. 2007 , 130, 986-8	272
2187	Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?. 2007 , 33, 391-406	53
2186	The many ways of Wnt in cancer. 2007 , 17, 45-51	751
2185	Variation, "evolution", immortality and genetic instabilities in tumour cells. 2007 , 253, 155-69	12
2184	Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro. 2007 , 255, 57-70	67
2183	Flesh and blood: the story of Vav1, a gene that signals in hematopoietic cells but can be transforming in human malignancies. 2007 , 255, 241-54	41
2182	Laser capture microdissection technology. 2007 , 7, 647-57	140
2181	A luminal breast cancer genome atlas: progress and barriers. 2007 , 106, 125-9	6
2180	A review of the mutagenicity and rodent carcinogenicity of ambient air. 2007 , 636, 36-94	95
2179	Genetic constraints on protein evolution. 2007 , 42, 313-26	93
2178	What can we learn from the population incidence of cancer? Armitage and Doll revisited. 2007 , 8, 1030-8	35

2177	Genetic alterations in lung cancer: assessing limitations in routine clinical use. 2007 , 13, 9-34	
2176	Network-based classification of breast cancer metastasis. 2007 , 3, 140	1109
2175	What have we gained from the application of biological rationales? 2007 , 5, 83-88	
2174	The continuing search for cancer-causing somatic mutations. 2007 , 9, 101	2
2173	Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. 2007 , 9, R5	23
2172	High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. 2007 , 8, R215	230
2171	The hedgehog signaling network, mammary stem cells, and breast cancer: connections and controversies. 2006 , 181-217	14
2170	The dynamics of cancer chromosomes and genomes. 2007 , 118, 237-46	62
2169	Selective Raf inhibition in cancer therapy. 2007 , 11, 1587-609	50
2168	PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. 2007 , 6, 3158-68	202
2167	Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. 2007 , 16, 2024-32	71
2166	Pathway analysis software as a tool for drug target selection, prioritization and validation of drug mechanism. 2007 , 11, 411-21	23
2165	Modeling cancer: integration of "omics" information in dynamic systems. 2007 , 5, 977-86	11
2164	Connecting Seed Lists of Mammalian Proteins Using Steiner Trees. 2007 ,	4
2163	Optimization of naphthalimide-imidazoacridone with potent antitumor activity leading to clinical candidate (HKH40A, RTA 502). 2007 , 50, 5557-60	23
2162	High-throughput methylation profiling by MCA coupled to CpG island microarray. 2007 , 17, 1529-36	137
2161	Cancer genomics: integrating form and function. 2007 , 28, 1387-92	14
2160	The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. 2007 , 67, 1883-6	298

2159	Growth factors and oncogenes as targets in melanoma: lost in translation?. 2007 , 23, 99-129	15
2158	Mutational analysis of p27 (CDKN1B) and p18 (CDKN2C) in sporadic pancreatic endocrine tumors argues against tumor-suppressor function. 2007 , 9, 533-5	15
2157	Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. 2007 , 1, 26-41	134
2156	Integrative analysis of a cancer somatic mutome. 2007 , 6, 13	20
2155	A map of human cancer signaling. 2007 , 3, 152	208
2154	Origins of breast cancer subtypes and therapeutic implications. 2007 , 4, 516-25	126
2153	BMP signaling in the intestine: cross-talk is key. 2007 , 133, 1035-8	17
2152	Cancer genome analysis: a landscape seen from many angles. 2007 , 4, 269-276	
2151	[Towards an integrated cellular and molecular: definition of breast cancers]. 2007 , 23, 626-32	1
2150	Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. 2007 , 2, e426	73
2149	Breast cancer: origins and evolution. <i>Journal of Clinical Investigation</i> , 2007 , 117, 3155-63	15.9 369
2148	Comparative integromics on the breast cancer-associated gene KIAA1632: Clues to a cancer antigen domain. 2007 ,	0
2147	Section 2: Patient Records: Integrating Bioinformatics into Clinical Practice: Progress and Evaluation. 2007 , 16, 106-108	
2146	Will knowledge of human genome variation result in changing cancer paradigms?. 2007 , 29, 678-85	9
2145	Cancer genome sequencing: the challenges ahead. 2007 , 29, 783-94	79
2144	Using Lessons from Cellular and Molecular Structures for Future Materials. 2007 , 19, 3761-3770	37
2143	ADAMTSL3/punctin-2, a gene frequently mutated in colorectal tumors, is widely expressed in normal and malignant epithelial cells, vascular endothelial cells and other cell types, and its mRNA is reduced in colon cancer. 2007 , 121, 1710-6	21
2142	Targeted treatment of prostate cancer. 2007 , 102, 571-9	47

2141	Biomarkers, regecons, and pathways to lethal cancer. 2007 , 102, 1076-86	1
2140	Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis. 2007 , 46, 661-9	74
2139	Rapid high-resolution karyotyping with precise identification of chromosome breakpoints. 2007 , 46, 675-83	17
2138	Distinct roles of individual Smads in skin carcinogenesis. 2007 , 46, 660-4	16
2137	GSK-3 inhibitors induce chromosome instability. 2007 , 8, 34	77
2136	Grading gastrointestinal dysplasia and what to call it when you don't know what it is. 2007 , 212, 121-3	1
2135	Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3. 2007 , 7, 313-22	51
2134	Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth. 2007 , 26, 4580-9	69
2133	p53 alterations in human cancer: more questions than answers. 2007 , 26, 2145-56	189
2132	Reactivation of mutant p53: molecular mechanisms and therapeutic potential. 2007 , 26, 2243-54	155
2131	Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. 2007 , 26, 7490-8	91
2130	Cancer: drivers and passengers. 2007 , 446, 145-6	158
2129	Materials science: silicon life forms. 2007 , 446, 146-7	6
2128	The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. 2007 , 25, 1251-5	1556
2127	Network modeling links breast cancer susceptibility and centrosome dysfunction. 2007 , 39, 1338-49	516
2126	Genome-wide in situ exon capture for selective resequencing. 2007 , 39, 1522-7	565
2125	The devil is in the DNA. 2007 , 39, 283-4	14
2124	Enhancing genome annotation with chromatin. 2007 , 39, 284-5	7

2123	High-throughput oncogene mutation profiling in human cancer. 2007 , 39, 347-51	847
2122	MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. 2007 , 39, 759-69	148
2121	Primer-site SNPs mask mutations. 2007 , 4, 192	26
2120	Highly efficient somatic-mutation identification using Escherichia coli mismatch-repair detection. 2007 , 4, 713-5	5
2119	Microarray-based genomic selection for high-throughput resequencing. 2007 , 4, 907-9	340
2118	Multiplex amplification of large sets of human exons. 2007 , 4, 931-6	357
2117	Genetic knockouts and knockins in human somatic cells. 2007 , 2, 2734-46	97
2116	Darwinian medicine: a case for cancer. 2007 , 7, 213-21	126
2115	Epidermal growth factor receptor mutations in lung cancer. 2007 , 7, 169-81	2272
2114	The impact of translocations and gene fusions on cancer causation. 2007 , 7, 233-45	997
2113	Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. 2007 , 7, 357-69	508
2112	Are oncoantigens suitable targets for anti-tumour therapy?. 2007 , 7, 707-13	50
2111	Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. 2007 , 7, 791-9	365
2110	Emerging roles of proteases in tumour suppression. 2007 , 7, 800-8	646
2109	Cancer epigenomics: DNA methylomes and histone-modification maps. 2007 , 8, 286-98	1674
2108	Genetic determinants of cancer metastasis. 2007 , 8, 341-52	624
2107	Mining gene expression profiles: expression signatures as cancer phenotypes. 2007 , 8, 601-9	152
2106	Splicing in disease: disruption of the splicing code and the decoding machinery. 2007 , 8, 749-61	735

2105	Single base instability is promoted in vulvar lichen sclerosus. 2007 , 127, 2563-76	15
2104	Identification of T-cell epitopes for cancer immunotherapy. 2007 , 21, 1859-74	102
2103	The gene encoding the splicing factor SF2/ASF is a proto-oncogene. 2007 , 14, 185-93	659
2102	Release of autoinhibition of ASEF by APC leads to CDC42 activation and tumor suppression. 2007 , 14, 814-23	73
2101	Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. 2007 , 96, 352-6	47
2100	Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. 2007 , 96, 952-9	73
2099	Patterns of somatic mutation in human cancer genomes. 2007 , 446, 153-8	2400
2098	A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. 2007 , 448, 439-44	981
2097	Genetic defects underlying Peutz-Jeghers syndrome (PJS) and exclusion of the polarity-associated MARK/Par1 gene family as potential PJS candidates. 2007 , 72, 568-73	37
2096	Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. 2007 , 75, 843-52	37
2095	Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours. 2008 , 68, 271-7	16
2094	Epigenetic changes in cancer. 2007 , 115, 1039-59	282
2093	Absence of MLL3 mutations in colorectal carcinomas of Korean patients. 2007 , 115, 859-60	6
2092	The evolution of targeted biologic therapies. 2007 , 16 Suppl 2, S1-3	
2091	A new mutational AKTivation in the PI3K pathway. 2007 , 12, 104-7	210
2090	Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. 2007 , 12, 192-9	55
2089	Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. 2007 , 12, 501-13	154
2088	Backseat drivers take the wheel. 2007 , 12, 493-4	14

2087	Wnt/beta-catenin signaling in cancer stemness and malignant behavior. 2007 , 19, 150-8	648
2086	Capicua regulates cell proliferation downstream of the receptor tyrosine kinase/ras signaling pathway. 2007 , 17, 728-33	73
2085	Telomerase and the aging process. 2007 , 42, 575-81	61
2084	Plakins in development and disease. 2007 , 313, 2189-203	223
2083	Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines. 2007 , 313, 3141-52	86
2082	S1P and LPA have an attachment-dependent regulatory effect on invasion of epithelial ovarian cancer cells. 2007 , 107, 298-309	31
2081	DLC-1:a Rho GTPase-activating protein and tumour suppressor. 2007 , 11, 1185-207	163
2080	Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?. 2007 , 17, 459-68	44
2079	The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. 2007 , 34, 546-54	47
2078	Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. 2007 , 1113, 202-16	418
2077	Reconstructing signal transduction pathways: challenges and opportunities. 2007 , 1115, 32-50	17
2076	Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge!. 2007 , 14, 3290-2	3
2075	The genomic landscapes of human breast and colorectal cancers. <i>Science</i> , 2007 , 318, 1108-13	333 2717
2074	Plan cancer: priorit�la pr�vention environnementale. 2007 , 1, 27-28	
2073	NALP inflammasomes: a central role in innate immunity. 2007 , 29, 213-29	161
2072	Cancer systems biology: exploring cancer-associated genes on cellular networks. 2007 , 64, 1752-62	94
2071	Molecular profiling of breast cancer: transcriptomic studies and beyond. 2007 , 64, 3185-200	11
2070	Molecular subtyping of breast cancer: opportunities for new therapeutic approaches. 2007 , 64, 3219-32	20

2069	Promise and progress for functional and molecular imaging of response to targeted therapies. 2007 , 24, 1172-85	61
2068	Hedgehog signaling in mammary gland development and breast cancer. 2007 , 12, 163-73	60
2067	Modeling metastatic breast cancer in mice. 2007 , 12, 191-203	53
2066	Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes. 2007 , 18, 865-79	37
2065	Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. 2007 , 33, 189-95	43
2064	Germ-line DNA copy number variation frequencies in a large North American population. 2007 , 122, 345-53	122
2063	Involvement of mutation-based inhibition of beta-catenin phosphorylation at Ser33 in the malignant progression of lung (pre)neoplastic lesions induced by N-nitrosobis(2-hydroxypropyl)amine in male Fischer 344 rats. 2007 , 185, 271-278	
2062	Genomic instability: on the birth and death of cancer. 2007 , 9, 216-20	13
2061	Epidemiology of colorectal cancer: the 21-year experience of a specialised registry. 2007 , 2, 269-79	22
2060	Genome mirror-2007. 2007 , 1, 147-8	
2059	Epigenetic biomarkers for human cancer: the time is now. 2008 , 68, 1-11	177
2058	FBXW7 and DNA copy number instability. 2008 , 109, 47-54	7
2057	Association of the TCF7L2 polymorphism with colorectal cancer and adenoma risk. 2008 , 19, 975-80	33
2056	The tyrosine phosphatase Shp2 (PTPN11) in cancer. 2008 , 27, 179-92	287
2055	Hereditary diffuse gastric cancer: association with lobular breast cancer. 2008 , 7, 73-82	106
2054	Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. 2008 , 65, 3981-99	370
2053	Identifying cancer genes from cancer mutation profiles by cancer functions. 2008 , 51, 569-74	0
2052	Array-CGH flüdie Analyse von Tumorgenomen. 2008 , 20, 395-400	

2051	Molecular cytogenetics in translational oncology: when chromosomes meet genomics. 2008 , 10, 20-9	6
2050	Bioinformatics and cancer research: building bridges for translational research. 2008 , 10, 85-95	12
2049	Cancerogenèse. Accroissement des connaissances et évolution des concepts. 2008 , 10, 319-347	2
2048	Hereditary breast cancer: new genetic developments, new therapeutic avenues. 2008 , 124, 31-42	233
2047	Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. 2008 , 214, 357-67	264
2046	Most low-level microsatellite instability in colorectal cancers can be explained without an elevated slippage rate. 2008 , 215, 204-10	12
2045	Human tumour clonality assessment--flawed but necessary. 2008 , 215, 351-4	20
2044	Wild-type APC regulates caveolin-1 expression in human colon adenocarcinoma cell lines via FOXO1a and C-myc. 2008 , 47, 947-55	28
2043	Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. 2008 , 113, 975-84	166
2042	PIK3CA cancer mutations display gender and tissue specificity patterns. 2008 , 29, 284-8	107
2041	Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD). 2008 , 29, 441-50	19
2040	High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling. 2008 , 29, 757-64	41
2039	Breast cancer-associated mutations in metalloprotease disintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein. 2008 , 122, 2634-40	32
2038	Organ-specific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression. 2008 , 123, 2735-40	73
2037	Inactivation of the p19(ARF) tumor suppressor affects intestinal epithelial cell proliferation and integrity. 2008 , 104, 2228-40	3
2036	Inflammation as the primary aetiological agent of human prostate cancer: a stem cell connection?. 2008 , 105, 931-9	35
2035	QSAR model for alignment-free prediction of human breast cancer biomarkers based on electrostatic potentials of protein pseudofolding HP-lattice networks. 2008 , 29, 2613-22	45
2034	Aberrant splicing of the PTPRD gene mimics microdeletions identified at this locus in neuroblastomas. 2008 , 47, 197-202	19

2033	SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. 2008 , 47, 253-9		33
2032	Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. 2008 , 47, 1211-22		146
2031	The gene-centric concept: a new liability?. 2008 , 30, 196-7		13
2030	Cancer vaccines: accomplishments and challenges. 2008 , 67, 93-102		41
2029	Proteomics-driven cancer biomarker discovery: looking to the future. 2008 , 12, 72-7		88
2028	Single-molecule DNA sequencing of a viral genome. <i>Science</i> , 2008 , 320, 106-9	33.3	518
2027	Antigens for cancer immunotherapy. 2008 , 20, 286-95		131
2026	An integrated genomic analysis of human glioblastoma multiforme. <i>Science</i> , 2008 , 321, 1807-12	33.3	4419
2025	Absence of E17K mutation in the pleckstrin homology domain of AKT1 in gastrointestinal and liver cancers in the Korean population. 2008 , 116, 530-3		2
2024	Absence of ERCC6 gene mutation in common cancers of Korean patients. 2008 , 116, 1009-10		0
2023	Absence of the AKT1 pleckstrin homology domain mutation in Japanese gastrointestinal and liver cancer patients. 2008 , 116, 931-3		1
2022	Strategies and challenges in eliciting immunity to melanoma. 2008 , 222, 28-42		18
2021	Identification of novel sense and antisense transcription at the TRPM2 locus in cancer. 2008 , 18, 1128-40		84
2020	An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. 2008 , 22, 2269-72		28
2019	Somatic mutations affect key pathways in lung adenocarcinoma. 2008 , 455, 1069-75		2280
2018	Journal club. 2008 , 451, 503-503		
2017	Array painting reveals a high frequency of balanced translocations in breast cancer cell lines that break in cancer-relevant genes. 2008 , 27, 3345-59		52
2016	PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. 2008 , 27, 4657-65		117

2015	PI3K/Akt: getting it right matters. 2008 , 27, 6473-88	531
2014	EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids. 2008 , 27, 4336-43	57
2013	Radiation carcinogenesis: lessons from Chernobyl. 2008 , 27 Suppl 2, S9-18	97
2012	Next-generation DNA sequencing. 2008 , 26, 1135-45	3040
2011	What would you do if you could sequence everything?. 2008 , 26, 1125-33	155
2010	Identification of ten loci associated with height highlights new biological pathways in human growth. 2008 , 40, 584-91	482
2009	Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. 2008 , 40, 102-7	289
2008	From risk to function. 2008 , 40, 929	
2007	Ral GTPases and cancer: linchpin support of the tumorigenic platform. 2008 , 8, 133-40	189
2006	Ca ²⁺ signalling checkpoints in cancer: remodelling Ca ²⁺ for cancer cell proliferation and survival. 2008 , 8, 361-75	500
2005	The ADAMs: signalling scissors in the tumour microenvironment. 2008 , 8, 929-41	389
2004	Comparing whole genomes using DNA microarrays. 2008 , 9, 291-302	159
2003	Role of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancer. 2008 , 24, 540-53	21
2002	Mutation in aging mice occurs in diverse cell types that proliferate postmutation. 2008 , 7, 667-80	3
2001	Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis. 2008 , 99, 1977-83	26
2000	Inferring relative numbers of human leucocyte genome replications. 2008 , 141, 862-71	15
1999	Novel computational methods for increasing PCR primer design effectiveness in directed sequencing. 2008 , 9, 191	29
1998	Aspects of coverage in medical DNA sequencing. 2008 , 9, 239	24

1997	Evaluation of human gene variant detection in amplicon pools by the GS-FLX parallel Pyrosequencer. 2008 , 9, 464	18
1996	Sequence divergence of <i>Mus spretus</i> and <i>Mus musculus</i> across a skin cancer susceptibility locus. 2008 , 9, 626	15
1995	Somatic mutation analysis of MYH11 in breast and prostate cancer. 2008 , 8, 263	21
1994	High-resolution array CGH clarifies events occurring on 8p in carcinogenesis. 2008 , 8, 288	36
1993	Genome-wide linkage scan for colorectal cancer susceptibility genes supports linkage to chromosome 3q. 2008 , 8, 87	32
1992	All along the watchtower: is the cilium a tumor suppressor organelle?. 2008 , 1786, 114-25	25
1991	Eph-ephrin signalling in adult tissues and cancer. 2008 , 20, 194-200	107
1990	The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine. 2008 , 13, 481-7	13
1989	Deregulation of signaling pathways in acute myeloid leukemia. 2008 , 35, 336-45	117
1988	Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. 2008 , 18, 311-21	212
1987	Proteomics: methodologies and applications in oncology. 2008 , 18, 115-25	23
1986	Mining for JAK-STAT mutations in cancer. 2008 , 33, 122-31	120
1985	Defining 'chromosomal instability'. 2008 , 24, 64-9	225
1984	Low duplicability and network fragility of cancer genes. 2008 , 24, 427-30	56
1983	Colorectal cancers in patients with the (9A/6A) polymorphism of TGFBR1 exhibit lesser inter-(simple sequence repeat) PCR genomic instability and present clinically at greater age. 2008 , 645, 27-32	
1982	Breast Cancer. 2008 , 423-429	
1981	Epigenetic gene regulation in cancer. 2008 , 61, 247-67	69
1980	Genetic Mouse Models of Cancer. 2008 , 129-138	

1979	Translational approaches to addressing complex genetic pathways in colorectal cancer. 2008 , 151, 10-6	13
1978	Inherited susceptibility to common cancers. 2008 , 359, 2143-53	379
1977	From cytogenetics to next-generation sequencing technologies: advances in the detection of genome rearrangements in tumors. 2008 , 86, 81-91	28
1976	The consequences of tetraploidy and aneuploidy. 2008 , 121, 3859-66	266
1975	Network-based global inference of human disease genes. 2008 , 4, 189	475
1974	The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. 2008 , 134, 1332-41	135
1973	Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. 2008 , 135, 1358-1368, 1368.e1-4	368
1972	Signalling by the EGF receptor in human cancers: accentuate the positive, eliminate the negative. 2008 , 224-244	1
1971	The utility of conventional and molecular pathology in managing breast cancer. 2008 , 10 Suppl 4, S4	4
1970	Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. 2008 , 10, R26	66
1969	A sequence-based survey of the complex structural organization of tumor genomes. 2008 , 9, R59	30
1968	EGFR Signaling Networks in Cancer Therapy. 2008 ,	7
1967	Pathways to tumorigenesis--modeling mutation acquisition in stem cells and their progeny. 2008 , 10, 1170-82	67
1966	An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. 2008 , 68, 6084-91	806
1965	Cancer proliferation gene discovery through functional genomics. <i>Science</i> , 2008 , 319, 620-4	333 323
1964	Oncogene addiction. 2008 , 68, 3077-80; discussion 3080	718
1963	MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not. 2008 , 98, 1820-3	35
1962	The ADAM metalloproteinases. 2008 , 29, 258-89	810

1961	Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. 2008 , 48, 163-70	200
1960	Properdin: New roles in pattern recognition and target clearance. 2008 , 45, 4048-56	78
1959	Organizing the fluid membrane bilayer: diseases linked to spectrin and ankyrin. 2008 , 14, 28-36	140
1958	About human tumor antigens to be used in immunotherapy. 2008 , 20, 301-7	34
1957	Functional classification analysis of somatically mutated genes in human breast and colorectal cancers. 2008 , 91, 508-11	44
1956	Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. <i>Science</i> , 2008 , 321, 1801-6	333 3223
1955	A new era of cancer therapy: cancer cell targeted therapies are coming of age. 2008 , 40, 1-8	12
1954	Cellular roles of ADAM12 in health and disease. 2008 , 40, 1685-702	133
1953	Telomere instability and cancer. 2008 , 90, 73-82	74
1952	High-content analysis of cancer genome DNA alterations. 2008 , 18, 68-72	13
1951	Functional genomics of cancer. 2008 , 18, 251-6	17
1950	Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene, MLH1. 2008 , 423, 188-93	10
1949	Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. 2008 , 133, 727-41	149
1948	TGFbeta in Cancer. 2008 , 134, 215-30	2821
1947	[Generalities about carcinogenesis]. 2008 , 331, 114-25	2
1946	Nuclear pore composition regulates neural stem/progenitor cell differentiation in the mouse embryo. 2008 , 14, 831-42	132
1945	Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. 2008 , 8, 29-39	75
1944	A critical role for Rac1 in tumor progression of human colorectal adenocarcinoma cells. 2008 , 172, 156-66	47

1943	Molecular Genetics of Pancreatic Cancer. 2008 , 27-39		3
1942	Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. 2008 , 10, 1253-8		56
1941	Advances in chemical carcinogenesis: a historical review and prospective. 2008 , 68, 6863-72		215
1940	Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. <i>Science</i> , 2008 , 321, 1361-5	33-3	124
1939	Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. 2008 , 180, 2011-7; discussion 2017-8		19
1938	Proteinase-activated receptor 2 (PAR-2) in gastrointestinal and pancreatic pathophysiology, inflammation and neoplasia. 2008 , 43, 902-9		18
1937	Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. <i>Science</i> , 2008 , 320, 230-3	33-3	241
1936	Molecular systems biology of ErbB1 signaling: bridging the gap through multiscale modeling and high-performance computing. 2008 , 4, 1151-9		24
1935	Xenobiotic-activated receptors: from transcription to drug metabolism to disease. 2008 , 21, 1651-71		67
1934	Modern cancer drug discovery: integrating targets, technologies and treatments. 2008 , 3-38		3
1933	The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis. 2008 , 105, 9023-8		117
1932	Scanning the human genome at kilobase resolution. 2008 , 18, 751-62		15
1931	Cyclooxygenase-2 Expression in Pretreatment Biopsy as a Predictor of Tumor Responses After Preoperative Chemoradiation in Rectal Cancer Invited Critique. 2008 , 143, 1097		
1930	PP2A regulates HDAC4 nuclear import. 2008 , 19, 655-67		91
1929	A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. 2008 , 105, 19432-7		70
1928	Aurora kinases and their inhibitors: more than one target and one drug. 2008 , 610, 54-73		34
1927	From oncogene to network addiction: the new frontier of cancer genomics and therapeutics. 2008 , 4, 569-77		24
1926	Clonal selection in malignant transformation of human fibroblasts transduced with defined cellular oncogenes. 2008 , 68, 1417-26		18

1925	Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. 2008 , 68, 2841-9	84
1924	RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. 2008 , 68, 7975-84	286
1923	Period 2 mutation accelerates ApcMin/+ tumorigenesis. 2008 , 6, 1786-93	129
1922	Epitope landscape in breast and colorectal cancer. 2008 , 68, 889-92	328
1921	Genetic and epigenetic tumor suppressor gene silencing are distinct molecular phenotypes driven by growth promoting mutations in nonsmall cell lung cancer. 2008 , 2008, 215809	3
1920	Genomic information and the public-private imbalance. 2008 , 32, 71-105	
1919	Somatic mutations to CSMD1 in colorectal adenocarcinomas. 2008 , 7, 609-13	35
1918	HDACs and HDAC inhibitors in colon cancer. 2008 , 3, 28-37	168
1917	Identifying candidate genes involved in brain tumor formation. 2008 , 113, 1-38	13
1916	Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma: defining the pancreatic cancer [corrected] epigenome. 2008 , 7, 1157-9	4
1915	Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. 2008 , 7, 1793-802	101
1914	The 2007 Marie Curie prize: the linear no threshold relationship and advances in our understanding of carcinogenesis. 2008 , 5, 173	14
1913	DNA methylation and cancer pathways in gastrointestinal tumors. 2008 , 9, 1917-28	41
1912	Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. 2008 , 68, 998-1002	69
1911	Estrogen Receptors as Therapeutic Targets in Breast Cancer. 2008 , 127-199	7
1910	Nested Patch PCR enables highly multiplexed mutation discovery in candidate genes. 2008 , 18, 1844-50	49
1909	Molecular profiling in the age of cancer genomics. 2008 , 8, 263-76	8
1908	A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. 2008 , 68, 2592-8	369

1907	Autocrine motility factor receptor: a clinical review. 2008 , 8, 207-17	43
1906	Tamoxifen-stimulated growth of breast cancer due to p21 loss. 2008 , 105, 288-93	77
1905	Unbiased screening for transcriptional targets of ZKSCAN3 identifies integrin beta 4 and vascular endothelial growth factor as downstream targets. 2008 , 283, 35295-304	32
1904	Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. 2008 , 105, 13081-6	283
1903	Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. 2008 , 105, 3443-8	314
1902	Gain and loss of phosphorylation sites in human cancer. 2008 , 24, i241-7	81
1901	A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. 2008 , 105, 9697-702	143
1900	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. 2008 , 105, 3005-10	533
1899	A DNA transposon-based approach to validate oncogenic mutations in the mouse. 2008 , 105, 19904-9	15
1898	Coordinating the initial steps of base excision repair. Apurinic/aprimidinic endonuclease 1 actively stimulates thymine DNA glycosylase by disrupting the product complex. 2008 , 283, 32680-90	76
1897	Clinicopathologic factors identify sporadic mismatch repair-defective colon cancers. 2008 , 129, 238-44	34
1896	Cell competition and its possible relation to cancer. 2008 , 68, 5505-7	61
1895	DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer. 2008 , 36, e49	87
1894	Investigating the fixation and spread of mutations in the gastrointestinal epithelium. 2008 , 4, 825-39	3
1893	Prioritization of candidate cancer genes--an aid to oncogenomic studies. 2008 , 36, e115	27
1892	Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation. 2008 , 9, 349-60	28
1891	Genética y genómica del cáncer. 2008 , 457-480	
1890	Commentary: Novel therapies for cancer: why dirty might be better. 2008 , 13, 277-83	47

1889	Alternative splicing and tumor progression. 2008 , 9, 556-70	134
1888	Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice. 2008 , 65, S15-21; quiz S22-4	11
1887	Defining the blueprint of the cancer genome. 2008 , 29, 1087-91	51
1886	Total number of genome alterations in sporadic gastrointestinal cancer inferred from pooled analyses in the literature. 2008 , 29, 343-50	16
1885	Principles of Molecular Oncology. 2008 ,	1
1884	Myeloid translocation gene family members associate with T-cell factors (TCFs) and influence TCF-dependent transcription. 2008 , 28, 977-87	39
1883	Genetic instability is not a requirement for tumor development. 2008 , 68, 3558-60; discussion 3560-1	58
1882	Modeling cancer progression via pathway dependencies. 2008 , 4, e28	54
1881	Genomic instability and carcinogenesis: an update. 2008 , 9, 535-41	28
1880	Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme. 2008 , 68, 2564-9	43
1879	Introducing new molecular technologies into routine clinical cancer care: is there an impact on the treatment of breast cancer?. 2008 , 19 Suppl 7, vii177-83	3
1878	Role of duplicate genes in robustness against deleterious human mutations. 2008 , 4, e1000014	70
1877	Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing. 2008 , 45, 81-94	322
1876	The quest for the 1p36 tumor suppressor. 2008 , 68, 2551-6	166
1875	Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. 2008 , 68, 8137-45	49
1874	The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. 2008 , 7, 1251-7	30
1873	Tilting at quixotic trait loci (QTL): an evolutionary perspective on genetic causation. 2008 , 179, 1741-56	57
1872	Transcriptome sequencing of malignant pleural mesothelioma tumors. 2008 , 105, 3521-6	126

1871	Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. 2008 , 68, 1707-14	94
1870	Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. 2008 , 68, 10300-6	97
1869	Cellular expression patterns of genes upregulated in murine and human colonic neoplasms. 2008 , 56, 433-41	6
1868	Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. 2008 , 105, 16224-9	230
1867	The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. 2008 , 68, 4321-30	52
1866	A syngeneic variance library for functional annotation of human variation: application to BRCA2. 2008 , 68, 5023-30	59
1865	Comparative lesion sequencing provides insights into tumor evolution. 2008 , 105, 4283-8	616
1864	A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. 2008 , 68, 6727-33	44
1863	Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation. 2008 , 28, 6234-47	56
1862	Genome-wide promoter analysis uncovers portions of the cancer methylome. 2008 , 68, 2661-70	120
1861	Epigenetic signatures of familial cancer are characteristic of tumor type and family category. 2008 , 68, 4597-605	72
1860	Pharmacoeigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response. 2008 , 9, 1903-16	21
1859	Does menopausal hormone therapy initiate new breast cancers or promote the growth of existing ones?. 2008 , 4, 207-10	12
1858	Eph, a protein family coming of age: more confusion, insight, or complexity?. 2008 , 1, re2	118
1857	PTP-Pez: a novel regulator of TGFbeta signaling. 2008 , 7, 2290-5	15
1856	Proliferation of breast cancer cells: regulation, mediators, targets for therapy. 2008 , 8, 872-85	19
1855	Getting a Grip on Signalling Pathways: A Crucial Challenge for Basic Research in Oncology. 2008 , 68, 244-250	
1854	Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. 2008 , 3, 210-5	64

1853	Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. 2008 , 4, 803-14	41
1852	The potential for targeting oncogenic WNT/beta-catenin signaling in therapy. 2008 , 9, 532-47	24
1851	Plasma membrane phospholipid labeling to estimate tumor burden and kinetics. 2008 , 7, 748-9	
1850	The role of histone deacetylases in prostate cancer. 2008 , 3, 300-9	107
1849	Structure and function of the enigmatic Sec14 domain-containing proteins and the etiology of human disease. 2008 , 3, 399-410	16
1848	Colorectal Cancer Prevention. 2008 , 285-294	1
1847	RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. 2008 , 111, 2238-45	62
1846	High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. 2008 , 111, 4788-96	77
1845	Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. 2008 , 111, 4797-808	166
1844	Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. 2008 , 111, 4716-22	67
1843	Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells. 2008 , 112, 721-32	46
1842	Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. <i>Journal of Clinical Investigation</i> , 2008 , 118, 2722-32	15.9 145
1841	Wnt signaling in development, disease and translational medicine. 2008 , 9, 513-31	56
1840	Computational Approaches for Predicting Causal Missense Mutations in Cancer Genome Projects. 2008 , 3, 46-55	5
1839	Identification of genes that exhibit changes in expression on the 8p chromosomal arm by the Systematic Multiplex RT-PCR (SM RT-PCR) and DNA microarray hybridization methods. 2008 , 14, 217-27	9
1838	Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer. 2008 , 143, 1091-7; discussion 1097	17
1837	Sclerosing lobular hyperplasia: an unusual cause of a benign breast mass in young women. 2008 , 40, 97-8	
1836	Stem cells as common ancestors in a colorectal cancer ancestral tree. 2008 , 24, 59-63	16

1835	A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells. 2008 , 18, 73-84	15
1834	Systematic analyses of the cancer genome: lessons learned from sequencing most of the annotated human protein-coding genes. 2008 , 20, 66-71	15
1833	Bibliography. Current world literature. Endocrine tumors and cancer biology. 2008 , 20, 122-43	
1832	Bibliography. Current world literature. Gastrointestinal infections. 2008 , 24, 75-85	
1831	. 2008 ,	2
1830	. 2008 ,	14
1829	Waiting for \$m\$ mutations. 2008 , 13,	26
1828	Testing significance of features by lassoed principal components. 2008 , 2,	16
1827	Ancestral trees for modeling stem cell lineages genetically rather than functionally: understanding mutation accumulation and distinguishing the restrictive cancer stem cell propagation theory and the unrestricted cell propagation theory of human tumorigenesis. 2008 , 29, 15-25	2
1826	Cancer Genomics. 2008 , 267-282	
1825	Cancer Detection and Biomarkers. 143-154	
1824	Generation of small 32P-labeled peptides as a potential approach to colorectal cancer therapy. 2008 , 3, e2508	2
1823	Exon expression arrays as a tool to identify new cancer genes. 2007 , 3, e3007	10
1822	Functional copy-number alterations in cancer. 2008 , 3, e3179	129
1821	Connecting Seed Lists of Mammalian Proteins Using Steiner Trees. 2008 ,	1
1820	Absence of GNAS and EGFL6 mutations in common human cancers. 2008 , 40, 95-7	15
1819	Protein complex, gene, and regulatory modules in cancer heterogeneity. 2008 , 14, 543-5	1
1818	HSP90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways. 2008 , 305-335	1

1817	From Bench to Bedside with Targeted Therapies. 2008 , 521-530	4
1816	. 2009 ,	20
1815	Black Cohosh: Chemopreventive and Anticancer Potential. 2009 , 193-227	1
1814	Divide and conquer: progress in the molecular stratification of cancer. 2009 , 50, 464-73	4
1813	The benefits of oestrogen following menopause: why hormone replacement therapy should be offered to postmenopausal women. 2009 , 190, 321-5	32
1812	Ser/Thr/Tyr protein phosphorylation in the archaeon <i>Halobacterium salinarum</i> --a representative of the third domain of life. 2009 , 4, e4777	69
1811	Altering chemosensitivity by modulating translation elongation. 2009 , 4, e5428	71
1810	Mutator mutations enhance tumorigenic efficiency across fitness landscapes. 2009 , 4, e5860	29
1809	Distinct high-profile methylated genes in colorectal cancer. 2009 , 4, e7012	111
1808	Sequence and structure signatures of cancer mutation hotspots in protein kinases. 2009 , 4, e7485	57
1807	A predictive phosphorylation signature of lung cancer. 2009 , 4, e7994	12
1806	The Cancer Genome. 2009 , 24, 17-22	
1805	Functional genomic screens identify CINP as a genome maintenance protein. 2009 , 106, 19304-9	48
1804	MtDNA mutation pattern in tumors and human evolution are shaped by similar selective constraints. 2009 , 19, 576-80	28
1803	Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. 2009 , 30, 1132-8	60
1802	Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade. 2009 , 284, 35308-13	106
1801	RNAi screen for rapid therapeutic target identification in leukemia patients. 2009 , 106, 8695-700	88
1800	High-throughput, high-accuracy array-based resequencing. 2009 , 106, 6712-7	20

1799	Multiplex padlock targeted sequencing reveals human hypermutable CpG variations. 2009 , 19, 1606-15	59
1798	Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. 2009 , 69, 5901-7	42
1797	Cancer genome sequencing--an interim analysis. 2009 , 69, 4948-50	60
1796	Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. 2009 , 106, 12944-9	143
1795	Role of two strictly conserved residues in nucleotide flipping and N-glycosylic bond cleavage by human thymine DNA glycosylase. 2009 , 284, 36680-36688	44
1794	Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. 2009 , 106, 1886-91	93
1793	Technological challenges of theranostics in oncology. 2009 , 3, 381-93	11
1792	Nuclear oxidative damage correlates with poor survival in colorectal cancer. 2009 , 100, 381-8	36
1791	Molecular classification of solid tumours: towards pathway-driven therapeutics. 2009 , 100, 1517-22	59
1790	Star Graphs of Protein Sequences and Proteome Mass Spectra in Cancer Prediction. 2009 , 6, 275-288	15
1789	Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]. 2009 , 27, 5861-2	42
1788	N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. 2009 , 101, 916-27	157
1787	Protective roles of matrix metalloproteinases: from mouse models to human cancer. 2009 , 8, 3657-62	103
1786	Copy number variation has little impact on bead-array-based measures of DNA methylation. 2009 , 25, 1999-2005	32
1785	Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. 2009 , 69, 4724-32	54
1784	Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. 2009 , 106, 16387-92	67
1783	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. 2009 , 106, 9435-40	196
1782	Organization, Variation and Expression of the Human Genome as a Foundation of Genomic and Personalized Medicine. 2009 , 4-21	7

1781	Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific. 2009 , 11, 414-22	43
1780	Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer. 2009 , 30, 1857-64	34
1779	Circadian time-dependent tumor suppressor function of period genes. 2009 , 8, 309-16	37
1778	Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. 2009 , 69, 7357-65	96
1777	Development of mammary tumors by conditional expression of GLI1. 2009 , 69, 4810-7	90
1776	Critical role of Smad2 in tumor suppression and transforming growth factor-beta-induced apoptosis of prostate epithelial cells. 2009 , 69, 2185-90	52
1775	Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development. 2009 , 69, 678-86	49
1774	Mutant metabolic enzymes are at the origin of gliomas. 2009 , 69, 9157-9	117
1773	Somatic mutations of the CDC4 (FBXW7) gene in hereditary colorectal tumors. 2009 , 76, 430-4	21
1772	Biomarkers in Osteosarcoma. 2009 , 3, 13-23	36
1771	Novel integrative methods for gene discovery associated with head and neck squamous cell carcinoma development. 2009 , 135, 487-95	9
1770	Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis. 2009 , 8, 3319-27	54
1769	Systematically linking drug susceptibility to cancer genome aberrations. 2009 , 8, 3652-6	3
1768	The hematopoietic-specific beta1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression. 2009 , 8, 3914-24	15
1767	Origin of carcinoma associated fibroblasts. 2009 , 8, 589-95	94
1766	Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents. 2009 , 9, 652-74	38
1765	Targeting ADAM12 in human disease: head, body or tail?. 2009 , 15, 2300-10	32
1764	Approaches to biomarkers in human colorectal cancer: looking back, to go forward. 2009 , 3, 385-396	13

1763	Immunological markers of cancer vaccine efficacy and their clinical relevance. 2009 , 3, 253-64	3
1762	Epigenetics of neurological cancers. 2009 , 5, 1615-29	19
1761	Cancer genomes on a shoestring budget. 2009 , 360, 2781-3	4
1760	Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology. 2009 , 13, 291-300	26
1759	Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. 2009 , 8, 2432-40	78
1758	Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. 2009 , 16, 66-93	228
1757	Urgent need to develop independent biomarkers for functional, diagnostic and prognostic application in oncology research. 2009 , 3, 329-33	6
1756	HistoneHits: a database for histone mutations and their phenotypes. 2009 , 19, 674-81	42
1755	Adenomatous polyposis coli and Asef function downstream of hepatocyte growth factor and phosphatidylinositol 3-kinase. 2009 , 284, 22436-22443	21
1754	A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. 2009 , 5, e1000640	20
1753	A preliminary operational classification system for nonmutagenic modes of action for carcinogenesis. 2009 , 39, 97-138	23
1752	MoKCa database--mutations of kinases in cancer. 2009 , 37, D824-31	45
1751	Multipeptide vaccination in cancer patients. 2009 , 9, 1043-55	48
1750	Beta-catenin induces beta-TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice. 2009 , 145, 289-97	54
1749	Recognition of live phosphatidylserine-labeled tumor cells by dendritic cells: a novel approach to immunotherapy of skin cancer. 2009 , 69, 2487-96	9
1748	Hedgehog signalling in breast cancer. 2009 , 30, 903-11	117
1747	Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. 2009 , 5, e1000487	63
1746	Exploiting synthetic lethal interactions for targeted cancer therapy. 2009 , 8, 3112-9	87

1745	Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. 2009 , 15, 758-61	67
1744	Emerging roles of the EBF family of transcription factors in tumor suppression. 2009 , 7, 1893-901	63
1743	Mutation patterns in cancer genomes. 2009 , 106, 21766-70	62
1742	Immune rejection of mouse tumors expressing mutated self. 2009 , 69, 3545-53	14
1741	Down-regulation of Rap1GAP via promoter hypermethylation promotes melanoma cell proliferation, survival, and migration. 2009 , 69, 449-57	64
1740	Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer. 2009 , 69, 4926-34	66
1739	The forest and the trees: pathways and proteins as colorectal cancer biomarkers. 2009 , 27, 5866-7	8
1738	MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. 2009 , 69, 7803-10	56
1737	Integrated analysis of genetic and epigenetic alterations in cancer. 2009 , 1, 291-9	3
1736	Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. 2009 , 8, 2172-82	45
1735	A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. 2009 , 2, 270-8	199
1734	Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. <i>Science</i> , 2009 , 325, 1261-5	33-3 177
1733	IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. 2009 , 11, 341-7	435
1732	Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: a potential mechanism promoting human cancer. 2009 , 284, 18840-50	25
1731	An alternative approach to medical genetics based on modern evolutionary biology. Part 1: mutation and symbiogenesis. 2009 , 102, 272-7	5
1730	Loss of histone deacetylase 4 causes segregation defects during mitosis of p53-deficient human tumor cells. 2009 , 69, 6074-82	33
1729	Clock genes and cancer. 2009 , 8, 303-8	75
1728	A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. 2009 , 106, 3964-9	234

1727	Mammalian Rif1 contributes to replication stress survival and homology-directed repair. 2009 , 187, 385-98	101
1726	An interstitial deletion at 3p21.3 results in the genetic fusion of MLH1 and ITGA9 in a Lynch syndrome family. 2009 , 15, 762-9	12
1725	Automated inference of molecular mechanisms of disease from amino acid substitutions. 2009 , 25, 2744-50	580
1724	ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. 2009 , 7, 79-87	94
1723	A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. 2009 , 106, 8513-8	148
1722	Genetic pathways to colorectal cancer. 2009 , 670, 96-8	11
1721	XPC is involved in genome maintenance through multiple pathways in different tissues. 2009 , 670, 24-31	8
1720	Outcome of a workshop on applications of protein models in biomedical research. 2009 , 17, 151-9	102
1719	Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist. 2009 , 18, 31-50	53
1718	Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. 2009 , 240, 355-66	27
1717	Deciphering the genetic landscape of cancer--from genes to pathways. 2009 , 25, 455-62	30
1716	Common gene signature of cancer and longevity. 2009 , 130, 33-9	48
1715	Analyses of domains and domain fusions in human proto-oncogenes. 2009 , 10, 88	4
1714	A voting approach to identify a small number of highly predictive genes using multiple classifiers. 2009 , 10 Suppl 1, S19	5
1713	Extraction of human kinase mutations from literature, databases and genotyping studies. 2009 , 10 Suppl 8, S1	30
1712	Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. 2009 , 9, 374	201
1711	BRICHOS - a superfamily of multidomain proteins with diverse functions. 2009 , 2, 180	64
1710	Cancer gene discovery in mouse and man. 2009 , 1796, 140-61	8

1709	Models for prevention and treatment of cancer: problems vs promises. 2009 , 78, 1083-94	117
1708	Regulation of protein kinase C isozymes during early postnatal hippocampal development. 2009 , 1288, 29-41	15
1707	Nrf2-dependent sulfiredoxin-1 expression protects against cigarette smoke-induced oxidative stress in lungs. 2009 , 46, 376-86	97
1706	Cancer-causing karyotypes: chromosomal equilibria between destabilizing aneuploidy and stabilizing selection for oncogenic function. 2009 , 188, 1-25	46
1705	Low frequency of MLL3 mutations in colorectal carcinoma. 2009 , 189, 140-1	6
1704	Chromosomal changes in aggressive breast cancers with basal-like features. 2009 , 193, 29-37	36
1703	Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. 2009 , 15, 124-34	523
1702	Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. 2009 , 15, 441-53	89
1701	Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 2009 , 625, 6-22	18
1700	Computational prediction of the functional effects of amino acid substitutions in signal peptides using a model-based approach. 2009 , 30, 99-106	19
1699	IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. 2009 , 30, 7-11	320
1698	Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. 2009 , 30, 1167-74	34
1697	A gene-alteration profile of human lung cancer cell lines. 2009 , 30, 1199-206	100
1696	The role of Eph receptors and ephrin ligands in colorectal cancer. 2010 , 126, 2003-11	67
1695	Prostate cancer regulatory networks. 2009 , 107, 845-52	31
1694	Genetic signature for human risk assessment: lessons from trichloroethylene. 2009 , 50, 68-77	12
1693	Impact of inorganic nutrients on maintenance of genomic stability. 2009 , 50, 349-60	23
1692	Integrative approach for prioritizing cancer genes in sporadic colon cancer. 2009 , 48, 953-62	42

1691	Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. 2009 , 48, 1077-92	26
1690	Large gradient high magnetic field affects the association of MACF1 with actin and microtubule cytoskeleton. 2009 , 30, 545-55	45
1689	DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis. 2009 , 135, 567-80	2
1688	Mutational spectra of human cancer. 2009 , 125, 493-506	143
1687	Analytical methods for inferring functional effects of single base pair substitutions in human cancers. 2009 , 126, 481-98	17
1686	Multi-target QPDR classification model for human breast and colon cancer-related proteins using star graph topological indices. 2009 , 257, 303-11	56
1685	The pace of evolution across fitness valleys. 2009 , 259, 613-20	33
1684	Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. 2009 , 117, 423-31	114
1683	Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. 2009 , 28, 77-83	85
1682	Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. 2009 , 54, 2109-17	90
1681	Cell signaling via the P2X(7) nucleotide receptor: linkage to ROS production, gene transcription, and receptor trafficking. 2009 , 5, 175-87	36
1680	Ageing and cancer as diseases of epigenesis. 2009 , 34, 601-4	26
1679	Design of artificial nucleases and studies of their interaction with DNA. 2009 , 52, 402-414	18
1678	Preparing a re-sequencing DNA library of 2 cancer candidate genes using the ligation-by-amplification protocol by two PCR reactions. 2009 , 52, 483-91	2
1677	Genexpressionsprofile in der onkologischen Diagnostik. 2009 , 2, 44-52	
1676	Molecular classes of breast cancer and their clinical relevance. 2009 , 1, 183-189	
1675	A novel mechanism for inflammation-associated carcinogenesis; an important role of activation-induced cytidine deaminase (AID) in mutation induction. 2009 , 87, 1023-7	25
1674	Targeted next-generation sequencing by specific capture of multiple genomic loci using low-volume microfluidic DNA arrays. 2009 , 393, 171-5	48

1673	Basic principles and technologies for deciphering the genetic map of cancer. 2009 , 33, 615-29	12
1672	Sequencing the full-length of the phosphatase and tensin homolog (PTEN) gene in hepatocellular carcinoma (HCC) using the 454 GS20 and Illumina GA DNA sequencing platforms. 2009 , 33, 647-52	5
1671	Developing a tissue resource to characterize the genome of pancreatic cancer. 2009 , 33, 723-31	9
1670	Cancer-associated mutations are preferentially distributed in protein kinase functional sites. 2009 , 77, 892-903	25
1669	Older individuals appear to acquire mitotically older colorectal cancers. 2009 , 217, 483-8	7
1668	The haematopoietic specific signal transducer Vav1 is aberrantly expressed in lung cancer and plays a role in tumourigenesis. 2009 , 219, 25-34	49
1667	Function, regulation and pathological roles of the Gab/DOS docking proteins. 2009 , 7, 22	124
1666	High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. 2009 , 2, 21	71
1665	Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line. 2009 , 2, 26	7
1664	NMD inhibition fails to identify tumour suppressor genes in microsatellite stable gastric cancer cell lines. 2009 , 2, 39	4
1663	Discovering cancer genes by integrating network and functional properties. 2009 , 2, 61	30
1662	Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. 2009 , 90, 558-74	56
1661	From cancer genomes to cancer models: bridging the gaps. 2009 , 10, 359-66	29
1660	High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia. 2009 , 23, 406-9	14
1659	Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation. 2009 , 23, 1345-8	4
1658	The cancer genome. 2009 , 458, 719-24	2272
1657	Targeted capture and massively parallel sequencing of 12 human exomes. 2009 , 461, 272-6	1573
1656	Microdroplet-based PCR enrichment for large-scale targeted sequencing. 2009 , 27, 1025-31	373

1655	Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development. 2009 , 16, 807-9	69
1654	Targeted sequencing with microfluidics. 2009 , 27, 998-9	18
1653	Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. 2009 , 5, 100-7	1095
1652	Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. 2009 , 41, 518-20	131
1651	Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. 2009 , 41, 1127-32	284
1650	High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. 2009 , 9, 389-99	102
1649	When mutants gain new powers: news from the mutant p53 field. 2009 , 9, 701-13	803
1648	Integrative biology--a strategy for systems biomedicine. 2009 , 10, 64-8	10
1647	Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. 2009 , 28, 2969-78	89
1646	A study of pyrimidine base damage in relation to oxidative stress and cancer. 2009 , 101, 452-6	17
1645	Reduced FAS transcription in clones of U937 cells that have acquired resistance to Fas-induced apoptosis. 2009 , 276, 497-508	5
1644	Investigation and prediction of the severity of p53 mutants using parameters from structural calculations. 2009 , 276, 4142-55	12
1643	Evolutionary theory of cancer. 2009 , 1168, 23-51	80
1642	Specific sequence selection and next generation resequencing of 68 E. coli genes using HybSelect. 2009 , 26, 229-33	10
1641	A network-QSAR model for prediction of genetic-component biomarkers in human colorectal cancer. 2009 , 261, 449-58	62
1640	Antigen choice in adoptive T-cell therapy of cancer. 2009 , 21, 190-9	36
1639	Dendritic cells from bench to bedside and back. 2009 , 122, 128-30	76
1638	Mitochondrial kinases in cell signaling: Facts and perspectives. 2009 , 61, 1234-49	37

1637	Immunochemical and molecular-Genetic markers in diagnostics of gastric cancer. 2009 , 3, 33-43	
1636	Commercial high-throughput sequencing and its applications in DNA analysis. 2009 , 64, 20-26	3
1635	KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. 2009 , 8, 834-43	127
1634	Identifying Candidate Cancer Genes Based on Their Somatic Mutations Co-Occurring with Cancer Genes in Cancer Genome Profiling. 2009 ,	
1633	Pharmaceutical Perspectives of Cancer Therapeutics. 2009 ,	11
1632	The promises and pitfalls of epigenetic therapies in solid tumours. 2009 , 45, 1129-1136	78
1631	Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. 2009 , 71, 409-19	944
1630	Use of DNA methylation for cancer detection: promises and challenges. 2009 , 41, 147-54	43
1629	HDAC family: What are the cancer relevant targets?. 2009 , 277, 8-21	761
1628	Cancer driver mutations in protein kinase genes. 2009 , 281, 117-27	65
1627	Principles of cancer therapy: oncogene and non-oncogene addiction. 2009 , 136, 823-37	1328
1626	Evolutionary divergence of enzymatic mechanisms for posttranslational polyglycylation. 2009 , 137, 1076-87	103
1625	Integrative genomic approaches to understanding cancer. 2009 , 1790, 478-84	6
1624	Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells. 2009 , 390, 60-4	9
1623	A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. 2009 , 390, 547-51	90
1622	Development of novel agents for ovarian cancer. 2009 , 3, 119-132	5
1621	Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. 2009 , 20, 869-76	349
1620	Design and analysis issues in genome-wide somatic mutation studies of cancer. 2009 , 93, 17-21	75

1619	Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. 2009 , 40, 714-25	51
1618	Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis. 2009 , 40, 1418-26	39
1617	Oxidative stress in environmental-induced carcinogenesis. 2009 , 674, 36-44	254
1616	Improving prediction of chemical carcinogenicity by considering multiple mechanisms and applying toxicogenomic approaches. 2009 , 681, 230-240	64
1615	Molecular origins of cancer: Molecular basis of colorectal cancer. 2009 , 361, 2449-60	1331
1614	Proteomic methodologies and their application in colorectal cancer research. 2009 , 46, 319-42	17
1613	Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. 2009 , 96, 858-74	39
1612	Tumor-Targeted Macromolecular Drug Delivery Based on the Enhanced Permeability and Retention Effect in Solid Tumor. 2009 , 93-120	11
1611	Histamine pharmacogenomics. 2009 , 10, 867-83	60
1610	Recurring mutations found by sequencing an acute myeloid leukemia genome. 2009 , 361, 1058-66	1765
1609	Human tumor xenografts and mouse models of human tumors: re-discovering the models. 2009 , 4, 1295-305	9
1608	Next-generation sequencing of cancer genomes: back to the future. 2009 , 6, 653	20
1607	Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. 2009 , 113, 2022-7	58
1606	Knowledge driven decomposition of tumor expression profiles. 2009 , 10 Suppl 1, S20	1
1605	IDH1 and IDH2 mutations in gliomas. 2009 , 360, 765-73	4220
1604	The circadian clock gene Per1 suppresses cancer cell proliferation and tumor growth at specific times of day. 2009 , 26, 1323-39	88
1603	Genome and proteome annotation: organization, interpretation and integration. 2009 , 6, 129-47	36
1602	Methods for genomic partitioning. 2009 , 10, 263-84	98

1601	The MEN1 gene and pituitary tumours. 2009 , 71 Suppl 2, 131-8	30
1600	Glutathione, Sulfur Amino Acids, and Cancer. 471-500	
1599	Encyclopedia of Cancer. 2008 , 1764-1764	
1598	The breast cancer somatic 'muta-ome': tackling the complexity. 2009 , 11, 301	21
1597	Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death. 2009 , 11, R2	11
1596	Breast Cancer. 2009 , 659-686	1
1595	A decade of cancer gene profiling: from molecular portraits to molecular function. 2010 , 576, 61-87	9
1594	Textbook of Personalized Medicine. 2009 ,	55
1593	[Epigenetic changes and cancer]. 2009 , 29 Spec No 1, S17-8	
1592	Family cancer syndromes: inherited deficiencies in systems for the maintenance of genomic integrity. 2009 , 18, 1-17, vii	2
1591	KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. 2009 , 27, 1130-6	188
1590	New frontiers in cell-based immunotherapy of cancer. 2009 , 19, 623-41	9
1589	Insights into gliomagenesis: systems biology unravels key pathways. 2009 , 1, 101	1
1588	Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. 2009 , 113, 1315-25	336
1587	Bacterial infection of Smad3/Rag2 double-null mice with transforming growth factor-beta dysregulation as a model for studying inflammation-associated colon cancer. 2009 , 174, 317-29	33
1586	Triple negative breast cancers: clinical and prognostic implications. 2009 , 45 Suppl 1, 27-40	173
1585	Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. 2009 , 69, 6660-7	344
1584	Lack of inherited mutations of PTPRD in familial melanoma and melanoma-astrocytoma syndrome. 2009 , 22, 489-91	5

1583	Molecular pathways in tumor progression: from discovery to functional understanding. 2009 , 5, 902-8	26
1582	Applications of genomics in melanoma oncogene discovery. 2009 , 23, 397-414, vii	21
1581	Epigenetic modifiers: basic understanding and clinical development. 2009 , 15, 3918-26	120
1580	Cancer genome sequencing: a review. 2009 , 18, R163-8	154
1579	KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. 2009 , 15, 110-3	26
1578	Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma. 2009 , 249, 440-7	74
1577	Why is modern medicine stuck in a rut?. 2009 , 52, 500-17	15
1576	.	
1575	Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer. 2009 , 19, 513-25	17
1574	P-REX2a driving tumorigenesis by PTEN inhibition. 2009 , 2, pe68	6
1573	The intracellular interactions of the L1 family of cell adhesion molecules. 2009 , 419, 519-31	40
1572	High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. 2009 , 113, 1749-55	97
1571	C-terminal ADAMTS-18 fragment induces oxidative platelet fragmentation, dissolves platelet aggregates, and protects against carotid artery occlusion and cerebral stroke. 2009 , 113, 6051-60	45
1570	Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. 2009 , 114, 589-95	925
1569	Global reduction of the epigenetic H3K79 methylation mark and increased chromosomal instability in CALM-AF10-positive leukemias. 2009 , 114, 651-8	51
1568	Molecular genetics of gastroenteropancreatic neuroendocrine tumors. 2009 , 21, 29-33	34
1567	Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. 2009 , 9, 963-81	85
1566	Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer. 2009 , 38, e200-6	16

1565	Hedgehog signaling in the normal and neoplastic mammary gland. 2010 , 11, 1103-11	20
1564	Discovering tumor suppressor genes through genome-wide copy number analysis. 2010 , 11, 297-310	15
1563	A Bioinformatics Pipeline for Cancer Epigenetics. 2010 , 5, 153-163	2
1562	Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer. 2010 , 251, 275-80	41
1561	Artificial intelligence techniques for colorectal cancer drug metabolism: ontology and complex network. 2010 , 11, 347-68	42
1560	Bone morphogenetic proteins and cancer: review of the literature. 2010 , 66, 233-46; discussion 246	131
1559	Human variation databases. 2010 , 2010, baq015	17
1558	Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights. 2010 , 427, 225-36	23
1557	The Role of Flavonoids in Fruits and Vegetables Related to Breast Cancer Prevention. 2010 , 399-412	
1556	RalGDS family members couple Ras to Ral signalling and that's not all. 2010 , 22, 1804-10	59
1555	Personalized medicine: marking a new epoch in cancer patient management. 2010 , 8, 1175-87	125
1554	Recent advances in histone deacetylase targeted cancer therapy. 2010 , 40, 809-15	40
1553	Chronotherapy and the molecular clock: Clinical implications in oncology. 2010 , 62, 979-1001	118
1552	Indirect mechanisms of carcinogenesis via downregulation of PTEN function. 2010 , 50, 112-8	12
1551	Profiling the cancer genome. 2010 , 11, 133-59	36
1550	Emerging roles for WNK kinases in cancer. 2010 , 67, 1265-76	68
1549	Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. 2010 , 88, 1095-100	19
1548	Novel naphthalimide/indomethacin hybrids as potential antitumor agents: effects of linkers on hypoxic/oxic cytotoxicity and apoptosis-inducing activity. 2010 , 141, 893-899	7

1547	A law of mutation: power decay of small insertions and small deletions associated with human diseases. 2010 , 162, 321-8	4
1546	A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. 2010 , 6, 129-51	170
1545	Biomarkers in colorectal cancer: the future is getting closer. 2010 , 12, 241-2	2
1544	The Role of Circadian Rhythm in the Pathogenesis of Colorectal Cancer. 2010 , 6, 74-82	8
1543	Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. 2010 , 121, 53-64	207
1542	Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. 2010 , 29, 73-93	39
1541	DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability. 2010 , 29, 655-76	33
1540	Genotype to phenotype: analyzing the effects of inherited mutations in colorectal cancer families. 2010 , 693, 32-45	44
1539	Detection of genetic alterations in hereditary colorectal cancer screening. 2010 , 693, 19-31	29
1538	A quantitative analysis of genomic instability in lymphoid and plasma cell neoplasms based on the PIG-A gene. 2010 , 686, 1-8	12
1537	Colorectal cancer. 2010 , 693, 1-2	
1536	An "Omics" based survey of human colon cancer. 2010 , 693, 3-18	56
1535	DNA fingerprinting techniques for the analysis of genetic and epigenetic alterations in colorectal cancer. 2010 , 693, 61-76	15
1534	Toxicogenomic profiling of chemically exposed humans in risk assessment. 2010 , 705, 172-83	51
1533	Therapeutic targeting of p53 by small molecules. 2010 , 20, 46-56	67
1532	Lethal mutagenesis: targeting the mutator phenotype in cancer. 2010 , 20, 353-9	61
1531	Disruption of Smad-dependent signaling for growth of GST-P-positive lesions from the early stage in a rat two-stage hepatocarcinogenesis model. 2010 , 246, 128-40	14
1530	Functional modules, mutational load and human genetic disease. 2010 , 26, 168-76	81

1529	Statistical method on nonrandom clustering with application to somatic mutations in cancer. 2010 , 11, 11	46
1528	PETALS: Proteomic Evaluation and Topological Analysis of a mutated Locus' Signaling. 2010 , 11, 596	8
1527	Extracting consistent knowledge from highly inconsistent cancer gene data sources. 2010 , 11, 76	41
1526	A simple algebraic cancer equation: calculating how cancers may arise with normal mutation rates. 2010 , 10, 3	40
1525	Distinguishing between cancer driver and passenger gene alteration candidates via cross-species comparison: a pilot study. 2010 , 10, 426	17
1524	Aggressive mammary carcinoma progression in Nrf2 knockout mice treated with 7,12-dimethylbenz[a]anthracene. 2010 , 10, 540	52
1523	Multi-level reproducibility of signature hubs in human interactome for breast cancer metastasis. 2010 , 4, 151	30
1522	Mechanisms of chromosomal instability. 2010 , 20, R285-95	368
1521	Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. 2010 , 1803, 3-19	348
1520	Hedgehog beyond medulloblastoma and basal cell carcinoma. 2010 , 1805, 181-208	246
1519	Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. 2010 , 79, 130-6	89
1518	Analysis of the frequency of GNAS codon 201 mutations in advanced colorectal cancer. 2010 , 202, 67-9	17
1517	The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. 2010 , 17, 225-34	1473
1516	Integrative genomic profiling of human prostate cancer. 2010 , 18, 11-22	2666
1515	Cytokinesis and cancer. 2010 , 584, 2652-61	78
1514	Heterochromatin DNA replication and Rif1. 2010 , 316, 1907-13	5
1513	Generation, function, and prognostic utility of somatic mitochondrial DNA mutations in cancer. 2010 , 51, 427-39	18
1512	Decoding the evolution of a breast cancer genome. 2010 , 2, 3-5	2

1511	Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. 2010 , 2, 146-58	333
1510	A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. 2010 , 49, 342-52	58
1509	CanProVar: a human cancer proteome variation database. 2010 , 31, 219-28	55
1508	In silico functional profiling of human disease-associated and polymorphic amino acid substitutions. 2010 , 31, 335-46	55
1507	Inferring the functional effects of mutation through clusters of mutations in homologous proteins. 2010 , 31, 264-71	38
1506	Evidence linking CD44-positive cells and gemcitabine resistance in pancreatic cancer cells: need for further substantiation. 2010 , 127, 246-7	1
1505	IDH1 and IDH2 hotspot mutations are not found in canine glioma. 2010 , 127, 245-6	26
1504	Somatic mutations and germline sequence variants in patients with familial colorectal cancer. 2010 , 127, 2974-80	24
1503	Identification and functional relevance of de novo DNA methylation in cancerous B-cell populations. 2010 , 109, 818-27	11
1502	H. pylori Infection □The Route from Inflammation to Cancer. 31-41	
1501	Metalloproteinases and their regulators in colorectal cancer. 2010 , 101, 259-69	22
1500	Tumor classification by combining PNN classifier ensemble with neighborhood rough set based gene reduction. 2010 , 40, 179-89	69
1499	Multiplex parallel pair-end-ditag sequencing approaches in system biology. 2010 , 2, 224-234	3
1498	In silico models of cancer. 2010 , 2, 438-459	81
1497	Our changing view of the genomic landscape of cancer. 2010 , 220, 231-43	64
1496	The Sir Hans Krebs Lecture. How a lipid mediates tumour suppression. Delivered on 29 June 2010 at the 35th FEBS Congress in Gothenburg, Sweden. 2010 , 277, 4837-48	8
1495	DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. 2010 , 56, 167-79	162
1494	Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. 2010 , 29, 635-46	104

1493	Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. 2010 , 29, 2337-45	40
1492	Array-based genomic resequencing of human leukemia. 2010 , 29, 3723-31	211
1491	Nek7 kinase targeting leads to early mortality, cytokinesis disturbance and polyploidy. 2010 , 29, 4046-57	52
1490	The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways. 2010 , 29, 4567-75	73
1489	TGF β signaling in head and neck squamous cell carcinoma. 2010 , 29, 5437-46	78
1488	Analysis of the genome to personalize therapy for melanoma. 2010 , 29, 5545-55	105
1487	Cancer-associated IDH mutations: biomarker and therapeutic opportunities. 2010 , 29, 6409-17	221
1486	Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. 2010 , 102, 1636-44	127
1485	Rif1 provides a new DNA-binding interface for the Bloom syndrome complex to maintain normal replication. 2010 , 29, 3140-55	77
1484	Signatures of mutation and selection in the cancer genome. 2010 , 463, 893-8	538
1483	Genome remodelling in a basal-like breast cancer metastasis and xenograft. 2010 , 464, 999-1005	935
1482	Diverse somatic mutation patterns and pathway alterations in human cancers. 2010 , 466, 869-73	1003
1481	Big science: The cancer genome challenge. 2010 , 464, 972-4	73
1480	PtdIns(3)P controls cytokinesis through KIF13A-mediated recruitment of FYVE-CENT to the midbody. 2010 , 12, 362-71	169
1479	Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. 2010 , 42, 229-33	305
1478	Finding the tumor copycat. Therapy fails, patients don't. 2010 , 16, 974-5	88
1477	Targeting the cancer kinome through polypharmacology. 2010 , 10, 130-7	542
1476	Eph receptors and ephrins in cancer: bidirectional signalling and beyond. 2010 , 10, 165-80	864

1475	Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. 2010 , 10, 669-82	206
1474	Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. 2010 , 10, 842-57	529
1473	Advances in understanding cancer genomes through second-generation sequencing. 2010 , 11, 685-96	890
1472	Genomic instability--an evolving hallmark of cancer. 2010 , 11, 220-8	1393
1471	Intratumoral patterns of genomic imbalance in glioblastomas. 2010 , 20, 936-44	52
1470	Tumor antigen presentation by dendritic cells. 2010 , 30, 345-86	44
1469	The Roles of Ras Family Small GTPases in Breast Cancer. 2010 , 2763-2772	1
1468	Assessing molecular variability in cancer genomes. 91-112	2
1467	Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. 2010 , 3, 2411-2469	49
1466	Distinct genetic alterations in colorectal cancer. 2010 , 5, e8879	93
1465	Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. 2010 , 5, e11408	73
1464	Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas. 2010 , 5, e12653	11
1463	A network of cancer genes with co-occurring and anti-co-occurring mutations. 2010 , 5, e13180	26
1462	Intratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells. 2010 , 5, e13623	13
1461	Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer. 2010 , 5, e15094	15
1460	Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. 2010 , 5, e15661	169
1459	SH2 Domain-Containing Protein-Tyrosine Phosphatases. 2010 , 771-809	13
1458	Targeting Ras for Anticancer Drug Discovery. 2010 , 2837-2857	

1457	Targeting genetic instability in cancer cells. 2010 , 11, 1293-5	
1456	PTP1B regulates Eph receptor function and trafficking. 2010 , 191, 1189-203	55
1455	The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer. 2010 , 16, 2275-83	57
1454	The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. 2010 , 24, 4153-66	204
1453	Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H. 2010 , 20, 1188-200	90
1452	[Search for new genes involved in breast tumorigenesis by "Omics" analysis]. 2010 , 97, 1365-80	
1451	Protein microarrays for cancer diagnostics and therapy. 2010 , 19, 247-54	13
1450	A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. 2010 , 70, 2158-64	67
1449	Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. 2010 , 3, 1427-34	72
1448	Myeloid translocation gene 16 (MTG16) interacts with Notch transcription complex components to integrate Notch signaling in hematopoietic cell fate specification. 2010 , 30, 1852-63	22
1447	Clinical implications of the cancer genome. 2010 , 28, 5219-28	156
1446	Mammalian TIMELESS is required for ATM-dependent CHK2 activation and G2/M checkpoint control. 2010 , 285, 3030-4	67
1445	Tyrosine residues at the carboxyl terminus of Vav1 play an important role in regulation of its biological activity. 2010 , 285, 23075-85	18
1444	Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing. 2010 , 24, 2612-9	25
1443	Inferring tumor progression from genomic heterogeneity. 2010 , 20, 68-80	371
1442	DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions. 2010 , 3, 190-201	32
1441	Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?. 2010 , 16, 5972-80	98
1440	Androgen regulates ADAMTS15 gene expression in prostate cancer cells. 2010 , 28, 698-710	10

1439	Molecular evolutionary analysis of cancer cell lines. 2010 , 9, 279-91	8
1438	Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers. 2010 , 16, 2131-7	38
1437	Voltage-gated Na ⁺ channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion. 2010 , 70, 6957-67	182
1436	Expression of the tumor suppressor Krüppel-like factor 4 as a prognostic predictor for colon cancer. 2010 , 19, 2631-8	52
1435	Primary cilia are decreased in breast cancer: analysis of a collection of human breast cancer cell lines and tissues. 2010 , 58, 857-70	118
1434	Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. 2010 , 31, 208-15	65
1433	Making sense of missense in Lynch syndrome: the clinical perspective. 2010 , 3, 1371-4	8
1432	Adrenergic signaling polymorphisms and their impact on cardiovascular disease. 2010 , 90, 1013-62	62
1431	A role for KAI1 in promotion of cell proliferation and mammary gland hyperplasia by the gp78 ubiquitin ligase. 2010 , 285, 8830-9	28
1430	Drug Discovery in Pancreatic Cancer. 2010 ,	
1429	Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesion. 2010 , 30, 3262-74	42
1428	S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis. 2010 , 2, 19ra13	105
1427	Development of personalized tumor biomarkers using massively parallel sequencing. 2010 , 2, 20ra14	401
1426	Analysis of next-generation genomic data in cancer: accomplishments and challenges. 2010 , 19, R188-96	102
1425	COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. 2010 , 38, D652-7	450
1424	DNA sequence capture and enrichment by microarray followed by next-generation sequencing for targeted resequencing: neurofibromatosis type 1 gene as a model. 2010 , 56, 62-72	54
1423	Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. 2010 , 13, 1627-37	147
1422	Molecular target class is predictive of in vitro response profile. 2010 , 70, 3677-86	101

1421	Characterization of LRRFIP1. 2010 , 88, 899-906	17
1420	Global reactivation of epigenetically silenced genes in prostate cancer. 2010 , 3, 1084-92	35
1419	Memory T Cells. 2010 ,	1
1418	Population genetics meets cancer genomics. 2010 , 107, 18241-2	4
1417	Systematic interpretation of comutated genes in large-scale cancer mutation profiles. 2010 , 9, 2186-95	11
1416	Advances in translational bioinformatics: computational approaches for the hunting of disease genes. <i>Briefings in Bioinformatics</i> , 2010 , 11, 96-110	13.4 66
1415	Systems Pharmacology in Cancer. 2010 , 377-397	
1414	Oncogenic mutations of PIK3CA in human cancers. 2010 , 347, 21-41	164
1413	Comprehensive mapping of the human kinome to epidermal growth factor receptor signaling. 2010 , 285, 21134-42	28
1412	Liver cytochrome P450 3A ubiquitination in vivo by gp78/autocrine motility factor receptor and C terminus of Hsp70-interacting protein (CHIP) E3 ubiquitin ligases: physiological and pharmacological relevance. 2010 , 285, 35866-77	24
1411	The role of SnoN in transforming growth factor beta1-induced expression of metalloprotease-disintegrin ADAM12. 2010 , 285, 21969-77	30
1410	Cell selection as driving force in lung and colon carcinogenesis. 2010 , 70, 6797-803	29
1409	Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. 2010 , 70, 1389-97	74
1408	Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence. 2010 , 285, 11326-35	27
1407	Genome-wide association study for colorectal cancer identifies risk polymorphisms in German familial cases and implicates MAPK signalling pathways in disease susceptibility. 2010 , 31, 1612-9	48
1406	An integrative -omics approach to identify functional sub-networks in human colorectal cancer. 2010 , 6, e1000639	129
1405	Colorectal adenomas and cancer link to chromosome 13q22.1-13q31.3 in a large family with excess colorectal cancer. 2010 , 47, 692-9	13
1404	ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. 2010 , 19, 245-50	64

1403	Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. 2010 , 9, 336-46	295
1402	Spi-1/PU.1 oncogene accelerates DNA replication fork elongation and promotes genetic instability in the absence of DNA breakage. 2010 , 70, 6757-66	21
1401	Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. 2010 , 163, 747-55	69
1400	Fine architecture and mutation mapping of human brain inhibitory system ligand gated ion channels by high-throughput homology modeling. 2010 , 80, 117-52	8
1399	Targeted deep resequencing of the human cancer genome using next-generation technologies. 2010 , 27, 135-58	10
1398	A growing family: adding mutated Erbb4 as a novel cancer target. 2010 , 9, 1487-503	30
1397	Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). 2010 , 10, 582-7	70
1396	Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. 2010 , 8, 1513-25	41
1395	Extracting multi-function features for cancer genes. 2010 ,	
1394	Circadian rhythms and cancer. 2010 , 9, 1097-103	100
1393	Identification of high-quality cancer prognostic markers and metastasis network modules. <i>Nature Communications</i> , 2010 , 1, 34	17.4 228
1392	The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. 2010 , 23, 1477-85	158
1391	Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. 2010 , 9, 2365-76	146
1390	Multiple tumor-suppressor genes on chromosome 3p contribute to head and neck squamous cell carcinoma tumorigenesis. 2010 , 10, 689-93	17
1389	NHERF1/EBP50 is a new marker in colorectal cancer. 2010 , 12, 1013-22	64
1388	A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. 2010 , 12, 499-505	28
1387	Tgf-beta signaling alterations and colon cancer. 2010 , 155, 85-103	106
1386	Targeted exon sequencing by in-solution hybrid selection. 2010 , Chapter 18, Unit 18.4	37

1385	The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. 2010 , 19, 1049-66	212
1384	Making Mountains out of Molehills: Moving from Single Gene to Pathway Based Models of Colon Cancer Progression. 2010 , 73-87	
1383	The Genetics of Colorectal Cancer. 2010 , 65-100	
1382	Nonrandom Chromosome Abnormalities in Cancer—An Overview. 2010 , 25-43	4
1381	Molecular basis for therapy resistance. 2010 , 4, 284-300	36
1380	Whole genome sequencing. 2010 , 628, 215-26	116
1379	Krüppel-like factor 5 is a crucial mediator of intestinal tumorigenesis in mice harboring combined ApcMin and KRASV12 mutations. 2010 , 9, 63	42
1378	IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. 2010 , 28, 3636-43	615
1377	Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. 2010 , 138, 1429-40	228
1376	Molecular detection of colorectal neoplasia. 2010 , 138, 2127-39	105
1375	Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. 2010 , 138, 2357-67	105
1374	F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor. 2010 , 139, 929-41	101
1373	Novel candidate cancer genes identified by a large-scale cross-species comparative oncogenomics approach. 2010 , 70, 883-95	36
1372	Accumulation of driver and passenger mutations during tumor progression. 2010 , 107, 18545-50	574
1371	Quantitative proteomic profiling of matched normal and tumor breast tissues. 2010 , 9, 3891-902	33
1370	Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate. 2010 , 14, 935-49	143
1369	Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway. 2010 , 70, 9095-105	85
1368	Ras history: The saga continues. 2010 , 1, 2-27	457

1367	Properdin: emerging roles of a pattern-recognition molecule. 2010 , 28, 131-55	169
1366	Heterogeneity of Liver Cancer Stem Cells. 2010 , 301-317	
1365	Mutational heterogeneity in human cancers: origin and consequences. 2010 , 5, 51-75	172
1364	The Role of the Epigenome in Human Cancers. 2010 , 471-486	
1363	Optimization aspects of carcinogenesis. 2010 , 74, 922-7	2
1362	IDH mutations in glioma and acute myeloid leukemia. 2010 , 16, 387-97	274
1361	Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. 2010 , 121, 408-12	33
1360	Breast cancer genomes--form and function. 2010 , 20, 4-14	43
1359	Simplistic pathways or complex networks?. 2010 , 20, 15-22	37
1358	Catalogue, cause, complexity and cure; the many uses of cancer genome sequence. 2010 , 20, 336-41	4
1357	Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. 2010 , 13, 16-28	183
1356	Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. 2010 , 1799, 717-25	139
1355	IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. 2010 , 398, 585-7	45
1354	C. elegans screen identifies autophagy genes specific to multicellular organisms. 2010 , 141, 1042-55	309
1353	Autophagy shows its animal side. 2010 , 141, 922-4	1
1352	[Cancer genetic predisposition: current events and perspectives in 2010]. 2010 , 58, 324-30	2
1351	Histone methyltransferases in cancer. 2010 , 21, 209-20	228
1350	Systems biology approaches and tools for analysis of interactomes and multi-target drugs. 2010 , 662, 29-58	39

1349	Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. <i>Science</i> , 2010 , 330, 228-31	33-3	915
1348	Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. 2010 , 11, 747-61		27
1347	Multiple genetic variants in telomere pathway genes and breast cancer risk. 2010 , 19, 219-28		42
1346	Gene dysregulations driven by somatic copy number aberrations-biological and clinical implications in colon tumors: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology. 2010 , 12, 552-61		22
1345	Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. 2010 , 102, 932-41		372
1344	Origin of Cancers. 2010 ,		1
1343	RNA therapeutics: function, design, and delivery. Preface. 2010 , 629, v-vii		5
1342	Waiting Time Models of Cancer Progression. 2010 , 17, 115-135		18
1341	An Omics Perspective on Cancer Research. 2010 ,		9
1340	Danuserib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. 2010 , 184, 199-214		39
1339	Epigenetics of Aging. 2010 ,		4
1338	TP53 mutations in human cancers: origins, consequences, and clinical use. 2010 , 2, a001008		1039
1337	The Foundations of Genomic and Personalized Medicine. 2010 , 1-10		11
1336	Colorectal Cancer. 2010 , 457-476		
1335	The Tumor Microenvironment. 2010 ,		4
1334	Modern Molecular Biology. 2010 ,		2
1333	Cancer Genome and Tumor Microenvironment. 2010 ,		2
1332	Identification of biomarkers for colorectal cancer through proteomics-based approaches. 2010 , 7, 879-95		34

1331	A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. 2010 , 29, 132	121
1330	Are current development programs realising the full potential of new agents?. 2010 , 12 Suppl 4, S23	
1329	RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. 2010 , 12, R41	58
1328	Patient-oriented gene set analysis for cancer mutation data. 2010 , 11, R112	54
1327	Systematic detection of putative tumor suppressor genes through the combined use of exome and transcriptome sequencing. 2010 , 11, R114	32
1326	Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. 2010 , 11, R82	144
1325	A human functional protein interaction network and its application to cancer data analysis. 2010 , 11, R53	453
1324	Small Molecules in Oncology. 2010 ,	4
1323	Interactions between nuclei and the cytoskeleton are mediated by SUN-KASH nuclear-envelope bridges. 2010 , 26, 421-44	413
1322	Correlation between IDH2 mutations and disease status in acute myeloid leukemia. 2010 , 51, 2157-8	
1321	Somatic mutation of PIK3R1 gene is rare in common human cancers. 2010 , 49, 125-7	5
1320	A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. 2010 , 107, 17604-9	99
1319	The 1-carbamoyl-2-oxo-4,5-dihydroxyimidazolidine component of ROS-induced DNA damage in white blood cells. 2010 , 174, 101-6	6
1318	Bisulfite Patch PCR enables multiplexed sequencing of promoter methylation across cancer samples. 2010 , 20, 1279-87	52
1317	A pathway-based classification of human breast cancer. 2010 , 107, 6994-9	258
1316	Melanoma vaccines: developments over the past 10 years. 2011 , 10, 853-73	26
1315	. 2011 ,	1
1314	Mutations in CIC and FUBP1 contribute to human oligodendroglioma. <i>Science</i> , 2011 , 333, 1453-5	33-3 399

1313	Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. 2011 , 21, 56-67	156
1312	Probabilistic Methods in Cancer Biology. 2011 , 17, 483-511	8
1311	Comparison of allelic discrimination by dHPLC, HRM, and TaqMan in the detection of BRAF mutation V600E. 2011 , 13, 467-73	31
1310	Algorithms for detecting significantly mutated pathways in cancer. 2011 , 18, 507-22	333
1309	Hostility in adolescents and adults: a genome-wide association study of the Young Finns. 2011 , 1, e11	19
1308	Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. 2011 , 21, 47-55	134
1307	Multiplex amplification coupled with COLD-PCR and high resolution melting enables identification of low-abundance mutations in cancer samples with low DNA content. 2011 , 13, 220-32	26
1306	Notch: architect, landscaper, and guardian of the intestine. 2011 , 141, 448-59	67
1305	BMPRI1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. 2011 , 141, e23-6	42
1304	Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer. 2011 , 12, R103	140
1303	Drugging the cancer stem cell compartment: lessons learned from the hedgehog and Wnt signal transduction pathways. 2011 , 51, 289-310	41
1302	Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. 2011 , 43, 875-8	554
1301	Spatial structure increases the waiting time for cancer. 2011 , 13,	63
1300	Colorectal cancer epigenetics: complex simplicity. 2011 , 29, 1382-91	158
1299	Cancer epigenetics: linking basic biology to clinical medicine. 2011 , 21, 502-17	223
1298	ADAMTSL3 as a candidate gene for schizophrenia: gene sequencing and ultra-high density association analysis by imputation. 2011 , 127, 28-34	32
1297	Studies of genomic copy number changes in human cancers reveal signatures of DNA replication stress. 2011 , 5, 308-14	57
1296	The genetic landscape of the childhood cancer medulloblastoma. <i>Science</i> , 2011 , 331, 435-9	333 576

1295	The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors. 2011 , 10, 54		38
1294	Finding co-mutated genes and candidate cancer genes in cancer genomes by stratified false discovery rate control. 2011 , 7, 1158-66		8
1293	Encyclopedia of Cancer. 2011 , 2259-2259		
1292	Encyclopedia of Cancer. 2011 , 2258-2259		
1291	Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases. <i>Cancers</i> , 2011 , 3, 1195-231	6.6	16
1290	Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. 2011 , 71, 6195-207		163
1289	Algorithms in Bioinformatics. 2011 ,		
1288	Disease Gene Prioritization Based on Topological Similarity in Protein-Protein Interaction Networks. 2011 , 54-68		2
1287	Efficient and scalable serial extraction of DNA and RNA from frozen tissue samples. 2011 , 47, 547-9		10
1286	Drugs for HER-2-positive Breast Cancer. 2011 ,		
1285	Targeted Therapies. 2011 ,		3
1284	TP53 mutations in human cancer: database reassessment and prospects for the next decade. 2011 , 110, 107-39		57
1283	GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. 2011 , 12, R41		1614
1282	Cancer Systems Biology, Bioinformatics and Medicine. 2011 ,		3
1281	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. 2011 , 43, 964-968		242
1280	Use of gene expression and pathway signatures to characterize the complexity of human melanoma. 2011 , 178, 2513-22		12
1279	MADD-4 is a secreted cue required for midline-oriented guidance in <i>Caenorhabditis elegans</i> . 2011 , 21, 669-80		33
1278	ATXN1 protein family and CIC regulate extracellular matrix remodeling and lung alveolarization. 2011 , 21, 746-57		73

1277	Protein kinase signaling networks in cancer. 2011 , 21, 4-11		169
1276	Nuclear positioning: mechanisms and functions. 2011 , 43, 1698-707		67
1275	Identification of genetic susceptibility to childhood cancer through analysis of genes in parallel. 2011 , 204, 19-25		14
1274	The T/NK cell co-stimulatory molecule SECTM1 is an IFN "early response gene" that is negatively regulated by LPS in human monocytic cells. 2011 , 1810, 1294-301		14
1273	Identification of epigenetically silenced genes in human pancreatic cancer by a novel method "microarray coupled with methyl-CpG targeted transcriptional activation" (MeTA-array). 2011 , 411, 162-7		28
1272	The EGFR/ErbB Family in Breast Cancer: From Signalling to Therapy. 2011 , 1-32		
1271	Exploring the genomes of cancer cells: progress and promise. <i>Science</i> , 2011 , 331, 1553-8	33.3	488
1270	Next-generation sequencing applied to molecular diagnostics. 2011 , 11, 425-44		32
1269	Structural and functional impact of cancer-related missense somatic mutations. 2011 , 413, 495-512		33
1268	Mutation and copy number detection in human cancers using a custom genotyping assay. 2011 , 98, 296-301		1
1267	A new disease-specific machine learning approach for the prediction of cancer-causing missense variants. 2011 , 98, 310-7		56
1266	Correction of microtubule-kinetochore attachment errors: mechanisms and role in tumor suppression. 2011 , 22, 559-65		8
1265	Peto's Paradox: evolution's prescription for cancer prevention. 2011 , 26, 175-82		211
1264	Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. 2011 , 12, 83-91		167
1263	Role of activation-induced cytidine deaminase in inflammation-associated cancer development. 2011 , 111, 109-41		23
1262	The origins of cancer robustness and evolvability. 2011 , 3, 17-30		114
1261	Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. 2011 , 43, 1219-23		570
1260	Mutations in isocitrate dehydrogenase isoforms 1 and 2 are rare events in primary central nervous system and non-central nervous system diffuse large B cell lymphoma. 2011 , 4, 58-62		1

1259	Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis. 2011 , 15, 1833-46	68
1258	Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario site of the breast cancer family registry (CFR). 2011 , 13, R77	16
1257	Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44. 2011 , 2, 457-463	30
1256	Implication of IDH1 and IDH2 gene mutations in acute myeloid leukemia. 2011 , 17, 132-144	
1255	Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer. 2011 , 3, 79-98	19
1254	Histone Modification and Breast Cancer. 2011 ,	3
1253	Pharmacogenomics to Link Genetic Background with Therapeutic Efficacy and Safety. 293-300	
1252	Translational Research on Breast Cancer: miRNA, siRNA and Immunoconjugates in Conjugation with Nanotechnology for Clinical Studies. 2011 ,	
1251	. 2011 ,	22
1250	Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. 2011 , 2, 627-37	330
1249	A new era in blood and lymphatic cancer biology and therapy. 2011 , 1	
1248	Genetic instability in cancer. 2011 ,	1
1247	Role of Tumor Tissue Analysis in Rectal Cancer Pharmacogenetics. 2011 ,	
1246	NRCAM (neuronal cell adhesion molecule). 2011 ,	
1245	Signatures of drug sensitivity in nonsmall cell lung cancer. 2011 , 2011, 215496	18
1244	The roles of ADAMTS metalloproteinases in tumorigenesis and metastasis. 2011 , 16, 1861-72	70
1243	Patented Biomarker Panels in Early Detection of Cancer. 2011 , 1, 10-24	2
1242	Protein-bound polysaccharide-K reduces colitic tumors and improves survival of inflammatory bowel disease in vivo. 2011 , 2, 791-796	2

1241	A novel role for CD46 in wound repair. 2011 , 2, 28	19
1240	Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors. 2011 , 4, 47	45
1239	Early events during neoplastic progression in Barrett's esophagus. 2010 , 9, 307-24	17
1238	Detecting cancer gene networks characterized by recurrent genomic alterations in a population. 2011 , 6, e14437	18
1237	2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. 2011 , 6, e16812	92
1236	A tumor-associated mutation of FYVE-CENT prevents its interaction with Beclin 1 and interferes with cytokinesis. 2011 , 6, e17086	23
1235	Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma. 2011 , 6, e18369	40
1234	High DNA methylation pattern intratumoral diversity implies weak selection in many human colorectal cancers. 2011 , 6, e21657	18
1233	The Human Epigenome. 2011 ,	
1232	RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms. 2011 , 40, 627-33	17
1231	Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. 2011 , 24, 648-52	57
1230	Embryonic morphogenetic field induces phenotypic reversion in cancer cells. Review article. 2011 , 12, 243-53	26
1229	Genome-based and transcriptome-based molecular classification of breast cancer. 2011 , 23, 93-9	12
1228	CCR7 & lymphotoxin in lymphoma niche. 2011 , 118, 831-2	1
1227	Targeting mutations predictably. 2011 , 118, 830-1	5
1226	Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. 2011 , 1, 161	327
1225	Traveling waves of selective sweeps. 2011 , 21,	14
1224	Effect of classification based on combination of mutation and methylation in colorectal cancer prognosis. 2011 , 25, 789-94	42

1223	A novel potent tumour promoter aberrantly overexpressed in most human cancers. 2011 , 1, 15	13
1222	Representing Cancer Cell Trajectories in a Phase-Space Diagram: Switching Cellular States by Biological Phase Transitions. 2011 , 377-403	3
1221	Pharmaceutical Induction of ApoE Secretion. 2011 , 212-230	
1220	Expression of circadian genes correlates with liver metastasis and outcomes in colorectal cancer. 2011 , 25, 1439-46	84
1219	Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer. 2011 , 16, 980-96	200
1218	Combining magnetic resonance spectroscopy and molecular genomics offers better accuracy in brain tumor typing and prediction of survival than either methodology alone. 2011 , 38, 1113-27	4
1217	Remarkable difference of somatic mutation patterns between oncogenes and tumor suppressor genes. 2011 , 26, 1539-46	4
1216	False discovery rates in somatic mutation studies of cancer. 2011 , 5,	6
1215	Development of a phylogenetic tree model to investigate the role of genetic mutations in endometrial tumors. 2011 , 25, 1447-54	28
1214	Mechanisms of leukemogenesis by MLL fusion proteins. 2011 , 152, 141-54	132
1213	Exome sequencing identifies GRIN2A as frequently mutated in melanoma. 2011 , 43, 442-6	385
1212	Human cancers express mutator phenotypes: origin, consequences and targeting. 2011 , 11, 450-7	291
1211	What does physics have to do with cancer?. 2011 , 11, 657-70	143
1210	Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. 2011 , 11, 805-12	460
1209	Concurrent genetic alterations in DNA polymerase proofreading and mismatch repair in human colorectal cancer. 2011 , 19, 320-5	59
1208	The genomic complexity of primary human prostate cancer. 2011 , 470, 214-20	984
1207	A decade's perspective on DNA sequencing technology. 2011 , 470, 198-203	605
1206	Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. 2011 , 58, 1167-72	12

1205	Crystal structure of human Mre11: understanding tumorigenic mutations. 2011 , 19, 1591-602	61
1204	Roles of TGF β signaling Smads in squamous cell carcinoma. 2011 , 1, 41	24
1203	Dependence of substrate binding and catalysis on pH, ionic strength, and temperature for thymine DNA glycosylase: Insights into recognition and processing of GT mispairs. 2011 , 10, 545-53	28
1202	Evidence for upregulated repair of oxidatively induced DNA damage in human colorectal cancer. 2011 , 10, 1114-20	20
1201	Dissecting DNA hypermethylation in cancer. 2011 , 585, 2078-86	58
1200	Lipid hydroperoxide-induced and hemoglobin-enhanced oxidative damage to colon cancer cells. 2011 , 51, 503-15	42
1199	Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells. 2011 , 51, 1610-8	21
1198	The TGF- β receptor, CD109, promotes internalization and degradation of TGF- β receptors. 2011 , 1813, 742-53	97
1197	The RasGrf family of mammalian guanine nucleotide exchange factors. 2011 , 1815, 170-88	50
1196	Advances in carcinogenesis: a historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis. 2011 , 1816, 199-208	12
1195	Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. 2011 , 19, 72-85	159
1194	Nuclear mechanics during cell migration. 2011 , 23, 55-64	329
1193	Epigenetics and colorectal cancer. 2011 , 8, 686-700	459
1192	Breast cancer methylomes establish an epigenomic foundation for metastasis. 2011 , 3, 75ra25	215
1191	Mathematical and Computational Models in Cancer. 2011 , 113-126	
1190	What can exome sequencing do for you?. 2011 , 48, 580-9	263
1189	Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. 2011 , 18, 2338-47	121
1188	Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. 2011 , 18, 3694-700	45

1187	The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. 2011 , 63, 136-51	2580
1186	Characterization of germline mutations of MLH1 and MSH2 in unrelated south American suspected Lynch syndrome individuals. 2011 , 10, 641-7	24
1185	Innate immune cells in breast cancer--from villains to heroes?. 2011 , 16, 189-203	23
1184	The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations. 2011 , 30, 199-210	57
1183	Alterations of the retinoblastoma gene in metastatic breast cancer. 2011 , 28, 319-26	12
1182	Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain. 2011 , 28, 899-908	32
1181	Assessing the value of CAN-gene mutations using MALDI-TOF MS. 2011 , 137, 1239-44	
1180	Germline PKHD1 mutations are protective against colorectal cancer. 2011 , 129, 345-9	14
1179	High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein. 2011 , 28, 107-14	19
1178	New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status. 2011 , 28, 203-8	6
1177	Defining the cancer master switch. 2011 , 35, 1738-45	1
1176	[Malignancy potential of precursor lesions: determination using molecular markers]. 2011 , 32 Suppl 2, 188-94	
1175	The cytoprotective role of the Keap1-Nrf2 pathway. 2011 , 85, 241-72	687
1174	Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. 2011 , 49, 235-47	4
1173	Somatic mutations of the mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers. 2011 , 17, 429-33	44
1172	ADAM12 and ADAM17 gene expression in laser-capture microdissected and non-microdissected breast tumors. 2011 , 17, 375-85	7
1171	Analysis of the mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer. 2011 , 11, 173	14
1170	Cancer associated epigenetic transitions identified by genome-wide histone methylation binding profiles in human colorectal cancer samples and paired normal mucosa. 2011 , 11, 450	27

1169	Somatic mutations in cancer development. 2011 , 10 Suppl 1, S12	11
1168	Correction: Somatic mutations in cancer development. 2011 , 10, S16	0
1167	Systematic quantitative characterization of cellular responses induced by multiple signals. 2011 , 5, 88	53
1166	Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. 2011 , 4, 68	146
1165	Off-target effects dominate a large-scale RNAi screen for modulators of the TGF- β pathway and reveal microRNA regulation of TGFBR2. 2011 , 2, 3	67
1164	Clinical cancer genomics: how soon is now?. 2011 , 223, 318-26	30
1163	Protein-protein interaction networks and subnetworks in the biology of disease. 2011 , 3, 357-67	57
1162	Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. 2011 , 50, 82-94	64
1161	Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma. 2011 , 32, E2148-75	32
1160	Comparative analysis of germline and somatic microlesion mutational spectra in 17 human tumor suppressor genes. 2011 , 32, 620-32	11
1159	Identification of frequently mutated genes with relevance to nonsense mediated mRNA decay in the high microsatellite instability cancers. 2011 , 128, 2872-80	20
1158	Fields and field cancerization: the preneoplastic origins of cancer: asymptomatic hyperplastic fields are precursors of neoplasia, and their progression to tumors can be tracked by saturation density in culture. 2011 , 33, 224-31	38
1157	Preparation of new 5-fluorouracil-loaded zein nanoparticles for liver targeting. 2011 , 404, 317-23	188
1156	Molecular biomarkers of risk in premalignancy and breast cancer prevention. 2011 , 4, 1947-52	5
1155	Genomic and epigenomic integration identifies a prognostic signature in colon cancer. 2011 , 17, 1535-45	125
1154	Faulty epithelial polarity genes and cancer. 2011 , 111, 97-161	16
1153	TAN lines: a novel nuclear envelope structure involved in nuclear positioning. 2011 , 2, 173-81	91
1152	Non-genotoxic p53-activators and their significance as antitumor therapy of future. 2011 , 18, 1038-49	7

1151	Efficient simulation under a population genetics model of carcinogenesis. 2011 , 27, 837-43	9
1150	Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. 2011 , 17, 1591-602	198
1149	A Nup133-dependent NPC-anchored network tethers centrosomes to the nuclear envelope in prophase. 2011 , 192, 855-71	138
1148	Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors. 2011 , 195, 1033-45	73
1147	NFKBIA deletion in glioblastomas. 2011 , 364, 627-37	188
1146	Epigenetics of kidney cancer and bladder cancer. 2011 , 3, 19-34	45
1145	ADAM12 produced by tumor cells rather than stromal cells accelerates breast tumor progression. 2011 , 9, 1449-61	46
1144	Making sense of cancer genomic data. 2011 , 25, 534-55	260
1143	Targeted resequencing of candidate genes using selector probes. 2011 , 39, e8	57
1142	ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. 2011 , 71, 6524-34	22
1141	Ncb5or deficiency increases fatty acid catabolism and oxidative stress. 2011 , 286, 11141-54	26
1140	Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. 2011 , 17, 928-36	56
1139	Retrotransposon-encoded reverse transcriptase in the genesis, progression and cellular plasticity of human cancer. <i>Cancers</i> , 2011 , 3, 1141-57	6.6 21
1138	Functional synergies yet distinct modulators affected by genetic alterations in common human cancers. 2011 , 71, 3471-81	9
1137	Functional parsing of driver mutations in the colorectal cancer genome reveals numerous suppressors of anchorage-independent growth. 2011 , 71, 4359-65	24
1136	Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer. 2011 , 10, 1581-90	51
1135	Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues. 2011 , 84, 169-84	3
1134	A weak C' box renders U3 snoRNA levels dependent on hU3-55K binding. 2011 , 31, 2404-12	16

1133	Proteomic and functional genomic landscape of receptor tyrosine kinase and ras to extracellular signal-regulated kinase signaling. 2011 , 4, rs10	68
1132	Stoichiometry and affinity for thymine DNA glycosylase binding to specific and nonspecific DNA. 2011 , 39, 2319-29	31
1131	T-cell factor 4 functions as a tumor suppressor whose disruption modulates colon cell proliferation and tumorigenesis. 2011 , 108, 4914-9	83
1130	Advancing a clinically relevant perspective of the clonal nature of cancer. 2011 , 108, 12054-9	89
1129	A bioinformatics workflow for variant peptide detection in shotgun proteomics. 2011 , 10, M110.006536	73
1128	Encyclopedia of Cancer. 2011 , 2245-2250	
1127	MTGR1 is required for tumorigenesis in the murine AOM/DSS colitis-associated carcinoma model. 2011 , 71, 1302-12	31
1126	NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway. 2011 , 193, 633-42	116
1125	Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. 2010 , 32, 35-48	389
1124	Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. 2011 , 4, ra13	127
1123	Activation and involvement of Ral GTPases in colorectal cancer. 2011 , 71, 206-15	64
1122	The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery. 2011 , 2, 275-87	83
1121	cMyc is a principal upstream driver of beta-cell proliferation in rat insulinoma cell lines and is an effective mediator of human beta-cell replication. 2011 , 25, 1760-72	37
1120	Germline fitness-based scoring of cancer mutations. 2011 , 188, 383-93	10
1119	The filamins: organizers of cell structure and function. 2011 , 5, 160-9	321
1118	High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. 2011 , 108, 5384-9	106
1117	Metalloprotease-disintegrin ADAM12 expression is regulated by Notch signaling via microRNA-29. 2011 , 286, 21500-10	32
1116	Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway. 2011 , 286, 33954-62	41

1115	Identifying cancer driver genes in tumor genome sequencing studies. 2011 , 27, 175-81		146
1114	The WNKs: atypical protein kinases with pleiotropic actions. 2011 , 91, 177-219		183
1113	WNK2 kinase is a novel regulator of essential neuronal cation-chloride cotransporters. 2011 , 286, 30171-80		67
1112	Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. 2011 , 108, 4858-63		121
1111	Cancer. Another NOTCH for cancer. <i>Science</i> , 2011 , 333, 1102-3	33.3	22
1110	COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. 2011 , 39, D945-50		1774
1109	Vavien: an algorithm for prioritizing candidate disease genes based on topological similarity of proteins in interaction networks. 2011 , 18, 1561-74		56
1108	K ⁺ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. <i>Science</i> , 2011 , 331, 768-72	33.3	707
1107	Predicting the functional impact of protein mutations: application to cancer genomics. 2011 , 39, e118		1237
1106	Data mining using the Catalogue of Somatic Mutations in Cancer BioMart. 2011 , 2011, bar018		41
1105	Genetic alterations in glioma. <i>Cancers</i> , 2011 , 3, 1129-40	6.6	19
1104	Tumour suppressor function of protein tyrosine phosphatase receptor-T. 2011 , 31, 303-7		25
1103	A Preclinical Evaluation of Antrodia camphorata Alcohol Extracts in the Treatment of Non-Small Cell Lung Cancer Using Non-Invasive Molecular Imaging. 2011 , 2011, 914561		12
1102	CAERUS: predicting CANcER oUtcomeS using relationship between protein structural information, protein networks, gene expression data, and mutation data. 2011 , 7, e1001114		22
1101	Genetic and epigenetic traits as biomarkers in colorectal cancer. 2011 , 12, 9426-39		36
1100	Lysophosphatidic acid-induced p21Waf1 expression mediates the cytostatic response of breast and ovarian cancer cells to TGF β . 2011 , 9, 1562-70		10
1099	PathScan: a tool for discerning mutational significance in groups of putative cancer genes. 2011 , 27, 1595-602		72
1098	International Cancer Genome Consortium Data Portal—a one-stop shop for cancer genomics data. 2011 , 2011, bar026		382

1097	IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2. 2011 , 71, 2172-82	76
1096	A random mutation capture assay to detect genomic point mutations in mouse tissue. 2011 , 39, e73	12
1095	Role of isocitrate dehydrogenase in glioma. 2011 , 11, 1399-409	12
1094	Cancer genome sequencing and its implications for personalized cancer vaccines. <i>Cancers</i> , 2011 , 3, 4191-211	17
1093	Somatic genetics empowers the mouse for modeling and interrogating developmental and disease processes. 2011 , 7, e1002110	6
1092	Application of miRNA expression analysis on exfoliated colonocytes for diagnosis of colorectal cancer. 2012 , 11	1
1091	Interpretation of the consequences of mutations in protein kinases: combined use of bioinformatics and text mining. 2012 , 3, 323	7
1090	Evolution of the voltage sensor domain of the voltage-sensitive phosphoinositide phosphatase VSP/TPTE suggests a role as a proton channel in eutherian mammals. 2012 , 29, 2147-55	16
1089	ATM mutations in patients with hereditary pancreatic cancer. 2012 , 2, 41-6	365
1088	Spectraplakins: master orchestrators of cytoskeletal dynamics. 2012 , 197, 465-75	124
1087	The cancer antigenome. 2013 , 32, 194-203	172
1086	Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. 2012 , 8, e1002772	385
1085	Dynamic distribution of linker histone H1.5 in cellular differentiation. 2012 , 8, e1002879	55
1084	Climacteric Commentaries. 2012 , 16, 194-200	
1083	Emerging Roles of ADAMTSs in Angiogenesis and Cancer. <i>Cancers</i> , 2012 , 4, 1252-99	6.6 51
1082	TGF- β sensitivity is determined by N-linked glycosylation of the type II TGF- β receptor. 2012 , 445, 403-11	63
1081	Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop. 2012 , 18, 6101-9	42
1080	A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. 2012 , 22, 2339-55	137

1079	Cancer-associated isocitrate dehydrogenase mutations. 2012 , 17, 5-8	12
1078	Exploiting the mutanome for tumor vaccination. 2012 , 72, 1081-91	556
1077	Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). 2012 , 287, 42180-94	68
1076	KIF14 negatively regulates Rap1a-Radil signaling during breast cancer progression. 2012 , 199, 951-67	50
1075	Identification of ILK as a new partner of the ADAM12 disintegrin and metalloprotease in cell adhesion and survival. 2012 , 23, 3461-72	19
1074	Loss of giant obscurins promotes breast epithelial cell survival through apoptotic resistance. 2012 , 26, 2764-75	25
1073	Biological responses to TGF- β in the mammary epithelium show a complex dependency on Smad3 gene dosage with important implications for tumor progression. 2012 , 10, 1389-99	17
1072	Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. 2012 , 2, 899-905	301
1071	Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. 2012 , 14, 1465-72	33
1070	Receptor protein tyrosine phosphatases and cancer: new insights from structural biology. 2012 , 6, 356-64	22
1069	A single-nucleotide substitution mutator phenotype revealed by exome sequencing of human colon adenomas. 2012 , 72, 6279-89	50
1068	Expanding the reach of cancer metabolomics. 2012 , 5, 1337-40	16
1067	Back to the origin: reconsidering replication, transcription, epigenetics, and cell cycle control. 2012 , 3, 678-96	14
1066	Molecular pathogenesis of granulosa cell tumors of the ovary. 2012 , 33, 109-44	120
1065	Molecular logic underlying chromosomal translocations, random or non-random?. 2012 , 113, 241-79	15
1064	Argonaute2 regulation for K ⁺ channel-mediated human adipose tissue-derived stromal cells self-renewal and survival in nucleus. 2012 , 21, 1736-48	8
1063	The circadian mutation PER2(S662G) is linked to cell cycle progression and tumorigenesis. 2012 , 19, 397-405	78
1062	Different phenotypic consequences of simultaneous versus stepwise Apc loss. 2012 , 31, 2028-38	19

1061	Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence. 2012 , 31, 2545-54	17
1060	Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling. 2012 , 19, 543-9	23
1059	Passenger mutations take the wheel. 2012 , 5, 915-915	
1058	Proliferation and tissue remodeling in cancer: the hallmarks revisited. 2012 , 3, e397	46
1057	CDX2 is an amplified lineage-survival oncogene in colorectal cancer. 2012 , 109, E3196-205	54
1056	A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin A negatively controls the PI3K pathway. 2012 , 32, 1004-16	27
1055	The Capicua repressor--a general sensor of RTK signaling in development and disease. 2012 , 125, 1383-91	113
1054	Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. 2012 , 109, 17603-8	75
1053	miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the E β miR-155 transgenic mouse model. 2012 , 109, 20047-52	103
1052	Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. 2012 , 22, 208-19	95
1051	Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. 2012 , 7, 701-9	52
1050	Core module network construction for breast cancer metastasis. 2012 ,	
1049	Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. 2012 , 18, 688-99	113
1048	Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. 2012 , 61, 1085-94	110
1047	Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. 2012 , 17, 72-9	532
1046	Myeloid neoplasias: what molecular analyses are telling us. 2012 , 2012, 321246	2
1045	An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer. 2012 , 255, 720-30	70
1044	Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. 2012 , 109, 5934-41	179

1043	Human POLB gene is mutated in high percentage of colorectal tumors. 2012 , 287, 23830-9	62
1042	An analysis of substitution, deletion and insertion mutations in cancer genes. 2012 , 40, 6401-13	32
1041	Genetics of adrenocortical disease: an update. 2012 , 19, 159-67	6
1040	Transcriptomic landscape of breast cancers through mRNA sequencing. 2012 , 2, 264	67
1039	The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma. 2012 , 21, 1190-200	33
1038	SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study. 2012 , 2,	13
1037	A review of the genetic background and tumour profiling in familial colorectal cancer. 2012 , 27, 239-45	8
1036	DNA polymerase β variant Ile260Met generates global gene expression changes related to cellular transformation. 2012 , 27, 683-91	4
1035	Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates. 2012 , 44, 80-8	53
1034	ATP-ase as a Potential Drug Target for Cancer, Tumor Growth and Cellular Functions. 2012 , 12, 151-156	8
1033	Genomics and cancer drug resistance. 2012 , 13, 651-73	33
1032	Altered expression levels of IDH2 are involved in the development of colon cancer. 2012 , 4, 801-806	24
1031	Involvement of nuclear NHERF1 in colorectal cancer progression. 2012 , 28, 889-94	22
1030	Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. 2012 , 88, 53-71	191
1029	COLD-PCR enrichment of rare cancer mutations prior to targeted amplicon resequencing. 2012 , 58, 580-9	47
1028	Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. 2012 , 143, 550-563	269
1027	A novel missense-mutation-related feature extraction scheme for 'driver' mutation identification. 2012 , 28, 2948-55	36
1026	IDH mutation detection in formalin-fixed paraffin-embedded gliomas using multiplex PCR and single-base extension. 2012 , 22, 619-24	15

1025	Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies. 2012 , 25, 819-31	40
1024	Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. 2012 , 164, 138-44	621
1023	Effects of cancer-associated EPHA3 mutations on lung cancer. 2012 , 104, 1182-97	46
1022	The Keap1-Nrf2 cell defense pathway--a promising therapeutic target?. 2012 , 63, 43-79	121
1021	Emerging real-time technologies in molecular medicine and the evolution of integrated 'pharmacomics' approaches to personalized medicine and drug discovery. 2012 , 136, 295-304	11
1020	Histone deacetylases and cancer. 2012 , 6, 579-89	295
1019	Preserving the genome by regulating chromatin association with the nuclear envelope. 2012 , 22, 465-73	31
1018	1p36 tumor suppression--a matter of dosage?. 2012 , 72, 6079-88	70
1017	An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. 2012 , 31, 2090-100	99
1016	Delving into somatic variation in sporadic melanoma. 2012 , 25, 155-70	33
1015	Differential proteomic analysis of a human breast tumor and its matched bone metastasis identifies cell membrane and extracellular proteins associated with bone metastasis. 2012 , 11, 2247-60	19
1014	Prioritization of pathogenic mutations in the protein kinase superfamily. 2012 , 13 Suppl 4, S3	21
1013	Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity. 2012 , 14, 204	26
1012	Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer. 2012 , 14, R73	37
1011	Cell-extrinsic consequences of epithelial stress: activation of protumorigenic tissue phenotypes. 2012 , 14, R155	32
1010	Regulation and function of autophagy during cell survival and cell death. 2012 , 4,	215
1009	An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer. 2012 , 135, 759-69	26
1008	Anticancer activity of the cholesterol exporter ABCA1 gene. 2012 , 2, 580-90	122

1007	Une d̄sint̄grine et m̄alloprot̄ase 12 (ADAM12). 2012 , 27, 195-204	
1006	Methods for analysis of the cancer microenvironment and their potential for disease prediction, monitoring and personalized treatments. 2012 , 3, 7	4
1005	Characterising Somatic Mutations in Cancer Genome by Means of Next-generation Sequencing. 2012 ,	
1004	Recurrent R-spondin fusions in colon cancer. 2012 , 488, 660-4	711
1003	ECT2 and RASAL2 mediate mesenchymal-amoeboid transition in human astrocytoma cells. 2012 , 181, 662-74	36
1002	ADAMTS5 functions as an anti-angiogenic and anti-tumorigenic protein independent of its proteoglycanase activity. 2012 , 181, 1056-68	58
1001	Paradoxes in Carcinogenesis Should Spur New Avenues of Research: An Historical Perspective. 2012 , 1, 100-107	21
1000	A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers. 2012 , 8, 1553-70	28
999	Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer. 2012 , 5, 319-37	20
998	Naïve Bayes QSDR classification based on spiral-graph Shannon entropies for protein biomarkers in human colon cancer. 2012 , 8, 1716-22	20
997	Order and disorder in large multi-site docking proteins of the Gab family--implications for signalling complex formation and inhibitor design strategies. 2012 , 8, 33-46	40
996	Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets. 2012 , 19, R115-29	35
995	Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. 2012 , 51, 1464-75	50
994	Proteomic profiling of infiltrating ductal carcinoma reveals increased cellular interactions with tissue microenvironment. 2012 , 11, 2236-46	3
993	Wnt signaling in cancer. 2012 , 4,	633
992	Ectodomain structures of Eph receptors. 2012 , 23, 35-42	48
991	Concepts and consequences of Eph receptor clustering. 2012 , 23, 43-50	78
990	Danusertib, an aurora kinase inhibitor. 2012 , 21, 383-93	45

989	Global mutational profiling of formalin-fixed human colon cancers from a pathology archive. 2012 , 25, 1599-608	22
988	Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium. 2012 , 31, 4987-95	12
987	Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. 2012 , 104, 1576-90	60
986	TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer. 2012 , 180, 839-47	38
985	Role of ERRF, a novel ER-related nuclear factor, in the growth control of ER-positive human breast cancer cells. 2012 , 180, 1189-1201	15
984	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. 2012 , 56, 184-91	298
983	Crystal structure of human methyl-binding domain IV glycosylase bound to abasic DNA. 2012 , 420, 164-75	29
982	Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression. 2012 , 434, 488-93	35
981	The newcomer in the integrin family: integrin β in biology and cancer. 2012 , 52, 326-39	45
980	AFM nano-mechanics and calcium dynamics of prostate cancer cells with distinct metastatic potential. 2012 , 1820, 1111-20	56
979	Applications of next-generation sequencing to blood and marrow transplantation. 2012 , 18, S151-60	19
978	Histone modifications as a pathogenic mechanism of colorectal tumorigenesis. 2012 , 44, 1276-89	36
977	Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells. 2012 , 316, 77-84	6
976	Rap1GAP regulates renal cell carcinoma invasion. 2012 , 320, 65-71	39
975	Evolution of the cancer genome. 2012 , 13, 795-806	424
974	SnapShot: breast cancer. 2012 , 22, 562-562.e1	54
973	Lack of association between cancer history and PARKIN genotype: a family based study in PARKIN/Parkinson's families. 2012 , 51, 1109-13	7
972	Core module biomarker identification with network exploration for breast cancer metastasis. 2012 , 13, 12	31

971	Methods for visual mining of genomic and proteomic data atlases. 2012 , 13, 58	7
970	Accurate variant detection across non-amplified and whole genome amplified DNA using targeted next generation sequencing. 2012 , 13, 500	21
969	Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma. 2012 , 13, 505	25
968	Shared ancestral susceptibility to colorectal cancer and other nutrition related diseases. 2012 , 13, 94	4
967	Molecular pathways undergoing dramatic transcriptomic changes during tumor development in the human colon. 2012 , 12, 608	13
966	Triplex DNA-binding proteins are associated with clinical outcomes revealed by proteomic measurements in patients with colorectal cancer. 2012 , 11, 38	22
965	Immunohistochemical analysis of medullary breast carcinoma autoantigens in different histological types of breast carcinomas. 2012 , 7, 161	10
964	Cancer core modules identification through genomic and transcriptomic changes correlation detection at network level. 2012 , 6, 64	2
963	Comprehensive molecular characterization of human colon and rectal cancer. 2012 , 487, 330-7	5640
962	Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. 2012 , 44, 1310-5	305
961	Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. 2011 , 44, 165-9	145
960	Using genome-wide expression profiling to define gene networks relevant to the study of complex traits: from RNA integrity to network topology. 2012 , 104, 91-133	12
959	Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. 2012 , 44, 570-4	486
958	Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. 2012 , 44, 1117-21	313
957	IDH mutations in acute myeloid leukemia. 2012 , 43, 1541-51	92
956	Leukemic blasts with the paroxysmal nocturnal hemoglobinuria phenotype in children with acute lymphoblastic leukemia. 2012 , 181, 1862-9	3
955	Mitochondrial ABC transporters function: the role of ABCB10 (ABC-me) as a novel player in cellular handling of reactive oxygen species. 2012 , 1823, 1945-57	51
954	Chromatin-modifying agents in anti-cancer therapy. 2012 , 94, 2264-79	53

953	GCF2/LRRFIP1 promotes colorectal cancer metastasis and liver invasion through integrin-dependent RhoA activation. 2012 , 325, 99-107	29
952	In silico analysis of Single Nucleotide Polymorphisms (SNPs) in human BRAF gene. 2012 , 508, 188-96	50
951	Cancer heterogeneity: origins and implications for genetic association studies. 2012 , 28, 538-43	20
950	Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer. 2012 , 28, 138-44	10
949	Structural and genic characterization of stable genomic regions in breast cancer: relevance to chemotherapy. 2012 , 6, 347-59	12
948	HDAC inhibitor-based therapies: can we interpret the code?. 2012 , 6, 637-56	239
947	Molecular typing of colorectal cancer: applications in diagnosis and treatment. 2012 , 18, 70-80	6
946	The Cell Cycle. 2012 , 451-471	4
945	Identification and functional analysis of 9p24 amplified genes in human breast cancer. 2012 , 31, 333-41	65
944	Some Research Directions. 2012 , 69-80	
943	Influence of natural and synthetic histone deacetylase inhibitors on chromatin. 2012 , 17, 340-54	10
942	[Personalized therapeutic targeting by exome analysis]. 2012 , 32, S44-5	
941	Alterations of Histone Modifications in Cancer. 2012 , 53-87	5
940	NRF2 and cancer: the good, the bad and the importance of context. 2012 , 12, 564-71	725
939	Is there a biological cost of protein disorder? Analysis of cancer-associated mutations. 2012 , 8, 296-307	40
938	The Role of the Insulin-like Growth Factor-1 Receptor (IGF-1R), Phosphatase and Tensin Homolog (PTEN), c-Met, and the PI3-Kinase Pathway in Colorectal Cancer. 2012 , 8, 243-253	
937	Phosphoinositides and Disease. 2012 ,	1
936	Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. 2011 , 44, 133-9	313

935	Development of Antibody-Based Therapeutics. 2012,	5
934	TCF/LEFs and Wnt signaling in the nucleus. 2012, 4,	434
933	Inositol polyphosphate phosphatases in human disease. 2012, 362, 247-314	48
932	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. 2012, 366, 2443-54	8684
931	Computational and Bioinformatic Strategies for Drug Repositioning. 2012, 89-135	
930	Nesprin interchain associations control nuclear size. 2012, 69, 3493-509	70
929	Colon cancer associated genes exhibit signatures of positive selection at functionally significant positions. 2012, 12, 114	21
928	Finding driver pathways in cancer: models and algorithms. 2012, 7, 23	14
927	Improving the prediction of the functional impact of cancer mutations by baseline tolerance transformation. 2012, 4, 89	73
926	A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. 2012, 8, e1002337	46
925	LGR6 is a high affinity receptor of R-spondins and potentially functions as a tumor suppressor. 2012, 7, e37137	84
924	Functional analysis of a breast cancer-associated mutation in the intracellular domain of the metalloprotease ADAM12. 2012, 7, e37628	3
923	A new methodology for quantification of alternatively spliced exons reveals a highly tissue-specific expression pattern of WNK1 isoforms. 2012, 7, e37751	51
922	Identification and characterization of nucleolin as a COUP-TFII coactivator of retinoic acid receptor β transcription in breast cancer cells. 2012, 7, e38278	33
921	Genomic aberrations in an African American colorectal cancer cohort reveals a MSI-specific profile and chromosome X amplification in male patients. 2012, 7, e40392	27
920	Comprehensive mutation analysis in colorectal flat adenomas. 2012, 7, e41963	16
919	Cysteine dioxygenase 1 is a tumor suppressor gene silenced by promoter methylation in multiple human cancers. 2012, 7, e44951	84
918	Clonal evolution of a case of treatment refractory maxillary sinus carcinoma. 2012, 7, e45614	2

917	Frequent alteration of the tumor suppressor gene APC in sporadic canine colorectal tumors. 2012 , 7, e50813	17
916	The Dual Role of TGF β in Human Cancer: From Tumor Suppression to Cancer Metastasis. 2012 , 2012, 381428	219
915	Translesion DNA polymerases and cancer. 2012 , 3, 174	41
914	Chemical Carcinogenesis: Risk Factors, Early Detection and Biomedical Engineering. 2012 ,	
913	PIK3R1 (phosphoinositide-3-kinase, regulatory subunit 1 (alpha)). 2012 ,	
912	Distinct Pathologic Roles for Glycogen Synthase Kinase 3 β in Colorectal Cancer Progression. 2012 ,	2
911	Bioinformatics Approaches to the Functional Profiling of Genetic Variants. 2012 ,	
910	Novel Markers for Diagnosis and Prognosis of Oral Intraepithelial Neoplasia. 2012 ,	1
909	Mutational and expressional analysis of MLL genes in gastric and colorectal cancers with microsatellite instability. 2013 , 60, 188-95	17
908	AMFR (autocrine motility factor receptor). 2012 ,	
907	Cooperative Hedgehog-EGFR signaling. 2012 , 17, 90-9	44
906	The association between single-nucleotide polymorphisms of ORAI1 gene and breast cancer in a Taiwanese population. 2012 , 2012, 916587	6
905	Signal transduction pathways participating in homeostasis and malignant transformation of the intestinal tissue. 2012 , 59, 708-18	11
904	Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. 2012 , 3, 709-22	439
903	A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. 2012 , 227, 29-41	44
902	Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. 2012 , 28, 1811-7	1015
901	Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. 2012 , 22, 246-58	385
900	Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. 2012 , 366, 883-892	5559

899	Cancer genomics: technology, discovery, and translation. 2012 , 30, 647-60	134
898	Epigenomic enhancer profiling defines a signature of colon cancer. <i>Science</i> , 2012 , 336, 736-9	333 255
897	Genomic instability measured by inter-(simple sequence repeat) PCR and high-resolution microsatellite instability are prognostic of colorectal carcinoma survival after surgical resection. 2012 , 19, 344-50	2
896	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. 2012 , 483, 479-83	1373
895	Proteomics in studying cancer stem cell biology. 2012 , 9, 325-36	7
894	Emerging insights into the molecular and cellular basis of glioblastoma. 2012 , 26, 756-84	388
893	Molecular genetic analysis of the hepatocyte growth factor/MET signaling pathway in pediatric medulloblastoma. 2012 , 51, 675-88	12
892	Shattered and stitched chromosomes-chromothripsis and chromoanasythesis-manifestations of a new chromosome crisis?. 2012 , 51, 975-81	28
891	PON-P: integrated predictor for pathogenicity of missense variants. 2012 , 33, 1166-74	79
890	Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas. 2012 , 130, 2599-606	31
889	Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. 2012 , 4, 136ra68	882
888	Genetic variations in transcription factor 7-like 2 (TCF7L2) gene: association of TCF7L2 rs1225372(G/T) or rs7903146(C/T) with breast cancer risk and clinico-pathological parameters. 2012 , 29, 411-7	16
887	Applications of High-Throughput Sequencing. 2012 , 27-53	1
886	Mouse Rif1 is a key regulator of the replication-timing programme in mammalian cells. 2012 , 31, 3678-90	168
885	How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. 2012 , 12, 621-8	121
884	The chemical complexity of cellular microtubules: tubulin post-translational modification enzymes and their roles in tuning microtubule functions. 2012 , 69, 442-63	114
883	Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. 2012 , 118, 2665-73	36
882	High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. 2012 , 118, 2905-14	58

881	Oncogenomics methods and resources. 2012 , 2012,	7
880	BRACKing news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype. 2012 , 31, 131-42	9
879	Sequence analysis of mutations and translocations across breast cancer subtypes. 2012 , 486, 405-9	895
878	Inactivation of X-linked tumor suppressor genes in human cancer. 2012 , 8, 463-81	22
877	Molecular pathways: targeting the TGF- β pathway for cancer therapy. 2012 , 18, 4514-21	140
876	Eph-dependent cell-cell adhesion and segregation in development and cancer. 2012 , 69, 1813-42	73
875	Identification of putative cancer genes through data integration and comparative genomics between plants and humans. 2012 , 69, 2041-55	6
874	Cooperate concept of metastasis: site-specific requirement of activated differentiation and dynamic deterioration. 2012 , 31, 269-76	4
873	Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. 2012 , 133, 865-80	87
872	Germline mutation in ATR in autosomal- dominant oropharyngeal cancer syndrome. 2012 , 90, 511-7	49
871	Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. 2012 , 90, 986-1001	350
870	Somatic mutations of the KEAP1 gene in common solid cancers. 2012 , 60, 943-52	168
869	Safe harbours for the integration of new DNA in the human genome. 2011 , 12, 51-8	301
868	The nuclear envelope environment and its cancer connections. 2012 , 12, 196-209	237
867	Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer. 2012 , 586, 1984-92	49
866	NIRF/UHRF2 occupies a central position in the cell cycle network and allows coupling with the epigenetic landscape. 2012 , 586, 1570-83	30
865	Mutational profiling of sporadic versus toxin-associated brain cancer formation: initial findings using loss of heterozygosity profiling. 2012 , 215, 427-33	2
864	Drosophila Pez acts in Hippo signaling to restrict intestinal stem cell proliferation. 2012 , 22, 389-96	71

863	Unique mutational profile associated with a loss of TDG expression in the rectal cancer of a patient with a constitutional PMS2 deficiency. 2012 , 11, 616-23	29
862	CD95 signaling in colorectal cancer. 2012 , 1826, 189-98	10
861	The role of the second and third extracellular loops of the adenosine A1 receptor in activation and allosteric modulation. 2012 , 84, 76-87	45
860	Metabolomics as a key integrator for "omic" advancement of personalized medicine and future therapies. 2012 , 5, 285-8	36
859	Evolution of the cancer genome. 2012 , 28, 155-63	98
858	Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors. 2012 , 103, 535-41	61
857	Domain landscapes of somatic mutations in cancer. 2012 , 13 Suppl 4, S9	39
856	Hereditary breast cancer: practical pursuit for clinical translation. 2012 , 19, 1723-31	23
855	CD109-mediated degradation of TGF- β receptors and inhibition of TGF- β responses involve regulation of SMAD7 and Smurf2 localization and function. 2012 , 113, 238-46	60
854	Somatic mutations in the Notch, NF-KB, PIK3CA, and Hedgehog pathways in human breast cancers. 2012 , 51, 480-9	50
853	Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. 2012 , 33, 100-3	230
852	Increased frequency of 20q gain and copy-neutral loss of heterozygosity in mismatch repair proficient familial colorectal carcinomas. 2012 , 130, 837-46	22
851	Candidate driver genes in microsatellite-unstable colorectal cancer. 2012 , 130, 1558-66	78
850	IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. 2012 , 91, 519-25	86
849	Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. 2012 , 132, 29-39	70
848	Breast cancer risk in atomic bomb survivors from multi-model inference with incidence data 1958-1998. 2012 , 51, 1-14	18
847	Next generation sequencing and a new era of medicine. 2013 , 62, 920-32	19
846	Molecular pathways in pancreatic carcinogenesis. 2013 , 107, 8-14	62

845	Protein tyrosine phosphatase-1B regulates the tyrosine phosphorylation of the adapter Grb2-associated binder 1 (Gab1) in the retina. 2013 , 11, 20	3
844	Modelling gene expression profiles related to prostate tumor progression using binary states. 2013 , 10, 37	4
843	Functional aspects of primary cilia in signaling, cell cycle and tumorigenesis. 2013 , 2, 6	127
842	Cancer Genomics. 2013 ,	4
841	The genetics of melanoma: recent advances. 2013 , 14, 257-79	61
840	Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?. 2013 , 32, 673-705	15
839	Evidence for APOBEC3B mutagenesis in multiple human cancers. 2013 , 45, 977-83	507
838	Natural mutations lead to enhanced proteasomal degradation of human Ncb5or, a novel flavoheme reductase. 2013 , 95, 1403-10	8
837	Sequencing PCR-amplified DNA in lipoprotein and cardiovascular disease research. 2013 , 1027, 139-55	
836	Hsp90, an unlikely ally in the war on cancer. 2013 , 280, 1381-96	142
835	Utilizing protein structure to identify non-random somatic mutations. 2013 , 14, 190	42
834	Detecting recurrent gene mutation in interaction network context using multi-scale graph diffusion. 2013 , 14, 29	28
833	Revealing selection in cancer using the predicted functional impact of cancer mutations. Application to nomination of cancer drivers. 2013 , 14 Suppl 3, S8	11
832	Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis. 2013 , 14, 505	25
831	Gene rearrangements in hormone receptor negative breast cancers revealed by mate pair sequencing. 2013 , 14, 165	28
830	Mutation spectrum in human colorectal cancers and potential functional relevance. 2013 , 14, 32	8
829	Suppression subtractive hybridization identified differentially expressed genes in lung adenocarcinoma: ERGIC3 as a novel lung cancer-related gene. 2013 , 13, 44	23
828	Eradication of gastric cancer is now both possible and practical. 2013 , 23, 492-501	76

827	Computational approaches to identify functional genetic variants in cancer genomes. 2013 , 10, 723-9	129
826	TargetHunter: an in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database. 2013 , 15, 395-406	126
825	Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. 2013 , 20, 3802-8	127
824	DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies. 2013 , 93, 439-51	53
823	Computational studies on Alzheimer's disease associated pathways and regulatory patterns using microarray gene expression and network data: revealed association with aging and other diseases. 2013 , 334, 109-21	27
822	Next Generation Sequencing in Cancer Research. 2013 ,	4
821	Novel mutations and expression alterations in SMAD3/TGFBR2 genes in oral carcinoma correlate with poor prognosis. 2013 , 52, 1042-52	14
820	The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. 2013 , 24, 365-78	102
819	Polymorphism of transglutaminase 2: unusually low frequency of genomic variants with deficient functions. 2013 , 44, 215-25	6
818	The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia. 2013 , 37, 1200-7	46
817	The tumor suppressor Chd5 is induced during neuronal differentiation in the developing mouse brain. 2013 , 13, 482-9	17
816	The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. 2013 , 73, 4372-82	207
815	Genome-wide association and sequencing studies on colorectal cancer. 2013 , 23, 502-11	13
814	The regulatory landscape for actively personalized cancer immunotherapies. 2013 , 31, 880-2	52
813	Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. 2013 , 45, 1459-63	326
812	Identification of candidate oncogenes in human colorectal cancers with microsatellite instability. 2013 , 145, 540-3.e22	40
811	Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. 2013 , 12, 1002-15	80
810	Epigenetics and colorectal cancer pathogenesis. <i>Cancers</i> , 2013 , 5, 676-713	6.6 159

809	Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. 2013 , 110, 13481-6	127
808	Micro and Nano Flow Systems for Bioanalysis. 2013 ,	2
807	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. 2013 , 45, 1470-1473	464
806	Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies. 2013 , 50, 61-9	13
805	Mutational landscape and significance across 12 major cancer types. 2013 , 502, 333-339	2803
804	Fundamentals of Pharmaceutical Nanoscience. 2013 ,	13
803	Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. 2013 , 5, 197ra102	178
802	Targeted Sequencing Strategies in Cancer Research. 2013 , 137-163	2
801	IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. 2013 , 15, 1114-26	85
800	Nrf2 is a potential therapeutic target in radioresistance in human cancer. 2013 , 88, 706-15	72
799	The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. 2013 , 12, 1994-2005	22
798	SAVI: a statistical algorithm for variant frequency identification. 2013 , 7 Suppl 2, S2	29
797	The emerging role of the Nrf2-Keap1 signaling pathway in cancer. 2013 , 27, 2179-91	828
796	Germline variants in MRE11/RAD50/NBN complex genes in childhood leukemia. 2013 , 13, 457	10
795	Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis. 2013 , 15, R66	61
794	Whole transcriptome sequencing identifies tumor-specific mutations in human oral squamous cell carcinoma. 2013 , 6, 28	21
793	Automated serial extraction of DNA and RNA from biobanked tissue specimens. 2013 , 13, 66	15
792	Clinical Pharmacogenomics. 2013 , 1009-1031	

791	wKinMut: an integrated tool for the analysis and interpretation of mutations in human protein kinases. 2013 , 14, 345	5
790	ASYMMETRIC CELL DIVISION: IMPLICATIONS FOR GLIOMA DEVELOPMENT AND TREATMENT. 2013 , 4, 484-503	11
789	Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis. 2013 , 6, 54	27
788	Histone H3 lysine 4 methyltransferases and demethylases in self-renewal and differentiation of stem cells. 2013 , 3, 39	63
787	Emerging patterns of somatic mutations in cancer. 2013 , 14, 703-18	366
786	TIMELESS is overexpressed in lung cancer and its expression correlates with poor patient survival. 2013 , 104, 171-7	37
785	A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. 2013 , 7, 776-90	116
784	Advances in the development of cancer immunotherapies. 2013 , 34, 90-8	34
783	Biomarkers in Oncology. 2013 ,	1
782	Next-generation sequencing in cancer research & diagnostics. 2013 , 20-40	
781	Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. 2013 , 9, 637	192
780	TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. 2013 , 110, 6021-6	968
779	Needles in a haystack: finding recurrent genomic changes in breast cancer. 2013 , 14, 304	2
778	Differences in the regulation of K-Ras and H-Ras isoforms by monoubiquitination. 2013 , 288, 36856-62	49
777	Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. 2013 , 63, 347-53	115
776	The epigenetic landscape of oral squamous cell carcinoma. 2013 , 108, 370-9	69
775	Parameter space exploration within dynamic simulations of signaling networks. 2013 , 10, 103-20	3
774	Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis. 2013 , 182, 646-67	20

773	SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. 2013 , 73, 725-35	202
772	Leukemias. 2013 , 675-690	
771	Biomarker Discovery Strategies: DNA, RNA, and Protein. 2013 , 401-416	
770	Epigenetic regulation by Z-DNA silencer function controls cancer-associated ADAM-12 expression in breast cancer: cross-talk between MeCP2 and NF1 transcription factor family. 2013 , 73, 736-44	36
769	A Bayesian ensemble approach with a disease gene network predicts damaging effects of missense variants of human cancers. 2013 , 132, 15-27	3
768	The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. 2013 , 288, 3804-15	116
767	MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. 2013 , 229, 99-110	58
766	Impact of Genomics on Personalization of Breast Cancer Care. 2018 , 331-372	1
765	Wingless/Wnt Signaling in Intestinal Development, Homeostasis, Regeneration and Tumorigenesis: A Drosophila Perspective. 2018 , 6,	12
764	Metabolic Regulation of Hypoxia-Inducible Transcription Factors: The Role of Small Molecule Metabolites and Iron. 2018 , 6,	25
763	Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells. 2018 , 10, 2	2
762	IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53. 2018 , 293, 9747-9758	15
761	Importance of genetic background of oxysterol signaling in cancer. 2018 , 153, 109-138	8
760	Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. 2018 , 102, 31-39	14
759	The LINC Complex. 2018 ,	
758	Data Harmonization for a Molecularly Driven Health System. 2018 , 174, 1045-1048	10
757	Dysregulation of NRF2 in Cancer: from Molecular Mechanisms to Therapeutic Opportunities. 2018 , 26, 57-68	51
756	shRNA-induced knockdown of the SPERT gene inhibits proliferation and promotes apoptosis of human colorectal cancer RKO cells. 2018 , 40, 813-822	5

755	N-(2-hydroxypropyl)methacrylamide polymer conjugated pyropheophorbide-a, a promising tumor-targeted theranostic probe for photodynamic therapy and imaging. 2018 , 130, 165-176	26
754	The additive to background assumption in cancer risk assessment: A reappraisal. 2018 , 166, 175-204	16
753	Identification of metastasis driver genes by massive parallel sequencing of successive steps of breast cancer progression. 2018 , 13, e0189887	17
752	SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. 2018 , 17, 1124-1137	9
751	G protein-coupled receptor LGR6 is an independent risk factor for colon adenocarcinoma. 2019 , 13, 482-491	2
750	Immune checkpoints and cancer in the immunogenomics era. 2019 , 18, 133-139	7
749	Unraveling obscurins in heart disease. 2019 , 471, 735-743	12
748	Exome Sequencing of ABCB5 Identifies Recurrent Melanoma Mutations that Result in Increased Proliferative and Invasive Capacities. 2019 , 139, 1985-1992.e10	1
747	The LINC complex, mechanotransduction, and mesenchymal stem cell function and fate. 2019 , 13, 68	39
746	Epigenetic Biomarkers and Their Therapeutic Applications in Colorectal Cancer. 2019 ,	
745	The epigenomic impact of methylation in metabolic dysfunction and cancer. 2019 , 67-83	1
744	Inhibition of p53 inhibitors: progress, challenges and perspectives. 2019 , 11, 586-599	60
743	Genetic Aberration Analysis in Thai Colorectal Adenoma and Early-Stage Adenocarcinoma Patients by Whole-Exome Sequencing. <i>Cancers</i> , 2019 , 11,	6.6 4
742	Methylation Density Pattern of Gene in Lung Cancer Cell Lines Detected by Quantitative Methylation Specific PCR and Pyrosequencing. 2019 , 20,	13
741	Prognostic Impact of Canonical TGF- β Signaling in Urothelial Bladder Cancer. 2019 , 55,	7
740	Dendrimer-Based Nanoparticulate Delivery System for Cancer Therapy. 2019 , 233-255	7
739	Identification of shared genomic aberrations between angiomatous and microcystic meningiomas. 2019 , 1, vdz028	0
738	. 2019 ,	

737	WITHDRAWN: Evolutionary Game Dynamics and Cancer. 2019,		
736	The prognostic value of faciogenital dysplasias as biomarkers in head and neck squamous cell carcinoma. 2019, 13, 1399-1415		5
735	The Serotonergic System. 2019, 81-120		
734	The GABAergic System. 2019, 199-226		1
733	Estrogen receptor 1 mutations in 260 cervical cancer samples from Chinese patients. 2019, 18, 2771-2776		3
732	Understanding Cancer Through the Lens of Epigenetic Inheritance, Allele-Specific Gene Expression, and High-Throughput Technology. 2019, 9, 794		7
731	A network of nuclear envelope proteins and cytoskeletal force generators mediates movements of and within nuclei throughout development. 2019, 244, 1323-1332		7
730	Defective modulation of LINE-1 retrotransposition by cancer-associated SAMHD1 mutants. 2019, 519, 213-219		5
729	Passenger Hotspot Mutations in Cancer. 2019, 36, 288-301.e14		38
728	Ventricular Zone Expressed PH Domain Containing 1 (VEPH1): an adaptor protein capable of modulating multiple signaling transduction pathways during normal and pathological development. 2019, 17, 116		4
727	Purine-Metabolising Enzymes and Apoptosis in Cancer. <i>Cancers</i> , 2019, 11,	6.6	27
726	Chicken or Egg: Is Clonal Hematopoiesis Primarily Caused by Genetic or Epigenetic Aberrations?. 2019, 10, 785		3
725	Two Proximally Close Priority Candidate Genes for diplopodia-1, an Autosomal Inherited Craniofacial-Limb Syndrome in the Chicken: MRE11 and GPR83. 2019, 110, 194-210		
724	Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers. 2019, 9, 8946		26
723	Integration of Random Forest Classifiers and Deep Convolutional Neural Networks for Classification and Biomolecular Modeling of Cancer Driver Mutations. 2019, 6, 44		20
722	The Role of Forkhead Box Proteins in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11,	6.6	9
721	Nonreceptor tyrosine phosphatase 14 promotes proliferation and migration through regulating phosphorylation of YAP of Hippo signaling pathway in gastric cancer cells. 2019, 120, 17723-17730		6
720	Cancer Stem Cells: From Birth to Death. 2019, 1-30		

719	Bibliography. 2019 , 489-533	
718	The significance of gene mutations across eight major cancer types. 2019 , 781, 88-99	8
717	Potential Applications of NRF2 Inhibitors in Cancer Therapy. 2019 , 2019, 8592348	92
716	Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations. 2019 , 9, 7436	4
715	The Activin Social Network: Activin, Inhibin, and Follistatin in Breast Development and Cancer. 2019 , 160, 1097-1110	5
714	Pharmacological Applications of Nrf2 Inhibitors as Potential Antineoplastic Drugs. 2019 , 20,	27
713	Effects of obesity and weight loss on mitochondrial structure and function and implications for colorectal cancer risk. 2019 , 78, 426-437	9
712	SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. 2019 , 142, 423-434	3
711	Hormone therapy use and breast tissue DNA methylation: analysis of epigenome wide data from the normal breast study. 2019 , 14, 146-157	4
710	Clinicopathological, immune and molecular correlates of methylation in gastric adenocarcinomas. 2019 , 11, 639-653	9
709	Systemic Metabolism, Its Regulators, and Cancer: Past Mistakes and Future Potential. 2019 , 10, 65	6
708	Kaiso is required for MTG16-dependent effects on colitis-associated carcinoma. 2019 , 38, 5091-5106	6
707	Whole-exome sequencing revealed mutational profiles of giant cell glioblastomas. 2019 , 29, 782-792	8
706	Intratumoral Polymorphism of Peroxisome Proliferator-Activated Receptor Delta-87 T>C in Colorectal Cancer. 2019 , 66, 609-618	0
705	Obscurin is a semi-flexible molecule in solution. 2019 , 28, 717-726	3
704	Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers. 2019 , 15, e1006658	45
703	Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. 2019 , 24,	91
702	Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression. 2019 , 43, 2044-2054	10

701	Leucine Rich Repeat Proteins: Sequences, Mutations, Structures and Diseases. 2019 , 26, 108-131	28
700	Role of genomic instability in human carcinogenesis. 2019 , 244, 227-240	20
699	CFP suppresses breast cancer cell growth by TES-mediated upregulation of the transcription factor DDIT3. 2019 , 38, 4560-4573	10
698	The knockout zebrafish line: a model to study Vici syndrome. 2019 , 15, 1438-1454	11
697	Exome sequencing in 51 early onset non-familial CRC cases. 2019 , 7, e605	10
696	Gli Proteins: Regulation in Development and Cancer. 2019 , 8,	61
695	Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents. 2019 , 24, 685-702	33
694	Key genes associated with pancreatic cancer and their association with outcomes: A bioinformatics analysis. 2019 , 20, 1343-1352	8
693	Exploring Pancreatic Metabolism and Malignancy. 2019 ,	1
692	HDAC Inhibitors in Acute Myeloid Leukemia. <i>Cancers</i> , 2019 , 11,	6.6 53
691	The Effect of Oncomutations and Posttranslational Modifications of Histone H1 on Chromatosome Structure and Stability. 2019 , 74, 121-126	1
690	Ontology-based prediction of cancer driver genes. 2019 , 9, 17405	9
689	Novel IDH1-Targeted Glioma Therapies. 2019 , 33, 1155-1166	22
688	pMHC Structural Comparisons as a Pivotal Element to Detect and Validate T-Cell Targets for Vaccine Development and Immunotherapy-A New Methodological Proposal. 2019 , 8,	1
687	Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer. 2019 , 9, 17358	40
686	Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer. 2019 , 8, 408-417	41
685	The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas. 2019 , 97, 457-469	23
684	Mechanisms of DNA Damage Tolerance: Post-Translational Regulation of PCNA. 2018 , 10,	40

683	Structure and function of the Fgd family of divergent FYVE domain proteins. 2019 , 97, 257-264	12
682	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. 2019 , 30, 44-56	784
681	Hereditary brain tumor with a homozygous germline mutation in PMS2: pedigree analysis and prenatal screening in a family with constitutional mismatch repair deficiency (CMMRD) syndrome. 2019 , 18, 261-265	1
680	The Impact of Next-Generation Sequencing on Cancer Genomics: From Discovery to Clinic. 2019 , 9,	16
679	A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer. 2019 , 144, 1685-1696	11
678	Biophysical simulations and structure-based modeling of residue interaction networks in the tumor suppressor proteins reveal functional role of cancer mutation hotspots in molecular communication. 2019 , 1863, 210-225	21
677	Caroli syndrome: a clinical case with detailed histopathological analysis. 2019 , 12, 106-111	3
676	Novel therapeutic compound acridine-retrotuftsins action on biological forms of melanoma and neuroblastoma. 2019 , 145, 165-179	3
675	Primate-specific miR-944 activates p53-dependent tumor suppression in human colorectal cancers. 2019 , 440-441, 168-179	16
674	Unraveling the Exposome. 2019 ,	6
673	Cancer Driver Genes. 2019 ,	1
672	Range Expansion Theories Could Shed Light on the Spatial Structure of Intra-tumour Heterogeneity. 2019 , 81, 4761-4777	4
671	Heparan sulfate proteoglycan - A common receptor for diverse cytokines. 2019 , 54, 115-121	33
670	Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition. 2019 , 10, 441-448	3
669	Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans. 2019 , 49, 200-210	10
668	Oleanolic acid 3-acetate, a minor element of ginsenosides, induces apoptotic cell death in ovarian carcinoma and endometrial carcinoma cells via the involvement of a reactive oxygen species-independent mitochondrial pathway. 2020 , 44, 96-104	6
667	Mountains and Chasms: Surveying the Oncogenomic Publication Landscape. 2020 , 98, 332-343	3
666	Cancer Immunology. 2020 , 84-96.e5	

665	Molecular and Genetic Markers in Appendiceal Mucinous Tumors: A Systematic Review. 2020 , 27, 85-97		11
664	Tumor Liquid Biopsies. 2020 ,		5
663	Cancer of the Breast. 2020 , 1560-1603.e12		6
662	Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. 2020 , 59, 417-426		11
661	2-Hydroxyglutarate in Cancer Cells. 2020 , 33, 903-926		30
660	Nesprin-1 impact on tumorigenic cell phenotypes. <i>Molecular Biology Reports</i> , 2020 , 47, 921-934	2.8	8
659	Stathmin levels alter PTPN14 expression and impact neuroblastoma cell migration. 2020 , 122, 434-444		4
658	The Etiology of Cancer. 2020 , 1-35		0
657	Overexpression of Gene is a Favorable Prognostic Marker in Lower-Grade Gliomas and Predicts a Favorable Outcome in Patients with Mutations and Chromosome 1p19q Codeletion. <i>Cancers</i> , 2019 , 12,	6.6	15
656	Profiling of Tumor Microenvironment Components Identifies Five Stroma-Related Genes with Prognostic Implications in Colorectal Cancer. 2020 ,		8
655	Generating realistic null hypothesis of cancer mutational landscapes using SigProfilerSimulator. 2020 , 21, 438		9
654	Mutational landscape of K-Ras substitutions at 12th position-a systematic molecular dynamics approach. 2020 , 1-15		11
653	The Resistance Mechanisms of Lung Cancer Immunotherapy. 2020 , 10, 568059		14
652	-Associated Disorders and the Model of Arts Syndrome. 2020 , 21,		
651	Das molekulare Tumorboard. 2020 , 26, 679-684		
650	Linker histone H1.5 is an underestimated factor in differentiation and carcinogenesis. 2020 , 6, dvaa013		1
649	Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma. 2020 , 11, 998		10
648	Analysis of Human Mutations in the Supernumerary Subunits of Complex I. 2020 , 10,		2

647	Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort. 2020 , 10, 19304	3
646	IRF3 prevents colorectal tumorigenesis via inhibiting the nuclear translocation of Ectatinin. <i>Nature Communications</i> , 2020 , 11, 5762	17.4 15
645	Overexpression of Extradomain-B Fibronectin is Associated with Invasion of Breast Cancer Cells. 2020 , 9,	9
644	A compendium of mutational cancer driver genes. 2020 , 20, 555-572	185
643	Clonal evolution driven by superdriver mutations. 2020 , 20, 89	1
642	The Expressions and Mechanisms of Sarcomeric Proteins in Cancers. 2020 , 2020, 8885286	1
641	Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, -mutant glioblastoma: a case report from a Phase I study. 2020 , 9, CNS62	8
640	Progress in Neoantigen Targeted Cancer Immunotherapies. 2020 , 8, 728	12
639	A Genetic Analysis of Tumor Progression in <i>Drosophila</i> Identifies the Cohesin Complex as a Suppressor of Individual and Collective Cell Invasion. 2020 , 23, 101237	6
638	A Survey of Reported Disease-Related Mutations in the MRE11-RAD50-NBS1 Complex. 2020 , 9,	9
637	Structure, regulatory factors and cancer-related physiological effects of ADAM9. 2020 , 14, 165-181	0
636	Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation. 2020 , 5, 429-438	1
635	Usefulness of a novel device to divide core needle biopsy specimens in a spatially matched fashion. 2020 , 10, 17098	0
634	Association of Body Mass Index with Fecal Microbial Diversity and Metabolites in the Northern Finland Birth Cohort. 2020 , 29, 2289-2299	6
633	Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress. 2020 , 16, 2959-2979	12
632	Status Quo of Glycosylation in Cancer: What Is, What Is Not and What Is to Be. 2020 , 10, 8401	
631	Computational methods for detecting cancer hotspots. 2020 , 18, 3567-3576	5
630	Light Pollution and Cancer. 2020 , 21,	18

629	Cutting the Brakes on Ras-Cytoplasmic GAPs as Targets of Inactivation in Cancer. <i>Cancers</i> , 2020 , 12,	6.6	2
628	KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer. 2021 , 15, 2412-2422		6
627	ADAMTS-15 Has a Tumor Suppressor Role in Prostate Cancer. 2020 , 10,		7
626	Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression. 2020 , 12, 74		7
625	IDH-Mutant Gliomas. 2020 ,		3
624	in Breast and Ovarian Cancers. 2020 , 21,		7
623	CRL4 and USP11 oppositely regulate the stability of myeloid leukemia factors (MLFs). 2020 , 529, 127-132		4
622	Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. 2020 , 123, 803-810		18
621	An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. <i>Nature Communications</i> , 2020 , 11, 1395	17.4	44
620	Intratumoral heterogeneity and genetic characteristics of prostate cancer. 2020 , 146, 3369-3378		9
619	ABCA1 Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms. 2020 , 30, 3397-3410.e5		7
618	PTPN14, a target gene of miR-4295, restricts the growth and invasion of osteosarcoma cells through inactivation of YAP1 signalling. 2020 , 47, 1301-1310		7
617	Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer. 2020 , 7, 1716618		7
616	Loss of the nuclear Wnt pathway effector TCF7L2 promotes migration and invasion of human colorectal cancer cells. 2020 , 39, 3893-3909		18
615	OncoOmics approaches to reveal essential genes in breast cancer: a panoramic view from pathogenesis to precision medicine. 2020 , 10, 5285		17
614	A New Maximum Weight Submatrix Solver Tool for Identifying Mutated Driver Pathways in Cancer using Python. 2020 ,		
613	Flaming the fight against cancer cells: the role of microRNA-93. 2020 , 20, 277		5
612	Knockout of by CRISPR/Cas9 Mediated Inhibition of Tumor Angiogenesis in Ovarian Cancer. 2020 , 10, 1451		4

611	PTPN14 acts as a candidate tumor suppressor in prostate cancer and inhibits cell proliferation and invasion through modulating LATS1/YAP signaling. 2020 , 53, 101642		4
610	PD1 gene polymorphism is associated with a poor prognosis in hepatocellular carcinoma following liver resection, cohort study. 2020 , 80, 84-90		1
609	Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics. <i>Molecular Biology Reports</i> , 2020 , 47, 5523-5533	2.8	11
608	Making heads or tails - the emergence of capicua (CIC) as an important multifunctional tumour suppressor. 2020 , 250, 532-540		11
607	Early-onset colorectal cancer: initial clues and current views. 2020 , 17, 352-364		100
606	Epigenetics/epigenomics of triterpenoids in cancer prevention and in health. 2020 , 175, 113890		15
605	Ras-Mediated Activation of NF- κ B and DNA Damage Response in Carcinogenesis. 2020 , 38, 185-208		8
604	Identification of germline and somatic mutations in pancreatic adenocarcinoma using whole exome sequencing. 2020 , 27, 389-397		4
603	Sensitivity analysis methods in the biomedical sciences. 2020 , 323, 108306		30
602	Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism. 2020 , 33, 966-997		29
601	Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. 2020 , 3, 56		77
600	Prioritizing Gene Cascading Paths to Model Colorectal Cancer Through Engineered Organoids. 2020 , 8, 12		1
599	Myristoylated TMEM39AS41, a cell-permeable peptide, causes lung cancer cell death. 2020 , 36, 123-130		18
598	Ciliary Genes in Renal Cystic Diseases. 2020 , 9,		12
597	Pan-cancer analysis and applications. 2020 , 307-316		
596	Molecular Links between the Circadian Clock and the Cell Cycle. 2020 , 432, 3515-3524		24
595	A Preliminary Study on the Establishment of the PDTX Model. 2020 , 12, 1969-1979		0
594	Pharmacogenetics of Breast Cancer. 2020 ,		

593	Isocitrate dehydrogenase 1 gene variants analysis of glioma patients from Pakistan. 2021 , 85, 73-79		
592	DNA polymerase eta: A potential pharmacological target for cancer therapy. 2021 , 236, 4106-4120		6
591	Candidate gene association of gene expression data in sugarcane contrasting for sucrose content. 2021 , 113, 229-237		2
590	Genomic Analyses for Predictors of Response to Chemoradiation in Stage III Non-Small Cell Lung Cancer. 2021 , 6, 100615		2
589	Association between histone deacetylase activity and vitamin D-dependent gene expressions in relation to sulforaphane in human colorectal cancer cells. 2021 , 101, 1833-1843		1
588	Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine. 2021 , 8, 133-145		24
587	In Silico Identification of Contradictory Role of ADAMTS5 in Hepatocellular Carcinoma. 2021 , 20, 1533033820986826		
586	Phosphorylation of PKC β by FER tips the balance from EGFR degradation to recycling. 2021 , 220,		5
585	Drebrin regulates cytoskeleton dynamics in migrating neurons through interaction with CXCR4. 2021 , 118,		5
584	From genetic data and structures to drug development: New approaches to target Eph receptors. 2021 , 227-249		
583	Bioinformatics & computer programming. 2021 , 125-148		
582	Prognostic Value of Complement Properdin in Cancer. 2020 , 11, 614980		4
581	Genomic Variation, Evolvability, and the Paradox of Mental Illness. 2020 , 11, 593233		0
580	Understanding cell-cell communication and signaling in the colorectal cancer microenvironment. 2021 , 11, e308		12
579	Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy. <i>Cancers</i> , 2021 , 13,	6.6	12
578	Sequence neighborhoods enable reliable prediction of pathogenic mutations in cancer genomes.		
577	Myosin Motors: Novel Regulators and Therapeutic Targets in Colorectal Cancer. <i>Cancers</i> , 2021 , 13,	6.6	6
576	Potential Use of Shared Frameshift Mutations in 'Off-the-Shelf' Neoantigen Vaccines. 2021 , 7, 175-177		0

575	Molecular Oncology in Management of Colorectal Cancer. 2021 , 12, 169-180		
574	Protein tyrosine phosphatases in cell adhesion. 2021 , 478, 1061-1083		5
573	Virtual Screening of Cablin Patchouli Herb as a Treatment for Heat Stress: A Study Based on Network Pharmacology, Molecular Docking, and Experimental Verification. 2021 , 2021, 8057587		0
572	IDH1 gene mutation activates Smad signaling molecules to regulate the expression levels of cell cycle and biological rhythm genes in human glioma U87-MG cells. 2021 , 23,		0
571	Genomic Instability Profiles at the Single Cell Level in Mouse Colorectal Cancers of Defined Genotypes. <i>Cancers</i> , 2021 , 13,	6.6	2
570	Biochemical and structural characterization of analogs of MRE11 breast cancer-associated mutant F237C. 2021 , 11, 7089		1
569	Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study. 2021 , 65, 103242		2
568	DNASE1L3 as a Prognostic Biomarker Associated with Immune Cell Infiltration in Cancer. 2021 , 14, 2003-2017		7
567	Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches. 2021 , 11, 1024-1039		17
566	regulatory mutations with driver hallmarks in major cancers. 2021 , 24, 102144		4
565	A New Insight for the Identification of Oncogenic Variants in Breast and Prostate Cancers in Diverse Human Populations, With a Focus on Latinos. 2021 , 12, 630658		1
564	Sequence features, structure, ligand interaction, and diseases in small leucine rich repeat proteoglycans. 2021 , 15, 519-531		3
563	Replication Stress, Genomic Instability, and Replication Timing: A Complex Relationship. 2021 , 22,		3
562	Pharmacological and nutritional targeting of voltage-gated sodium channels in the treatment of cancers. 2021 , 24, 102270		3
561	Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite. <i>Cancers</i> , 2021 , 13,	6.6	3
560	Molecular Processes Involved in Pancreatic Cancer and Therapeutics. 2021 , 15, 85-108		
559	DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use. 2021 , 11,		2
558	Whole exome sequencing of a gut-associated lymphoid tissue neoplasm points to precursor or early form of sporadic colon carcinoma. <i>Pathology Research and Practice</i> , 2021 , 220, 153406		3-4

557	Normalization of metabolic data to total thymine content and its application to determination of 2-hydroxyglutarate. 2021 , 618, 114129		0
556	Protein Acetylation at the Interface of Genetics, Epigenetics and Environment in Cancer. 2021 , 11,		6
555	IDH1 and IDH2 Mutations in Colorectal Cancers. 2021 , 156, 777-786		3
554	Exploring the Conformational Landscape of the Neh4 and Neh5 Domains of Nrf2 Using Two Different Force Fields and Circular Dichroism. 2021 , 17, 3145-3156		6
553	Synonymous mutations that regulate translation speed might play a non-negligible role in liver cancer development. 2021 , 21, 388		9
552	Non-coding mutations reveal cancer driver cistromes in luminal breast cancer.		
551	Genomic prediction of neoantigens: immunogenomics before NGS. 2021 , 22, 550-551		1
550	Sequence Neighborhoods Enable Reliable Prediction of Pathogenic Mutations in Cancer Genomes. <i>Cancers</i> , 2021 , 13,	6.6	1
549	IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells. 2021 , 12, 520		5
548	GLI1: A Therapeutic Target for Cancer. 2021 , 11, 673154		6
547	Emerging Roles of Wild-type and Mutant IDH1 in Growth, Metabolism and Therapeutics of Glioma. 61-78		1
546	Organoids in cancer research: a review for pathologist-scientists. 2021 , 254, 395-404		2
545	Precision Oncology. 2021 , 1, 97-112		
544	Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes. 2021 , 22,		4
543	The structure-based cancer-related single amino acid variation prediction. 2021 , 11, 13599		0
542	Aberrant Expression of PTPN-14 and Wilms Tumor 1 as Putative Biomarker for Locoregional Recurrence in Oral Squamous Cell Carcinoma.		
541	Enrichment of low abundance DNA/RNA by oligonucleotide-clicked iron oxide nanoparticles. 2021 , 11, 13053		0
540	IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. 2021 , 25, 457-473		3

539	The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape. 2021 , 49, 1041-1054		3
538	Silencing of LRRFIP1 enhances the sensitivity of gemcitabine in pancreatic cancer cells by activating JNK/c-Jun signaling. 2021 , 21, 771-778		1
537	Biomarkers of therapeutic response with immune checkpoint inhibitors. 2021 , 9, 1040		1
536	A crucial residue in the hydrophobic core of the solenoid structure of leucine rich repeats. 2021 , 1869, 140631		2
535	Metabolic Rewiring and the Characterization of Oncometabolites. <i>Cancers</i> , 2021 , 13,	6.6	8
534	Yeast-based screening of cancer mutations in the DNA damage response protein Mre11 demonstrates importance of conserved capping domain residues. <i>Molecular Biology Reports</i> , 2021 , 48, 4107-4119	2.8	
533	Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells. 2021 , 34, 1428-1483		4
532	ZNF668 deficiency causes a recognizable disorder of DNA damage repair. 2021 , 140, 1395-1401		
531	A systematic view of computational methods for identifying driver genes based on somatic mutation data. 2021 , 20, 333-343		1
530	Nutrition Strategy and Life Style in Polycystic Ovary Syndrome-Narrative Review. 2021 , 13,		11
529	YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. 2021 , 475, 205-221		12
528	Machinery, regulation and pathophysiological implications of autophagosome maturation. 2021 , 22, 733-750		33
527	Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma. <i>Cancers</i> , 2021 , 13,	6.6	2
526	Pan-cancer analysis of the oncogenic role of discs large homolog associated protein 5 (DLGAP5) in human tumors. 2021 , 21, 457		2
525	Obscurin: A multitasking giant in the fight against cancer. 2021 , 1876, 188567		2
524	Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy. <i>Cancers</i> , 2021 , 13,	6.6	1
523	A glitch in the snitch: the role of linker histone H1 in shaping the epigenome in normal and diseased cells. 2021 , 11, 210124		2
522	Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer. 2021 , 40, 5880-5892		2

521	[The molecular tumor board]. 2021 , 92, 1011-1015	2
520	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. 2021 ,	3
519	SYS-Mut: Decoding the Functional Significance of Rare Somatic Mutations in Cancer.	
518	Obesity and inflammation: colorectal cancer engines. 2021 ,	4
517	Deep structure of DNA for genomic analysis. 2021 ,	2
516	Mutations in Noncoding -Regulatory Elements Reveal Cancer Driver Cistromes in Luminal Breast Cancer. 2021 ,	0
515	Advancement in bioinformatics and microarray-based technologies for genome sequence analysis and its application in bioremediation of soil and water pollutants. 2021 , 209-225	
514	Computational cancer genomics. 2021 , 329-359	
513	Co nř uřřory. Paralely v chovřř bunřř a lidřř 2021 ,	
512	The Role of Linker Histones in Carcinogenesis. 2021 , 47, 278-287	
511	Aberrant Methylation of Tumour Suppressor Gene ADAM12 in Chronic Lymphocytic Leukemia Patients: Application of Methylation Specific-PCR Technique. 2021 , 22, 85-91	1
510	Redefining Disease and Pharmaceutical Targets Through Molecular Definitions and Personalized Medicine. 1	0
509	Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead. 2008 , 617, 23-40	11
508	Molecular network analysis using reverse phase protein microarrays for patient tailored therapy. 2008 , 610, 177-86	14
507	Somatic Genetic Development in Epithelial Ovarian Cancer. 2009 , 215-246	1
506	Somatic Alterations and Implications in Breast Cancer. 2009 , 183-213	1
505	Epigenetic Silencing of Progeroid Syndromes. 2010 , 345-369	1
504	TGF-β Signaling Alterations in Neoplastic and Stromal Cells. 2010 , 335-348	1

503	Wnt/ β Catenin Signaling and Oral Cancer Metastasis. 2009 , 231-264	1
502	Memory T-cell responses and survival in human cancer: remember to stay alive. 2010 , 684, 166-77	8
501	Genetics and Epigenetics of Head and Neck Cancer. 2011 , 93-106	1
500	Understanding Cancer Metabolism Through Global Metabolomics. 2012 , 177-190	5
499	Integrating Omics Data for Quantitative and Systems Pharmacology in Translational Oncology. 2013 , 187-206	1
498	Molecular Pathology of Breast Cancer. 2013 , 95-128	3
497	The PI3K Pathway in Colorectal Cancers. 2013 , 157-199	1
496	Regulating Chromatin by Histone Acetylation. 2014 , 147-212	18
495	Mechanisms of nuclear size regulation in model systems and cancer. 2014 , 773, 537-69	44
494	Systems Biology of Personalized Medicine. 2009 , 615-630	2
493	Genomic Instability, DNA Repair Pathways and Cancer. 2008 , 269-279	1
492	5'-azacytidine expression arrays. 2009 , 507, 165-74	8
491	Bioinformatic tools for identifying disease gene and SNP candidates. 2010 , 628, 307-19	30
490	Cancer genome analysis informatics. 2010 , 628, 75-102	7
489	Targeted Therapy in Colorectal Cancer. 2008 , 101-123	2
488	Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation. 2010 , 629, 405-52	24
487	Heterogeneity of Breast Cancer: Gene Signatures and Beyond. 2012 , 13-25	2
486	Predicting the functional consequences of somatic missense mutations found in tumors. 2014 , 1101, 135-59	8

485	Enrichment and Analysis of ctDNA. 2020 , 215, 181-211	8
484	mRNA Vaccination and Personalized Cancer Therapy. 2014 , 89-100	2
483	Toluquinol, A Marine Fungus Metabolite, Inhibits Some of the Hallmarks of Cancer. 2015 , 269-299	1
482	Branching Process Models of Cancer. 2015 , 1-63	11
481	The Biology of AYA Cancers. 2017 , 43-67	3
480	Cancer Genomic and Epigenomic Variations in Sub-Saharan Africa. 2017 , 21-36	1
479	Oncogenic signaling pathways and deregulated target genes. 2007 , 176, 7-24	6
478	Aging-associated Non-melanoma Skin Cancer: A Role for the Dermis. 2010 , 587-599	1
477	Algorithms for Detecting Significantly Mutated Pathways in Cancer. 2010 , 506-521	14
476	IL-23 orchestrates the switch from tumor immune surveillance to tumor-promoting inflammation. 2009 , 161-172	1
475	Molecular Parameters for Prognostic and Predictive Assessment in Colorectal Cancer. 2013 , 41-62	2
474	Application of Bioinformatics in Cancer Research. 2010 , 211-233	2
473	Methylation in Colorectal Cancer. 2015 , 373-455	1
472	Functional and therapeutic significance of protein kinase D enzymes in invasive breast cancer. 2015 , 72, 4369	1
471	Colorectal Cancer. 2009 , 879-897	2
470	DNA Damage Response Pathways and Cancer. 2008 , 139-152	3
469	Cancer of the Breast. 2008 , 1875-1943	8
468	Molecular Oncology of Breast Cancer. 2009 , 501-531	1

467	Cancer Immunology. 2014 , 78-97.e5	2
466	Cancer of the Breast. 2014 , 1630-1692.e9	1
465	Molecular Abnormalities in Colon and Rectal Cancer. 2008 , 409-421	1
464	Untangling a complex web: Computational analyses of tumor molecular profiles to decode driver mechanisms. 2020 , 47, 595-609	0
463	Targeting Hippo signaling pathway by phytochemicals in cancer therapy. 2020 ,	3
462	Cancer complexity slows quest for cure. 2008 , 455, 148	62
461	Evolution in Health and Disease. 2007 ,	32
460	Introducing Evolutionary Thinking For Medicine. 2007 , 3-16	2
459	Global spatial patterns of infectious diseases and human evolution. 2007 , 19-30	5
458	Human genetic variation of medical significance. 2007 , 51-62	1
457	Intimate relations: Evolutionary conflicts of pregnancy and childhood. 2007 , 65-76	3
456	How hormones mediate trade-offs in human health and disease. 2007 , 77-94	10
455	Functional significance of MHC variation in mate choice, reproductive outcome, and disease risk. 2007 , 95-108	2
454	The ecology and evolution of antibiotic-resistant bacteria. 2007 , 125-138	6
453	Pathogen evolution in a vaccinated world. 2007 , 139-152	6
452	The evolution and expression of virulence. 2007 , 153-168	8
451	Evolutionary origins of diversity in human viruses. 2007 , 169-184	1
450	The population structure of pathogenic bacteria. 2007 , 185-198	3

449	Emergence of new infectious diseases. 2007 , 215-228		5
448	Evolutionary biology as a foundation for studying aging and aging-related disease. 2007 , 241-252		3
447	Evolution, developmental plasticity, and metabolic disease. 2007 , 253-264		4
446	Lifestyle, diet, and disease: comparative perspectives on the determinants of chronic health risks. 2007 , 265-276		4
445	The disruption of trace element homeostasis due to aneuploidy as a unifying theme in the etiology of cancer.		2
444	Interplay of Driver, Mini-Driver, and Deleterious Passenger Mutations on Cancer Progression.		2
443	Unique genomic features and deeply-conserved functions of long non-coding RNAs in the Cancer LncRNA Census (CLC).		4
442	Pan-cancer analysis of whole genomes.		70
441	Ontology-based prediction of cancer driver genes.		1
440	OncoOmics approaches to reveal essential genes in breast cancer: a panoramic view from pathogenesis to precision medicine.		2
439	Passenger Hotspot Mutations in Cancer.		4
438	Comment on "The consensus coding sequences of human breast and colorectal cancers". <i>Science</i> , 2007 , 317, 1500; author reply 1500	33:3	44
437	Comment on "The consensus coding sequences of human breast and colorectal cancers". <i>Science</i> , 2007 , 317, 1500	33:3	106
436	Response to Comments on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers". <i>Science</i> , 2007 , 317, 1500-1500	33:3	10
435	Comment on "The consensus coding sequences of human breast and colorectal cancers". <i>Science</i> , 2007 , 317, 1500	33:3	40
434	Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy. <i>Journal of Clinical Investigation</i> , 2018 , 128, 3682-3691	15:9	42
433	APC-activated long noncoding RNA inhibits colorectal carcinoma pathogenesis through reduction of exosome production. <i>Journal of Clinical Investigation</i> , 2019 , 129, 727-743	15:9	72
432	Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. <i>Journal of Clinical Investigation</i> , 2020 , 130, 1595-1607	15:9	7

431	Adoptive T cell therapy for cancer in the clinic. <i>Journal of Clinical Investigation</i> , 2007 , 117, 1466-76	15.9	400
430	Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. <i>Journal of Clinical Investigation</i> , 2009 , 119, 454-64	15.9	168
429	Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. <i>Journal of Clinical Investigation</i> , 2013 , 123, 2921-34	15.9	232
428	Isocitrate dehydrogenase mutations in leukemia. <i>Journal of Clinical Investigation</i> , 2013 , 123, 3672-7	15.9	51
427	Radiation and immunotherapy: a synergistic combination. <i>Journal of Clinical Investigation</i> , 2013 , 123, 2756-63	15.9	186
426	The deubiquitinase USP9X regulates FBW7 stability and suppresses colorectal cancer. <i>Journal of Clinical Investigation</i> , 2018 , 128, 1326-1337	15.9	49
425	Capicua suppresses colorectal cancer progression via repression of ETV4 expression. 2020 , 20, 42		10
424	Cancer Cell. 2010 , 31-44		1
423	Oncodomains: A protein domain-centric framework for analyzing rare variants in tumor samples. 2017 , 13, e1005428		15
422	EGFR/Ras Signaling Controls Drosophila Intestinal Stem Cell Proliferation via Capicua-Regulated Genes. 2015 , 11, e1005634		80
421	A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer. 2017 , 13, e1006622		36
420	Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. 2008 , 5, e114		113
419	Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. 2016 , 13, e1002198		151
418	Identification of novel high-frequency DNA methylation changes in breast cancer. 2007 , 2, e1314		83
417	Cataloging coding sequence variations in human genome databases. 2008 , 3, e3575		11
416	Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells. 2008 , 3, e3597		17
415	Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events. 2008 , 3, e3714		19
414	Bi-directional SIFT predicts a subset of activating mutations. 2009 , 4, e8311		27

413	Detection of somatic mutations by high-resolution DNA melting (HRM) analysis in multiple cancers. 2011, 6, e14522	41
412	Differential expression of CHL1 gene during development of major human cancers. 2011, 6, e15612	70
411	Investigating the potential role of genetic and epigenetic variation of DNA methyltransferase genes in hyperplastic polyposis syndrome. 2011, 6, e16831	8
410	Functional characterization of human cancer-derived TRKB mutations. 2011, 6, e16871	31
409	Somatic mutagenesis with a Sleeping Beauty transposon system leads to solid tumor formation in zebrafish. 2011, 6, e18826	24
408	A flexible approach for highly multiplexed candidate gene targeted resequencing. 2011, 6, e21088	15
407	Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer. 2011, 6, e21639	16
406	Structural alterations from multiple displacement amplification of a human genome revealed by mate-pair sequencing. 2011, 6, e22250	8
405	Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer. 2011, 6, e23320	53
404	The temporal order of genetic and pathway alterations in tumorigenesis. 2011, 6, e27136	76
403	Effects of temperature on the p53-DNA binding interactions and their dynamical behavior: comparing the wild type to the R248Q mutant. 2011, 6, e27651	31
402	Cancer gene prioritization for targeted resequencing using FitSNP scores. 2012, 7, e31333	2
401	ER-alpha-cDNA as part of a bicistronic transcript gives rise to high frequency, long term, receptor expressing cell clones. 2012, 7, e31977	2
400	Personalized pathway enrichment map of putative cancer genes from next generation sequencing data. 2012, 7, e37595	10
399	TARGETgene: a tool for identification of potential therapeutic targets in cancer. 2012, 7, e43305	14
398	Kaiso directs the transcriptional corepressor MTG16 to the Kaiso binding site in target promoters. 2012, 7, e51205	15
397	Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells. 2012, 7, e51449	32
396	Exome capture sequencing of adenoma reveals genetic alterations in multiple cellular pathways at the early stage of colorectal tumorigenesis. 2013, 8, e53310	31

395	Characterization of two novel cell lines with distinct heterogeneity derived from a single human bile duct carcinoma. 2013 , 8, e54377	7
394	Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients. 2013 , 8, e58731	25
393	ToP: a trend-of-disease-progression procedure works well for identifying cancer genes from multi-state cohort gene expression data for human colorectal cancer. 2013 , 8, e65683	11
392	Mutational analysis of hedgehog signaling pathway genes in human malignant mesothelioma. 2013 , 8, e66685	25
391	Distinct gene expression signatures in lynch syndrome and familial colorectal cancer type x. 2013 , 8, e71755	26
390	Functional comparison between genes dysregulated in ulcerative colitis and colorectal carcinoma. 2013 , 8, e71989	5
389	Erlotinib inhibits growth of a patient-derived chordoma xenograft. 2013 , 8, e78895	31
388	Differentially expressed transcripts and dysregulated signaling pathways and networks in African American breast cancer. 2013 , 8, e82460	58
387	Variants of the PPAR δ gene and their clinicopathological significance in colorectal cancer. 2013 , 8, e83952	4
386	Prediction of the number of activated genes in multiple independent Cd(+2)- and As(+3)-induced malignant transformations of human urothelial cells (UROtsa). 2014 , 9, e85614	10
385	Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis. 2014 , 9, e100206	35
384	Type II transmembrane serine protease gene variants associate with breast cancer. 2014 , 9, e102519	16
383	A pathway-centric survey of somatic mutations in Chinese patients with colorectal carcinomas. 2015 , 10, e0116753	12
382	Crystal and EM structures of human phosphoribosyl pyrophosphate synthase I (PRS1) provide novel insights into the disease-associated mutations. 2015 , 10, e0120304	6
381	Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells. 2016 , 11, e0163272	9
380	Somatic Variations in Cervical Cancers in Indian Patients. 2016 , 11, e0165878	6
379	FGMD: A novel approach for functional gene module detection in cancer. 2017 , 12, e0188900	4
378	Reversing the aging stromal phenotype prevents carcinoma initiation. 2011 , 3, 407-16	50

377	Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGFR and ROCK as a potential treatment regimen for triple-negative breast cancer. 2016 , 7, 42859-42872	8
376	Loss of giant obscurins alters breast epithelial cell mechanosensing of matrix stiffness. 2017 , 8, 54004-54020	14
375	Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies. 2016 , 7, 66569-66585	17
374	Germline mutations in Japanese familial pancreatic cancer patients. 2016 , 7, 74227-74235	49
373	Loss of UHRF2 expression is associated with human neoplasia, promoter hypermethylation, decreased 5-hydroxymethylcytosine, and high proliferative activity. 2016 , 7, 76047-76061	12
372	Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas. 2013 , 4, 1931-2	9
371	Multiple mutations of lung squamous cell carcinoma shared common mechanisms. 2016 , 7, 79629-79636	12
370	Low expression of Rap1GAP is associated with epithelial-mesenchymal transition (EMT) and poor prognosis in gastric cancer. 2017 , 8, 8057-8068	15
369	Adamts18 deficiency promotes colon carcinogenesis by enhancing E-catenin and p38MAPK/ERK1/2 signaling in the mouse model of AOM/DSS-induced colitis-associated colorectal cancer. 2017 , 8, 18979-18990	19
368	Molecular markers of paragangliomas/pheochromocytomas. 2017 , 8, 25756-25782	26
367	KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. 2013 , 4, 2144-53	91
366	NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. 2014 , 5, 67-77	36
365	Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma. 2017 , 8, 23760-23774	14
364	In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma. 2017 , 8, 49165-49177	44
363	Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. 2014 , 5, 1515-25	187
362	PHLPP2 suppresses the NF- κ B pathway by inactivating IKK α kinase. 2014 , 5, 815-23	23
361	Clinically relevant morphological structures in breast cancer represent transcriptionally distinct tumor cell populations with varied degrees of epithelial-mesenchymal transition and CD44CD24 stemness. 2017 , 8, 61163-61180	16
360	Jagged-2 (JAG2) enhances tumorigenicity and chemoresistance of colorectal cancer cells. 2017 , 8, 53262-53275	50

359	The diagnostic and prognostic value of hypermethylation in colorectal cancer, a meta-analysis and literature review. 2017 , 8, 89142-89148	9
358	Integrating omics data and protein interaction networks to prioritize driver genes in cancer. 2017 , 8, 58050-58060	6
357	A comprehensive genomic meta-analysis identifies confirmatory role of gene in breast tumorigenesis. 2017 , 8, 102263-102276	13
356	Loss of the obscurin-RhoGEF downregulates RhoA signaling and increases microtentacle formation and attachment of breast epithelial cells. 2014 , 5, 8558-68	21
355	Impact of (rs2071543) gene polymorphism in increasing cancer risk: evidence from a meta-analysis and trial sequential analysis. 2018 , 9, 6572-6585	6
354	The transcriptional and mutational landscapes of lipid metabolism-related genes in colon cancer. 2018 , 9, 5919-5930	18
353	Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy. 2014 , 5, 9199-213	19
352	MicroRNA-873 inhibits colorectal cancer metastasis by targeting ELK1 and STRN4. 2019 , 10, 4192-4204	11
351	Two novel colorectal cancer risk loci in the region on chromosome 9q22.32. 2018 , 9, 11170-11179	2
350	Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing. 2018 , 9, 23960-23974	6
349	APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer. 2018 , 9, 30513-30526	5
348	FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15. 2015 , 6, 9240-56	25
347	IWR-1 inhibits epithelial-mesenchymal transition of colorectal cancer cells through suppressing Wnt/ β -catenin signaling as well as survivin expression. 2015 , 6, 27146-59	34
346	miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression. 2015 , 6, 23533-47	66
345	Regulation and functional significance of CDC42 alternative splicing in ovarian cancer. 2015 , 6, 29651-63	17
344	Vav1: A Dr. Jekyll and Mr. Hyde protein--good for the hematopoietic system, bad for cancer. 2015 , 6, 28731-42	19
343	Mutant IDH1 is required for IDH1 mutated tumor cell growth. 2012 , 3, 774-82	35
342	Decrease of 5hmC in gastric cancers is associated with TET1 silencing due to with DNA methylation and bivalent histone marks at TET1 CpG island 3'-shore. 2015 , 6, 37647-62	22

341	Involvement of SULF2 in γ -irradiation-induced invasion and resistance of cancer cells by inducing IL-6 expression. 2016 , 7, 16090-103		9
340	Period2 downregulation inhibits glioma cell apoptosis by activating the MDM2-TP53 pathway. 2016 , 7, 27350-62		13
339	What does the future hold for immunotherapy in cancer?. 2016 , 4, 177		8
338	Increasing incidence of colon cancer in patients . 2016 , 4, 164		9
337	Querying NeXtProt Nanopublications and Their Value for Insights on Sequence Variants and Tissue Expression.		2
336	The mutator phenotype in cancer: molecular mechanisms and targeting strategies. 2010 , 11, 1296-303		32
335	Sensitivity of UVB-Induced Mutant Detection in the λ 174 Transgenic Forward Mutation Assay. 2007 , 29, 38-53		2
334	The Interaction of CDH20 With β Catenin Inhibits Cervical Cancer Cell Migration and Invasion via TGF- β /Smad/SNAIL Mediated EMT. 2019 , 9, 1481		11
333	The Potential Role of Hedgehog Signaling in the Luminal/Basal Phenotype of Breast Epithelia and in Breast Cancer Invasion and Metastasis. <i>Cancers</i> , 2015 , 7, 1863-84	6.6	29
332	[Recent advances in mutant p53 and novel personalized strategies for cancer therapy]. 2011 , 33, 539-48		3
331	Colorectal carcinogenesis: road maps to cancer. 2007 , 13, 3784-91		99
330	Clinical applications of next-generation sequencing in colorectal cancers. 2013 , 19, 6784-93		26
329	Molecular classification of colorectal carcinomas: the genotype-to-phenotype relation. 2013 , 19, 8163-7		13
328	Evaluation of the colorectal cancer risk conferred by rare UNC5C alleles. 2014 , 20, 204-13		9
327	Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone?. 2014 , 20, 12391-406		43
326	Accumulation of aberrant DNA methylation during colorectal cancer development. 2014 , 20, 978-87		43
325	Integration of genome scale data for identifying new players in colorectal cancer. 2016 , 22, 534-45		3
324	Whole genome sequencing for lung cancer. 2012 , 4, 155-63		19

323	An improved understanding of cancer genomics through massively parallel sequencing. 2014 , 3, 243-259	8
322	Modeling Colorectal Cancer. 2013 , 53-75	1
321	Evaluation of rs1957106 Polymorphism of NF- κ B1 in Glioblastoma Multiforme in Isfahan, Iran. 2019 , 8, 9	3
320	Association between autocrine motility factor receptor gene polymorphism (rs2440472, rs373191257) and glioblastoma multiform in a representative Iranian population. 2018 , 23, 96	1
319	Multiscale Cancer Modeling and In Silico Oncology: Emerging Computational Frontiers in Basic and Translational Cancer Research. 2013 , 3,	5
318	Cancer Stem Cells in Colorectal Cancer: Genetic and Epigenetic Changes. 2012 , Suppl 7,	16
317	Arg-Ser- ⁷⁷⁵ , ⁷⁹² and ⁸²³ in Spacer Region of ADAMTS-18 Is Critical for Thrombin Cleavage. 2014 , 06, 2490-2498	1
316	A Pilot Trial Testing the Feasibility of Using Molecular-Guided Therapy in Patients with Recurrent Neuroblastoma. 2012 , 03, 602-612	11
315	Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas. 2016 , 8, 358-65	7
314	Activins and follistatins: Emerging roles in liver physiology and cancer. 2009 , 1, 17-27	24
313	Isoforms, structures, and functions of versatile spectraplaklin MACF1. 2016 , 49, 37-44	29
312	TMEM39A and Human Diseases: A Brief Review. 2017 , 33, 205-209	14
311	Omics of cancer. 2012 , 13, 4229-33	4
310	Aberrant expression of the autocrine motility factor receptor correlates with poor prognosis and promotes metastasis in gastric carcinoma. 2014 , 15, 989-97	13
309	Dynamics of preventive vs post-diagnostic cancer control using low-impact measures. 2015 , 4, e06266	7
308	Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing. 2020 , 9,	20
307	DGPathinter: a novel model for identifying driver genes via knowledge-driven matrix factorization with prior knowledge from interactome and pathways. 3, e133	3
306	Histone Deacetylases in the Process of Halisarca dujardini Cell Reaggregation. 2021 , 52, 319-333	

305	Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor. 2021 , 64, 15534-15548	2
304	HIST1H1B Promotes Basal-Like Breast Cancer Progression by Modulating CSF2 Expression. 2021 , 11, 780094	1
303	Lineage Recording Reveals the Phylodynamics, Plasticity and Paths of Tumor Evolution.	0
302	The Role of Emerin in Cancer Progression and Metastasis. 2021 , 22,	1
301	Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms. 2022 , 36, 95-111	1
300	RIF1 Links Replication Timing with Fork Reactivation and DNA Double-Strand Break Repair. 2021 , 22,	0
299	mRNA coexpression patterns of Wnt pathway components and their clinicopathological associations in breast and colorectal cancer. <i>Pathology Research and Practice</i> , 2021 , 227, 153649	3-4
298	Cancer Genetics and Genomics. 2007 , 461-484	1
297	Src Inhibitors. 2007 , 345-360	
296	The evolutionary context of human aging and degenerative disease. 2007 , 301-312	
295	Health consequences of ecogenetic variation. 2007 , 43-50	0
294	Cancer as a microevolutionary process. 2007 , 289-300	
293	Evolution of parasites. 2007 , 229-238	2
292	Perspectives on human health and disease from evolutionary and behavioral ecology. 2007 , 109-122	
291	Medically relevant variation in the human genome. 2007 , 31-42	
290	Cancer: evolutionary origins of vulnerability. 2007 , 277-288	
289	Whole-genome analysis of pathogen evolution. 2007 , 199-214	
288	Molecular Diagnostics. 2008 , 265-276	

- 287 Cancer-Specific Vaccines. **2008**, 649-669
- 286 Familial Pancreatic Cancer. **2008**, 65-79
- 285 Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. **2008**, 317-365
- 284 Clinical Pharmacogenomics. **2008**, 241-259
- 283 Pancreatic Cancer Genomics, Epigenomics, and Proteomics. **2008**, 229-252
- 282 Immunobiology and Immunotherapy of Multiple Myeloma. **2008**, 143-166
- 281 'Normal' genes key to cancer growth. **2008**, 451, 615
- 280 Cancer Immunology. **2008**, 77-93 1
- 279 Rasgrf2.
- 278 The Kinetochore-Cancer Connection. **2009**, 1-22
- 277 In Silico Functional Assessment of Sequence Variations: Predicting Phenotypic Functions of Novel Variations. **2008**, 6, 166-172
- 276 TGF β Mediated Epithelial Mesenchymal Transition and Metastasis in Skin and Head-and-Neck Cancer. **2009**, 69-80
- 275 Genomic and Proteomic Advances in Gastric Cancer. **2009**, 285-321
- 274 Kr μ pel-like Factors in Cancers. **2009**, 205-219
- 273 Personalized Therapy for Cancer. **2009**, 165-254
- 272 Tumorigenesis. **2009**, 1-17
- 271 Cancer Genes, Genomes, and the Environment. **2009**, 808-817
- 270 Cancer Stem Cells in Colorectal Cancer. **2009**, 223-250

269 An Oncogene-Induced DNA Replication Stress Model for Cancer Development. **2009**, 47-63

268 Emerging technologies for the genomic analysis of cancer. **2009**, 1, 35

267 Contribution of ADAMs and ADAMTSs to Tumor Expansion and Metastasis. **2010**, 293-314

1

266 Signaling through Galpha12/13 and RGS-RhoGEFs. **2010**, 59-76

265 Molecular Characteristics and Functions of PKHD1*. **2009**, 2009, 684-688

264 Protein Graphs in Cancer Prediction. **2010**, 125-140

263 Recent Advances in Cancer Genomics and Cancer-Associated Genes Discovery. **2010**, 11-29

262 Aberrant DNA Methylation in Cancer Cells. **2010**, 121-132

261 Methylation Detection and Epigenomics in Pancreatic Cancer. **2010**, 181-204

260 Analysis of Inherited and Acquired Genetic Variation. **2010**, 13-31

259 Cancer Targets. **2010**, 115-128

258 Dna Damage and Repair. **2010**, 31-39

257 Well-Differentiated Thyroid Follicular Carcinoma. **2010**, 73-93

256 Darwinismus in der Krise. **2010**, 19-38

255 The Micro- and Nanoscale Architecture of the Immunological Synapse. 323

254 [Identifying candidate cancer genes based on co-evolving gene modules]. **2010**, 32, 694-700

253 Cancer Genome Sequencing.

252 Malignant Glioma: Isocitrate Dehydrogenases 1 and 2 Mutations. **2011**, 53-62

- 251 Finding Driver Pathways in Cancer: Models and Algorithms. **2011**, 314-325
- 250 Mutation Rate. **2011**, 2412-2416
- 249 The Hallmarks of Cancer Revisited Through Systems Biology and Network Modelling. **2011**, 245-266 1
- 248 [Advances in early diagnosis of colorectal cancer based on detection of RNAs in stool.]. **2010**, 32, 994-1002
- 247 TGF- β Signaling in Fibroblasts Regulates Tumor Initiation and Progression in Adjacent Epithelia. **2011**, 223-243
- 246 The Dynamics of the Cell Signaling Network; Implications for Targeted Therapies. **2011**, 33-53
- 245 Hedgehog Signaling in Mammary Gland Development and Breast Cancer. **2011**, 131-149
- 244 Dynamic Simulations of Pathways Downstream of ERBB-Family: Exploration of Parameter Space and Effects of Its Variation on Network Behavior. **2011**, 229-241
- 243 Molecular Pathology. **2011**, 2358-2363
- 242 Cancer and Alcohol: An Overview of Tumorigenesis. **2011**, 5-18
- 241 Insertional Mutagenesis for Generating Mouse Models of Cancer. **2012**, 57-82
- 240 DNA Damage Checkpoint Signaling Pathways in Human Cancer. **2012**, 23-37
- 239 Preclinical Considerations for Development of Antibody-Based Therapeutics in Oncology. **2012**, 183-240
- 238 Novel Methods in the Study of the Breast Cancer Genome: Towards a Better Understanding of the Disease of Breast Cancer. **2012**, 03, 797-809
- 237 Genome-scale DNA methylation analysis in GI cancers. **2012**, 56, 5-8
- 236 High Throughput Affinity Purification and Mass Spectrometry to Determine Protein Complex Interactions. **2012**, 139-159
- 235 Molecular Genetics and Cancer Biology. **2012**, 530-567.e16
- 234 Dynamic Simulations of Pathways Downstream of TGF- β Wnt and EGF-Family Growth Factors, in Colorectal Cancer, including Mutations and Treatments with Onco-Protein Inhibitors. **2012**, 127-142

233 Colorectal Cancer. **2012**, 245-272

232 Activation of Immune-Mediated Tumor Cell Death by Chemotherapy. **2013**, 373-399

231 Nanomedicine: Emerging Field of Nanotechnology to Human Health. **2012**, 13-54

230 Capturing and Deciphering the Molecular Signatures of Head and Neck Cancer. **2013**, 97-130

229 Mutational Activation of KRAS and BRAF in Colorectal Cancer. **2013**, 121-156

1

228 Cancer Chemotherapy. **2013**, 401-427

1

227 TYPES OF DNA DAMAGE. **2013**, 115-118

226 Colorectal Cancer Genome and Its Implications. **2013**, 247-265

225 Identification and Characterization of a Human ProstateCancer Specific Long Non-Coding RNA.
2013, 1-4

224 Mouse Models to Study DNA Methylation in Cancer Research. **2014**, 43-66

223 Statistical tools and R software for cancer driver probabilities. **2014**, 1101, 113-34

222 DNA Damage Response Pathways and Cancer. **2014**, 142-153.e3

1

221 Emerging Anti-cancer Targets in Mitochondria. **2014**, 265-290

220 The PI3K Signaling Pathway in Head and Neck Squamous Cell Carcinoma. **2014**, 131-161

219 Drugs Affecting Epigenetic Modifications of ABC Transporters for Drug Resistance. **2015**, 273-297

218 Genomic Applications in Colorectal and Pancreatic Tumors. **2015**, 415-434

217 Encyclopedia of Cancer. **2015**, 1-6

216 Omics and Biomarkers Development for Intestinal Tumorigenesis. **2015**, 365-389

215 Encyclopedia of Cancer. **2015**, 1-5

214 Somatic Mutations in Overgrowth Syndromes. **2015**, 153-165

213 Cancer Pathway Network Analysis Using Cellular Automata. **2015**, 145-159

212 Encyclopedia of Cancer. **2015**, 2902-2907

211 Molecular Pathology of Lobular Carcinoma. **2015**, 95-105

210 Aging-Associated Nonmelanoma Skin Cancer: A Role for the Dermis. **2015**, 1-19

209 Mutation Rate. **2015**, 2961-2965

208 Neoplasia of the Gastrointestinal Tract. 587-616

207 Recent Advances in Molecular Pathology of Neuroendocrine Neoplasms. **2016**, 487-504

206 Mismatch Repair. **2016**, 305-339

0

205 Genetics and Epigenetics of Head and Neck Cancer. **2016**, 115-132

204 Genomic Analysis. **2016**, 83-106

203 Evaluating the Evaluation of Cancer Driver Genes.

1

202 Identification of outcome-related driver mutations in cancer using conditional co-occurrence distributions.

201 An exactly solvable, spatial model of mutation accumulation in cancer.

200 Simple Sequence Mutations. **2017**, 217-230

199 Analysis of Isocitrate Dehydrogenase -2 (IDH-2) Activity in Human Serum as a Biomarker in Chemotherapy Patients of Breast Carcinoma: A Case-Control Study. **2017**, 11, BC05-BC08

198 Allele Frequency Spectrum in a Cancer Cell Population.

1

197 Personalised Genomics and Molecular Profiles in Colorectal Cancer: Towards Precision Cancer Care. **2017**, 261-285

196 MCF-7 breast cancer cell line PacBio generated transcriptome has ~300 novel transcribed regions, un-annotated in both RefSeq and GENCODE, and absent in the liver, heart and brain transcriptomes. ○

195 ADAM and ADAMTS Family of Metalloproteinases: Role in Cancer Progression and Acquisition of Hallmarks. **2017**, 303-331

194 Shorter unreported sequences in a RACE-Seq study involving seven tissues confirms ~150 novel transcripts identified in MCF-7 cell line PacBio transcriptome, leaving ~100 non-redundant transcripts exclusive to the cancer cell line.

193 An immunohistochemical study of histone H1.5 in correlation with clinicopathologic features of invasive duct carcinoma (not otherwise specified). **2017**, 37, 339-344

192 Effect sizes of somatic mutations in cancer. 1

191 MYC Dysregulates Mitotic Spindle Function Creating a Dependency on TPX2.

190 The PI3K Signaling Pathway in Head and Neck Squamous Cell Carcinoma. **2018**, 117-154

189 MYC Dysregulates Mitotic Spindle Function Creating a Dependency on TPX2.

188 Identifying Driver Potential in Passenger Genes Using Chemical Properties of Mutated and Surrounding Amino Acids. **2019**, 107-118 ○

187 EXPOsOMICS: Meet-in-the-Middle and Network Perturbation. **2019**, 349-392

186 In Vitro Cancer Diagnostics. **2019**, 109-132

185 Arrayed shRNA Screening to Identify Suppressors of Anchorage-Independent Growth. **2019**, 1907, 115-123

184 Cancer Pathway Network Analysis Using Cellular Automata. **2019**, 2039-2053

183 Targeting Mitochondrial Enzymes in Pancreatic Cancer. **2019**, 95-110

182 A catalog of cis-regulatory mutations in 12 major cancer types. 2

181 Identification of High-Affinity Small Molecule Targeting IDH2 for the Clinical Treatment of Acute Myeloid Leukemia. **2019**, 20, 2287-2297 10

180 A Local-Network Guided Linear Discriminant Analysis for Classifying Lung Cancer Subtypes using Individual Genome-Wide Methylation Profiles. **2020**, 676-687

- 179 TP53 PATHOGENIC VARIANTS RELATED TO CANCER. **2019**, 30, 27-40
- 178 Targeted molecular profiling of genetic alterations in colorectal cancer using next-generation sequencing. **2020**, 19, 1137-1144
- 177 Nanoformulated Drug Delivery of Potential Betulinic Acid Derivatives: A Promising Approach Toward Cancer Therapy. **2020**, 127-153 0
- 176 Involvement of SAMHD1 in dNTP homeostasis and the maintenance of genomic integrity and oncotherapy (Review). **2020**, 56, 879-888 1
- 175 Knock-down of the TIM/TIPIN complex promotes apoptosis in melanoma cells. **2020**, 11, 1846-1861 1
- 174 A systematic screen of breast cancer patients' exomes for retrotransposon insertions reveals disease associated genes.
- 173 Multiplexed quantitative screens of single cell shape and YAP/TAZ localisation identify DOCK5 as a coincident detector of polarity and adhesion during migration.
- 172 Mouse Models of Diffuse Lower-Grade Gliomas of the Adult. **2021**, 3-38
- 171 Genomic and molecular alterations associated with early-onset and adolescent and young adult colorectal cancer. **2020**, 9, CRC30 1
- 170 Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers. **2021**, 5, 96 0
- 169 Introduction to biomedical logic. **2020**, 1-28
- 168 Generating realistic null hypothesis of cancer mutational landscapes using SigProfilerSimulator. 1
- 167 Discovery of potential epigenetic inhibitors against histone methyltransferases through molecular docking and molecular dynamics simulations.
- 166 Hormone replacement therapy and elevated breast cancer risk: An artifact of growth acceleration?. 0
- 165 The Immune Landscape of Colorectal Cancer. *Cancers*, **2021**, 13, 6.6 1
- 164 Concurrent Wnt pathway component expression in breast and colorectal cancer. *Pathology Research and Practice*, **2020**, 216, 153005 3.4 1
- 163 Mtg16-dependent repression of E protein activity is required for early lymphopoiesis. 0
- 162 Targeting Hsp90 Function to Treat Cancer: Much More to Be Learned. **2007**, 253-274

161	State-of-the-Art Lecture: Infection, inflammation and cancer [the future. 259-268	
160	Integrating the Genome and Epigenome in Human Disease. 2009 , 343-368	
159	Introduction: the rationale for the development of targeted drugs in cancer therapy. 2007 , 172, 1-3	
158	Gendiagnostik. 2008 , 346-376	
157	The Jeremiah Metzger Lecture: intelligent design of cancer therapy: trials and tribulations. 2007 , 118, 253-61	4
156	Thirty years into the genomics era: tumor viruses led the way. 2006 , 79, 179-85	1
155	Rarity of Somatic Mutation and Frequency of Normal Sequence Variation Detected in Sporadic Colon Adenocarcinoma Using High-Throughput cDNA Sequencing. 2007 , 1, 1-16	
154	Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics. 2009 , 16, 56-8	4
153	Somatic mutation signatures of cancer. 2008 , 202-6	1
152	Colorectal cancer: molecular features and clinical opportunities. 2010 , 31, 31-8	100
151	Novel Actions of Nonsteroidal Anti-Inflammatory Drugs on Vascular Ion Channels: Accounting for Cardiovascular Side Effects and Identifying New Therapeutic Applications. 2010 , 2, 15-19	27
150	Emerging tactical strategies for fighting the war on cancer based on the genetic landscape. 2011 , 3, 251-8	1
149	Systems approaches to molecular cancer diagnostics. 2010 , 10, 531-42	5
148	Potential non-oncological applications of histone deacetylase inhibitors. 2011 , 3, 454-67	17
147	Current status of immunotherapy for the treatment of lung cancer. 2010 , 2, 237-44	16
146	Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions. 2012 , 26, 487-500	4
145	Where medicine, business, and public policy intersect. 2007 , 4, 33-42	7
144	Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas. 2013 , 4, 1919-1932	1

143	TGFBR1 and cancer susceptibility. 2014 , 125, 300-12	15
142	Cancer Cell: Linking Oncogenic Signaling to Molecular Structure. 2011 , 2011, 31-44	1
141	A mathematical model for short-term vs. long-term survival in patients with glioma. 2014 , 4, 862-73	8
140	Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. 2015 , 5, 72-86	10
139	Genetics of colorectal cancer. 2014 , 7, 507-11	13
138	Into the eye of the storm: breast cancer's somatic mutation landscape points to DNA damage and repair. 2013 , 2, 59-61	1
137	ADAM12 expression predicts clinical outcome in estrogen receptor-positive breast cancer. 2015 , 8, 13279-83	10
136	Cancer Prevention and Treatment by Wholistic Nutrition. 2017 , 3,	5
135	Exploring conserved mRNA-miRNA interactions in colon and lung cancers. 2017 , 10, 184-193	5
134	[Relationship between single nucleotide polymorphism of the equilibrative nucleoside transporter ENT3 and susceptibility to lung cancer]. 2010 , 13, 458-63	
133	It's About Time: Advances in Understanding the Circadian Regulation of DNA Damage and Repair in Carcinogenesis and Cancer Treatment Outcomes. 2019 , 92, 305-316	11
132	High EGFL6 expression is associated with clinicopathological characteristics in colorectal cancer. 2018 , 11, 5893-5900	1
131	[Research Progress of Epigenetics in Pathogenesis and Treatment of Malignant Tumors]. 2020 , 23, 91-100	1
130	Identification of KIF23 as a prognostic signature for ovarian cancer based on large-scale sampling and clinical validation. 2020 , 12, 4955-4976	6
129	FAT1 and PTPN14 Regulate the Malignant Progression and Chemotherapy Resistance of Esophageal Cancer through the Hippo Signaling Pathway. 2021 , 2021, 9290372	
128	Giant obscurin regulates migration and metastasis via RhoA-dependent cytoskeletal remodeling in pancreatic cancer. 2021 , 526, 155-167	1
127	DCMP: database of cancer mutant protein domains. 2021 , 2021,	
126	CSMD1 Mutation Related to Immunity Can Be Used as a Marker to Evaluate the Clinical Therapeutic Effect and Prognosis of Patients with Esophageal Cancer. 2021 , 14, 8689-8710	2

125	DNASE1L3 as a Novel Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma Based on Data Mining. 2021 , 12, 699242		1
124	Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). 2021 , 1		1
123	Prognostic Value of Tumor Mutational Burden Related to Immune Infiltration in Cervical Squamous Cell Carcinoma. 2021 , 8, 755657		0
122	A Novel Prognostic Biomarker Panel for Early-Stage Colon Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	0
121	Tools used to assay genomic instability in cancers and cancer meiomitosis. 2021 , 16, 159		1
120	A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases. 2021 , 5,		2
119	Implication of ARID1A Undercurrents and PDL1, TP53 Overexpression in Advanced Gastric Cancer.. 2021 , 27, 1609826		
118	The Biochemistry and Physiology of A Disintegrin and Metalloproteinases (ADAMs and ADAM-TSs) in Human Pathologies.. 2022 ,		0
117	FAT1 and PTPN14 Regulate the Malignant Progression and Chemotherapy Resistance of Esophageal Cancer through the Hippo Signaling Pathway. 2021 , 2021, 1-9		2
116	Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making.. 2021 , 11,		1
115	An Iron Metabolism-Related Gene Signature for the Prognosis of Colon Cancer.. 2021 , 9, 786684		
114	Metastasis enhancer PGRMC1 boosts store-operated Ca entry by uncoiling Ca sensor STIM1 for focal adhesion turnover and actomyosin formation.. 2022 , 38, 110281		2
113	The structure of NLRP9 reveals a unique C-terminal region with putative regulatory function.. 2022 ,		0
112	Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types.. <i>Cancers</i> , 2022 , 14,	6.6	0
111	Lysine methyltransferase inhibitors: where we are now.. 2022 , 3, 359-406		2
110	Integrated analysis of ovarian juvenile granulosa cell tumors reveals distinct epigenetic signatures and recurrent rearrangements.. 2022 ,		0
109	Neurofibromin and suppression of tumorigenesis: beyond the GAP.. 2022 ,		0
108	Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer.. 2022 , 1877, 188676		2

107	Association Between Tumor Mutation Profile and Clinical Outcomes Among Hispanic-Latino Patients With Metastatic Colorectal Cancer.. 2021 , 11, 772225	0
106	The role of RNA binding proteins in hepatocellular carcinoma.. 2022 , 182, 114114	1
105	Put in a "Call" to Acute Myeloid Leukemia.. 2022 , 11,	1
104	A role for the NPM1/PTPN14/YAP axis in mediating hypoxia-induced chemoresistance to sorafenib in hepatocellular carcinoma.. 2022 , 22, 65	0
103	Mitochondrial Function Differences between Tumor Tissue of Human Metastatic and Premetastatic CRC.. 2022 , 11,	1
102	Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies.. 2022 , 23,	0
101	NCAPG facilitates colorectal cancer cell proliferation, migration, invasion and epithelial-mesenchymal transition by activating the Wnt/ β -catenin signaling pathway.. 2022 , 22, 119	3
100	Research development and potential therapeutic value of m6A modification in occurrence and progression of colorectal tumors. 2021 , 29, 1373-1381	
99	Aberrant post-translational modifications in endosomal trafficking are potential therapeutic targets to avert therapy resistance in solid cancers: Dysregulation of PTM-regulated endosomal interactions presents an opportunity to block oncogenic signalling from multiple receptors by targeting common trafficking pathways: Dysregulation of PTM-regulated endosomal interactions presents an opportunity to block oncogenic signalling from multiple receptors by targeting common trafficking pathways.. 2021 , e2100192	
98	The emergence of cancer genomics in diagnosis and precision medicine.. 2021 , 2, 1263-1264	1
97	The degradation of Rap1GAP via E6AP-mediated ubiquitin-proteasome pathway is associated with HPV16/18-infection in cervical cancer cells.. 2021 , 16, 71	
96	Isocitrate dehydrogenase gene variants in cancer and their clinical significance. 2021 ,	2
95	Time-restricted feeding alters the efficiency of mammary tumor growth.. 2021 , 1-12	1
94	Pan-cancer analyses reveal the regulation and clinical outcome association of PCLAF in human tumors.. 2022 , 60,	0
93	Systems biology of cancer progression. 1-6	
92	Lessons from cancer genome sequencing. 7-19	
91	Deregulated signaling networks in lung cancer. 421-442	
90	Data_Sheet_1.pdf. 2020 ,	

89	Table_1.XLS. 2020 ,		
88	Table_2.XLS. 2020 ,		
87	Table_3.XLS. 2020 ,		
86	Table_1.xlsx. 2019 ,		
85	Table_1.DOCX. 2020 ,		
84	The translational challenges of precision oncology.. 2022 ,		3
83	Research Progress of RNA Methylation Modification in Colorectal Cancer. 2022 , 13,		
82	Lineage tracing reveals the phylogenetics, plasticity, and paths of tumor evolution.. 2022 ,		4
81	The Current State of Precision Medicine and Targeted-Cancer Therapies: Where Are We?. 2022 , 119-200		
80	De quelques thésies de l'oncogénèse. 2022 ,		
79	Common Cancers and Their Genetic Alterations. 2022 , 317-354		
78	SpBLRSR: Schatten p-norm constrained bounded low-rank subspace recovery for predicting N7-methylguanosine (m7G)-disease associations. 2022 , 17,		
77	DNASE1L3 inhibits proliferation, invasion and metastasis of hepatocellular carcinoma by interacting with Eatenin to promote its ubiquitin degradation pathway.		1
76	Circulating tumor DNA: current challenges for clinical utility. <i>Journal of Clinical Investigation</i> , 2022 , 132,	15.9	1
75	Arterial Spin Labeling Perfusion in Determining the IDH1 Status and Ki-67 Index in Brain Gliomas. <i>Diagnostics</i> , 2022 , 12, 1444	3.8	
74	Epigenetic insights in the diagnosis, prognosis, and treatment selection in CRC, an updated review. <i>Molecular Biology Reports</i> ,	2.8	1
73	Genetic susceptibility to earlier ovarian ageing increases de novo mutation rate in offspring.		0
72	Genetic profile identification and clinicopathologic characteristics analysis of the thyroid-like low-grade nasopharyngeal papillary adenocarcinoma. <i>Pathology Research and Practice</i> , 2022 , 236, 153980 ^{3,4}		0

71	Scales of Cancer Evolution: Selfish Genome or Cooperating Cells?. <i>Cancers</i> , 2022 , 14, 3253	6.6	o
70	mRNA expression and epigenetic-based role of chromodomain helicase DNA-binding 5 in hepatocellular carcinoma. <i>Journal of International Medical Research</i> , 2022 , 50, 030006052211053	1.4	o
69	SYSMut: decoding the functional significance of rare somatic mutations in cancer. <i>Briefings in Bioinformatics</i> , 2022 , 23,	13.4	
68	Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays. <i>Nature Communications</i> , 2022 , 13,	17.4	1
67	Methylation-mediated silencing of PTPRD induces pulmonary hypertension by promoting pulmonary arterial smooth muscle cell migration via the PDGFRB/PLC β axis. <i>Journal of Hypertension</i> , Publish Ahead of Print,	1.9	o
66	Preface to the Second Edition. 2007 , v-vi		
65	Copyright Page. 2007 , iv-iv		
64	Contributors. 2007 , xix-xxii		
63	Lymph node positive pseudomyxoma peritonei. 2022 ,		
62	Recent advances of IDH1 mutant inhibitor in cancer therapy. 13,		o
61	Case Report: Clinical complete response of advanced renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion by treated by camrelizumab and axitinib: A rare case report. 13,		1
60	Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. 2022 , 349, 844-875		2
59	Evaluation of two new highly multiplexed PCR assays as an alternative to next-generation sequencing for IDH1 /2 mutation detection.		o
58	Implications of a Neuronal Receptor Family, Metabotropic Glutamate Receptors, in Cancer Development and Progression. 2022 , 11, 2857		o
57	Synthetic-Based Tumor-Infiltrating Lymphocytes (TILs) in Adoptive Cell Therapies. 2022 , 1-27		o
56	Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma.		o
55	Identification and verification of CCNB1 as a potential prognostic biomarker by comprehensive analysis. 2022 , 12,		o
54	FBXW7 Reduces the Cancer Stem Cell-Like Properties of Hepatocellular Carcinoma by Regulating the Ubiquitination and Degradation of ACTL6A. 2022 , 2022, 1-26		o

53	Disruptions in cell fate decisions and transformed enteroendocrine cells drive intestinal tumorigenesis in <i>Drosophila</i> .	0
52	The role of protein acetylation in carcinogenesis and targeted drug discovery. 13,	1
51	Rewired Metabolism of Amino Acids and Its Roles in Glioma Pathology. 2022 , 12, 918	1
50	Cancer is a devastating disease, but also an eye-opener and window into the deep mysteries of life and its origins. 2022 ,	0
49	Significance of NRF2 in physiological and pathological conditions an comprehensive review. 2022 , 730, 109417	1
48	Architecture and topologies of gene regulatory networks associated with breast cancer, adjacent normal, and normal tissues.	0
47	Cancer Genomics and Evolution. 1-30	0
46	Cancer Immunotherapy. 1-22	0
45	A Pan-Cancer Analysis of the Role of PBRM1 in Human Tumors. 2022 , 2022, 1-13	0
44	Mono- and biallelic germline variants of DNA glycosylase genes in colon adenomatous polyposis families from two continents. 12,	0
43	Genomic Profiling and Liquid Biopsies for Breast Cancer. 2022 ,	0
42	Identification of an ergosterol derivative with anti-melanoma effect from the sponge-derived fungus <i>Pestalotiopsis</i> sp. XWS03F09. 13,	0
41	The N-terminus of obscurin is flexible in solution.	0
40	Improvement of mutated peptide identification through MS/MS signals searching against the protein libraries generated from transcriptome and translome. 2023 , 483, 116965	0
39	Nuclear Morphological Abnormalities in Cancer: A Search for Unifying Mechanisms. 2022 , 443-467	1
38	Targeting IDH1/IDH2 mutations in gliomas. 2022 , 35, 787-793	1
37	IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF- κ B signaling to promote colorectal cancer progression.	1
36	Methylation of CpG island promoters at ZNF625, LONRF2, SDC2 and WDR17 in a patient with numerous non-granular type laterally spreading tumors and colorectal cancer: A case report. 2022 , 25,	0

35	Up-regulation of SAMHD1 gene construction of a prognosis biomarker for survival and prognostic in breast invasive carcinoma.	0
34	A protein microarray-based serum proteomic investigation reveals distinct autoantibody signature in colorectal cancer. 2200062	2
33	Comprehensive Genetic Exploration of Fused Teeth by Whole Exome Sequencing. 2022 , 12, 11899	0
32	Distributions of amino acids in the primary structure of monoamine oxidase family. 2022 ,	0
31	The Transition from Cancer Omics to Epi-omics through Next- and Third-Generation Sequencing. 2022 , 12, 2010	0
30	Transcriptional activity mediated by β CATENIN and TCF/LEF family members is completely dispensable for survival of multiple human colorectal cancer cell lines.	0
29	IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.	0
28	PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. 13,	2
27	Single-Cell Analysis of Circulating Tumor Cells from Patients with Colorectal Cancer Captured with a Dielectrophoresis-Based Micropore System. 2023 , 11, 203	1
26	Wild-type IDH1 Knockout Leads to G0/G1 Arrest, Impairs Cancer Cell Proliferation, Altering Glycolysis, and the TCA Cycle in Colon Cancer.	0
25	Transcriptional activity mediated by β CATENIN and TCF/LEF family members is completely dispensable for survival and propagation of multiple human colorectal cancer cell lines. 2023 , 13,	0
24	Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics. 2023 , 242, 108337	0
23	Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer. 2023 , 15, 183	2
22	Targeting the Hedgehog Pathway in Rhabdomyosarcoma. 2023 , 15, 727	0
21	Breast Cancer Disease Exploitation to Recure a Healthy Lifestyle. 2022 , 2617-2635	0
20	Metabolic reprogramming in colorectal cancer: regulatory networks and therapy. 2023 , 13,	0
19	In silico analysis of differentially expressed-aberrantly methylated genes in breast cancer for prognostic and therapeutic targets.	0
18	Time For obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment. 2023 , 91, 99-109	0

- 17 Mechanotherapy in oncology: Targeting nuclear mechanics and mechanotransduction. **2023**, 194, 114722 ○
- 16 The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer. **2023**, 13, 1438-1466 ○
- 15 IVT generation of guideRNAs for Cas9-enrichment Nanopore Sequencing. ○
- 14 Survival improvement for patients with metastatic colorectal cancer over twenty years. **2023**, 7, ○
- 13 Targeting the recurrent Rac1P29S neopeptide in melanoma with heterologous high-affinity T cell receptors. 14, ○
- 12 The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness. 14, ○
- 11 Pathogenesis of histologic variations of appendiceal mucinous neoplasms. **2023**, ○
- 10 Methylation of the tumor associated genes in head and neck squamous cell carcinoma. **2023**, 12, 61-70 ○
- 9 Clinical Progress of TTN and OBSCN Axes in Liver Metastasis of Colorectal Cancer. **2023**, 13, 3510-3514 ○
- 8 PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy. **2023**, 13, ○
- 7 A pan-cancer analysis of the role of WDFY2 in human tumors. 1-16 ○
- 6 Case Report: Identification of a rare nonsense mutation in the POC1A gene by NGS in a diabetes mellitus patient. 14, ○
- 5 Prognostic whole-genome and transcriptome signatures in colorectal cancers. ○
- 4 The Role of Genetic Mutations in Mitochondrial-Driven Cancer Growth in Selected Tumors: Breast and Gynecological Malignancies. **2023**, 13, 996 ○
- 3 Exploring scavenger receptor class F member 2 and the importance of scavenger receptor family in prediagnostic diseases. ○
- 2 The 10th International Conference on cGMP 2022: recent trends in cGMP research and development meeting report. ○
- 1 Late-stage MC38 tumours recapitulate features of human colorectal cancer – Implications for appropriate timepoint selection in preclinical studies. 14, ○